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Myocardial fibrosis is associated with ventricular arrhythmia. Late gadolinium 
enhancement cardiac magnetic resonance (LGE-CMR) has been the standard 
approach to visualise regional myocardial fibrosis. T1 mapping is a novel CMR 
technique that overcomes the inherent limitation of conventional LGE imaging to 
assess diffuse fibrosis. 
The incidence of arrhythmia and sudden death continues to be high despite the 
benefits of cardiac resynchronisation therapy (CRT) in terms of symptomatic 
improvement and overall mortality. As myocardial scar can have a structural and 
functional impact on remodeling, there is a need to further elucidate the effect of CRT 
on electrophysiology and to better select patients for CRT. 
Prospective clinical studies were conducted to assess the ability of CMR scar 
quantification to  
1. predict the risk of ventricular arrhythmia in both ischaemic and non-ischaemic 
cardiomyopathy (ICM, NICM) patients;  
2. predict reverse remodeling following CRT in dyssynchronous heart failure 
patients.  
Investigative studies were also carried out to  
1. explore CMR scar characterisation using high-resolution 3-dimensional scar 
image acquisition in heart failure patients;  
2. explore clinical utilisation of T1 mapping for myocardial fibrosis 
quantification;  
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3. understand the relationship between scar heterogeneity and substrate for 
ventricular arrhythmia;  
4. explore electrical remodeling effect of CRT in dyssynchronous heart failure 
patients 
The present study is the first to demonstrate that non-contrast native T1 is an 
independent predictor of ventricular arrhythmia in patients with ICM or NICM.  It 
provides confirmation that the extents of scar and grey zone derived from LGE-CMR 
are independently associated with ventricular arrhythmia. With regards to prediction 
of CRT remodeling, focal scar burden detected by LGE-CMR is associated with a 
poor response to CRT, whereas markers of diffuse interstitial fibrosis were not 
however predictive of CRT response. 
These findings have important clinical implications, lending support for the use of 
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Chapter 1 Thesis Outline 
 
1.1 Thesis Aims 
This thesis summarises the research work undertaken to test the hypothesis that 
quantitative left ventricular myocardial fibrosis assessment using cardiac magnetic 
resonance imaging can  
1. predict the risk of ventricular arrhythmia and provide additional predictive 
value in identifying patients with increased risk of ventricular arrhythmia in 
both ICM and NICM patients;  
2. predict reverse remodeling following CRT in dyssynchronous heart failure 
patients.  
 
1.2 Chapter Overview 
The following chapters describe the work undertaken to addressed the hypothesis 
listed above 
Chapter 2 introduces the background information in support of the proposed study 
hypothesis with a focus on why there is a need for using CMR quantitative 
myocardial scar assessment and the relevance of addressing scar heterogeneity 
assessment (rather than the simple binary assessment of the presence of scar) using T1 
mapping and grey zone assessment.  
Chapter 3 describes the general methods if used in more than one study. Detailed 
methodology with respect to each individual study is further described in the 
respective study chapters.  
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Chapter 4 describes an exploratory study conducted to assess the clinical applications 
of T1 mapping for myocardial scar assessment.  
Chapter 5 describes an exploratory study conducted to utilise a novel method of 
improving respiratory navigation during high-resolution scar imaging in patients with 
heart failure.  
Important limitations and drawbacks learnt from the work described in Chapter 4 and 
5 were used to refine the methods and develop data analysis tools for carrying out the 
large prospective clinical outcome study described in Chapter 7. 
Chapter 6 describes a study to explore the association between scar heterogeneity 
detected by CMR imaging and ventricular tachycardia substrate.  
Chapter 7 describes a large prospective clinical study that assesses the prognostic 
value of quantitative scar assessment using CMR in predicting ventricular arrhythmia 
in both patients with ICM and NICM. This included scar quantification using LGE 
images and T1 mappings with its associated derived index such as extracellular 
volume index (ECV).  
Chapter 8 describes a study that assesses the impact of CRT on left ventricular (LV) 
electrical remodeling in terms of action potential duration (APD) changes between 
responders and non-responders.  The findings may provide explanations to the 
persistent high incidence of arrhythmias in some patients with CRT and the additional 
mortality benefit observed in responders of CRT. 
Chapter 9 describes a study that assesses the relationship between the mechanical 
remodeling (regional strain) and electrical remodeling (regional APD) induced by 
CRT, providing evidence that the two processes are linked.  
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Chapter 10 describes a prospective clinical study that assesses the prognostic value 
of quantitative scar assessment using CMR to predicting RR to CRT in both 
dyssynchronous patients with ICM and NICM.  
Chapter 11 concludes the thesis by discussing the original contributions, clinical 
perspectives, implications, limitations and future directions of this work. 
 
The following flow chart describes the development journey of the various 
hypotheses put forward in this thesis and thus the order of the chapters listed. 
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Chapter 2 Introduction 
 
The aim of this thesis is to assess the prognostic value of quantitative myocardial scar 
assessment using cardiac magnetic resonance imaging (CMR) in predicting 
ventricular arrhythmia and myocardial remodeling.  
In this chapter, I will briefly describe the principles of cardiac magnetic resonance 
imaging, focusing in particular on T1 mapping which has recently emerged as a useful 
tool that overcomes of the limitation of conventional late gadolinium enhanced (LGE) 
CMR technique and allows the quantitative assessment of interstitial diffuse fibrosis.  
I will also describe the relevance of myocardial tissue scar heterogeneity in terms of 
providing substrate for ventricular arrhythmia and its potential impact on ventricular 
remodeling following cardiac resynchronisation therapy (CRT); and discuss the 
measure of CRT response.  
In turn, I will introduce the background to the aim of study explaining the rationale 
for the hypothesis proposed.  
 
2.1 Principles of cardiac magnetic resonance imaging 
2.1.1 Basic physics of MRI 
Cardiac magnetic resonance imaging (CMR) is the best noninvasive image modality 
to characterise human organ tissues. Visualisation of myocardial tissue is based on 
principles and technique using magnetic fields and radiofrequency (RF) pulses.  
Human organ tissues distinguish from one type to another by the amount of water and 
therefore hydrogen content. Each hydrogen atom consists of a central nucleus that 
contains one proton, surrounded by a single electron. Nuclei are in a constant state of 
 24 
spin in their “rest” magnetic state or moment. When an external magnetic field is 
applied, the “rest” magnetic moment is therefore affected and the hydrogen nuclei 
align themselves with the directions of the magnetic field. The nuclei precess about 
the magnetic field direction like gyroscopes, a behavior called Larmor precession. 
The frequency of the precession (ω0), measured in (M)Hz, is proportional to the 
applied magnetic field strength (B0).  
ω0 = γB0; where γ is the gyromagnetic ratio.  
(Gyromagnetic ratio is a nuclei specific constant, for hydrogen, γ = 42.6 MHz/Tesla) 
 
In order to obtain a magnetic resonance image, the subject is placed in a magnetic 
field, then a RF pulse is applied (with a frequency equal to the Larmor frequency of 
proton, so they are in “resonance”) to disturb the equilibrium state of the proton nuclei 
spin. This transfers the energy to, i.e. excite, the nuclei which then spin/precess to a 
greater degree. This leads to a measureable transverse magnetisation in 3-dimensional 
space. The z-axis usually refers to the direction of the external magnetic field, whilst 
x-axis or y-axis is perpendicular to the external magnetic field. The angle between the 
z-axis and the new net magnitisation vector is known as the flip angle and its 
magnitude depends on the amplitude and duration of the RF pulse.  
When the RF signal is removed, the nuclei realign themselves with the external 
magnetic field and continue precessing at their precession frequency, until their net 
magnetic moment is again parallel to the external magnetic field. This return to 
equilibrium is referred to as “relaxation”. During realignment, the change in magnetic 
flux induces an electric voltage, which can be detected by an RF antenna resulting a 
receptive RF signal. This signal is referred to as the free-induction decay (FID) 
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response signal. The FID response signal is measured by a conductive field coil 
placed around the object being imaged. These signals are processed or reconstructed 
to obtain 3-dimensional (3D) grey-scale magnetic resonance (MR) image.  
In order to produce a 3D image, the FID resonance signal must be encoded for each 
dimension. This is made possible by providing an additional gradient magnetic field. 
This gradient causes the Larmor frequency to change linearly in the axial direction. A 
2D spatial reconstruction in each axial slice can be accomplished using frequency and 
phase encoding by giving two magnetic gradients that are perpendicular to each other 
consecutively. As a result, the resonant frequencies of the nuclei vary in one direction 
due to one gradient, and have a phase variation in the other direction due the 
previously applied gradient. Thus frequency and phase encode the signals in each of 
the directions. These signals are acquired in an array known as K-space. Usually K-
space is filled linearly but it can also be filled with other pattern, for example radial. A 
Fourier transform can then be used to encode the image to the spatial domain and 
producing the MR images. 
The contrast in MR images, distinguishing one tissue type to another depends on the 
intensity of the FID response signal each tissue type exhibits. This will depends on the 
proton density of the tissue, i.e. the higher the proton density, the stronger the FID 
response signal.  
 
2.1.2 T1 and T2 relaxation  
Two other important parameters also influence the image contrast, the longitudinal 
relaxation time, T1, and the transverse relaxation time, T2. Following removal of the 
RF signal, the longitudinal relaxation time measures the time by which the proton 
nuclei spin returns to the magnetisation vector along the direction of the external 
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magnetic field (i.e. the lattice), thus longitudinal relaxation is also referred to as spin-
lattice relaxation. T1 time is defined as a time to reach 63% of the equilibrium 
longitudinal relaxation magnetisation. In contrast, T2 measures the time it takes for 
the transverse component of the magnetisation vector to exponentially decay towards 
its equilibrium value, i.e. spin-spin relaxation. T2 time is defined as the time it takes 
of the magnetic resonance signal to irreversibly decay to 37% of its initial value.  
2.1.3 Cardiac and respiratory motion compensation 
Another important aspect of CMR image processing is the correction for cardiac and 
respiratory motions. Electrocardiographic ECG gating is used to overcome cyclic 
cardiac motion. The timing of MR data collection is synchronised with each cardiac 
cycle. The pulse sequence is triggered according the amplitude of the ECG complex, 
R-wave. This can be achieved prospectively or retrospectively. Prospective gating 
detects the R-wave and starts RF excitation and data acquisition after a certain delay 
time (trigger delay). Figure 2.1 demonstrates the data acquisition window timed to the 
specific phase within the cardiac cycle. 
 




In retrospective cardiac gating, data are continuously acquired throughout the scan 
whilst ECG data are monitored and recorded. During post acquisition image 
reconstruction, data within the windows of interest during the defined cardiac cycles 
are selected and processed. An interpolation process is then performed in order to 
reconstruct the desired number of cardiac phases.  
Respiratory motion correction can be more challenging. Motion-compensation 
strategies such as breath-holding and the use of a respiratory belt and respiratory 
navigator echoes. Patients are asked to hold their breath at the end of expiratory phase 
because the position of the diaphragm is most reproducible due to the fixed end-
expiratory volume. However, for high-resolution imaging, and especially for 3D 
imaging, acquiring all the data in a single breath-hold would be very difficult. Thus 
respiratory belt or respiratory navigator is used. The pneumatic belt fixed to the 
patient’s upper abdomen has pressure sensors that detects the cyclic motion associated 
with respiration and is used to gate the image acquisition to a particular breathing 
phase. RF excitation pulse excites a rectangular slab or pencil beam of spins over a 
reference point within the thorax, usually over the diaphragm. The data is acquired 
along a single dimension (readout direction) in the direction of the movement of the 
diaphragm. MR image data is only acquired when the respiratory phases is within a 
predefined window of interest (again usually at the end-expiratory phase).  
This is however problematic with patients who have significantly impaired LV 
function. They have irregular breathing patterns, resulting in poor respiratory 
navigator efficiency thus prolonging the MR data acquisition time. Figure 2.1 (below) 
illustrates the breathing patterns in a subject with normal LV function and some one 
with poor LV function.  
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Figure 2- 2 Recording of diaphragm positions by the respiratory navigator over the right 
hemi-diaphragm showing an irregular breathing pattern often exhibited in patients with 
severely impaired LV dysfunction. 
 
2.2 Inversion recovery sequences and late gadolinium enhancement for 
myocardial scar imaging 
Inversion recovery (IR) sequences begin with a 180 degree pulse, which inverts the 
magnitisation. After a given time, known as the inversion time (TI), image data 
acquisition is carried out by a 90-degree RF pulse that brings the residual longitudinal 
magnetisation into the x-y or transverse plane where it can be detected by an RF coil. 
Late gadolinium enhancement (LGE) imaging uses a T1 dependent IR technique to 
exploit the differential shortening of T1 by gadolinium contrast agents dependent on 
the different concentrations of gadolinium contrast accumulating in different tissue. 
Gadolinium is a small paramagnetic molecule that preferentially accumulates in the 
tissue extracellular space.  
In normal myocardial tissue, the cells are closely packed with minimal interstitial 
space. This extracellular space is expanded in the presence where normal myocytes 
are replaced by fibrosis. This may be the result of inflammation, infarction or 
infiltrative pathologies. Furthermore, gadolinium is quickly washed out from the 
capillary circulation, but takes much longer to wash out of the extracellular space (10-
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30 minutes) and therefore sufficient gadolinium will preferentially accumulate in 
these regions.  
By imaging within this window, a TI  is chosen to provide the greatest signal contrast 
between normal myocardium (where net vector magnetisation vector is “zero”, i.e. 
magnetic resonance signal is “nulled” and appears black) and the region with 
expanded extracellular space (as a surrogate measure of myocardial fibrosis). See 
Figure 2.3 below.  
 
 
Figure 2- 3 Relative TI chosen to demonstrate the greatest image contrast difference between 
normal and scarred myocardium (shown in white in the LGE images on the right) from 
myocardial infarction. 
 
2.3 Grey zone  
Tissue death begins at the time of ischaemia with cellular necrosis. This is 
characterised by the rapid loss of cellular homeostasis and plasma membrane rupture. 
Collagen deposition then begins at the site of the MI several days after necrosis begins, 
forming scars.
1
 Infarcted myocardial tissue has limited or no contractile activity and 
leads to impairment of the heart’s functional capacity. Surrounding infarcted tissue is 
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an area that bridges the gap between non-viable and viable healthy myocardial tissue. 
This "peri-infarct" area consisting
 
of an admixture of scar tissues and surviving 
myocytes is defined as the grey zone.  
The standard image analysis technique for grey zone measurement is based on signal 
intensity quantification methods, classifying the grey zone with signal intensity 




Rather than providing a true quantitative assessment of tissue heterogeneity, these 
methods are susceptible to partial volume effects where both healthy and scarred 
tissues are found in a single voxel, especially when the 2D image slices are 8-10mm 
thick.  This may lead to inaccurate quantification. This partial volume effect, a major 
criticism of grey zone characterisation, can potentially be reduced with higher spatial 




2.4 T1 mapping 
The first medical application of magnetic resonance imaging measuring longitudinal 
proton relaxation time, T1, has been used to detect and characterise tumour.
6
 
Myocardial T1 map is a parametric reconstructed image where the signal intensity of 
each pixel represents the T1 longitudinal relaxation time of the corresponding 
myocardial voxel. The voxel-by-voxel T1 estimation is derived from multiple 
samplings along the recovery curve following a specific preparation sequence (Figure 
2.4). It allows true quantitative signal quantification on a standardised scale of image 
voxel to characterise tissue heterogeneity. This eliminates the influence of imprecise 
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inversion time selection, which is needed to null the apparently normal remote 
myocardium with standard delayed enhanced CMR. 
 
Figure 2- 4 Illustration of T1 mapping using Modified Look-Locker Inversion recovery 
imaging (MOLLI) sequence. The final T1 map merges images sampled from eleven different 
inversion times (TI). T1 value is determined by fitting a 3-parameter exponential model to the 
measured data on a voxel-by-voxel basis. 
 
There are many ways of assessing T1. Two methods, based on the standard Look-
Locker method, have largely been adopted and validated for T1 mapping in the 
literature.
7,8
 The Modified Look-Locker Inversion recovery sequence (MOLLI), 
proposed by Messroghli et al., merges images sampled from eleven different 
inversion times (TI) from three consecutive inversion-recovery (IR) experiments into 
one data set in a 17-heartbeat breath-hold; whereas Shortened Modified Look-Locker 
Inversion recovery (ShMOLLI), proposed by  Piechnik et al., samples from seven 
different TIs in a 9-heartbeat breath-hold.  Both methods have been readily applied in 
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T1 mapping data acquisition in patients with a variety of cardiac pathologies. 
However, both methods are susceptible to underestimation of the true T1 values. 
Especially at high T1 values, MOLLI demonstrated a greater dependence on heart rate 
requiring adjustment whereas ShMOLLI required only an empirical adjustment.
7-9
 
Myocardial fibrosis detection by delayed contrast enhancement CMR sequence is 
dependent on a greater distribution volume and slower wash-out of contrast agents 
within tissues of greater extracellular space. The delayed contrast-enhanced CMR 
pulse sequence has been the gold standard in detecting regional fibrosis. An important 
drawback of the method is the need for manual selection of IR time to generate an 
image with signal contrasts between the fibrotic region and apparently non-fibrotic 
region. Thus, delayed-enhancement imaging is good at differentiating between 
“normal” and diseased myocardium but less good at looking diffuse processes that 
affect the myocardium in a more homogeneous way. T1 mapping by assessing the 
voxel signal intensity on a standardised scale rather than an arbitrary scale does not 
depend on a “normal” reference and therefore has the advantage of detecting diffuse 
fibrosis.  
In addition to the type of acquisition sequence, heart rate and scanner field strength, 
the post-contrast T1 value in T1 mapping measurements is also largely dependent on 
the properties of the gadolinium contrast agents, the dose of contrast, the time delay of 
the T1 mapping after contrast injection, the haematocrit level which affects the 
partition coefficient of the gadolinium contrast agent, the contrast kinetics between 
regions of fibrosis and normal myocardium and the contrast wash-out rate which is 
also influenced by the renal clearance rate. Myocardial contrast volume of distribution 
(VD(m)) or extracellular volume (ECV) quantification has been therefore proposed as 
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a measure of myocardial fibrosis in order to circumvent some of these confounding 
factors related to standalone post-contrast T1 measurement.  
ECV is estimated from the concentration of extracellular contrast agent such as 
gadolinium in the myocardium relative to the blood in a dynamic steady sate.  
ECV = (1 – haematocrit) x  ((1/Post-contrast T1myocardium – 1/Pre-contrast T1myocardium)/ (1/Post-contrast 
T1blood – 1/Pre-contrast T1blood)) 
The formula holds true when the extracellular contrast concentration in the blood and 
the myocardium reaches equilibrium.  
Kehr et al. demonstrated a correlation between ECV and collagen volume fraction 
(CVF) in human myocardium in vitro.
10
 Using a bolus injection followed by a slow 
infusion of contrast protocol to ensure a steady contrast equilibrium when post-
contrast T1 is measured, Flett et al. has demonstrated a close correlation between 
ECV and CVF measured on histological samples indicating diffuse fibrosis from a 
group of patients with either aortic stenosis or hypertrophic cardiomyopathy (HCM).
11
 
There is an on going debate whether, instead of infusion, a bolus injection of contrast 
can achieve a steady state between the intravascular compartment and the myocardial 
interstitial compartment. A single bolus injection would make the CMR protocol 
simpler and easier to integrate into daily clinical practice. Schelbert et al. 
demonstrated that there is no significant difference between the measured ECV 12-50 
minutes after a bolus injection of contrast compared with an infusion protocol in 10 
volunteers with an age range between 20 and 81.
12
 However, Kawel et al. 
demonstrated that serial measurements between 5 and 45 minutes after bolus injection 
of contrast revealed a small but significant increase in measured ECV in a group of 
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younger healthy volunteers, implying that post-contrast T1 values for the estimation 
of ECV should be made at the same intervals post bolus injection in order to improve 
the accuracy of ECV as a biomarker for diffuse fibrosis.
13
 Messroghli et al. 
demonstrated a moderate correlation of ECV, estimated with post-contrast T1 
measured 20 minutes after bolus injection of contrast, with CVF found on cardiac 
histology in a rat model of cardiac diffuse interstitial fibrosis.
14
 
T1 mapping requires a fundamental post-imaging processing which is a voxel-by-
voxel registration between the different T1 images taken at different IR times; in 
addition, in order to generate ECV maps and analysis, further registration is required 
to match the pre- and post-contrast T1 maps. In its clinical application, we are likely 
to encounter image motions due to body movement given the significant time lapse 
between the pre- and post-contrast T1 maps acquisition (typically 15-30 minutes 
apart), respiratory motion artefact due to inadequate breath-hold as well as cardiac 
motion due to arrhythmia and heart rate variability. Xue et al. has described and 
validated a method that is non-rigid, fully automated and integrated to the image 
acquisition and processing of T1 mapping.
15
 Incorporating this method, Kellman et al. 
has devised a workflow that integrates the motion correction and co-registration of 
breath-holds to improve the accuracy of ECV mapping/calculation, which make its 
translation to clinical application feasible.
16
 They correlated the ECV on a continuous 
scale with the severity of fibrosis in a variety of disease pathologies that included 







2.5 Relevance of myocardial scar to ventricular arrhythmia  
The mixture of electrically conducting (viable) and non-conducting (scarred) tissue 
can lead to the formation of a re-entrant circuit and provide the substrate for VT.
5,17
 
Animal studies have shown that electrical remodelling occurs in the infarct border 
zone (the grey zone), leading to slow conduction within the myocardium and 
promoting re-entrant VT.
18,19
 Pathological studies in humans have also shown that 
small patchy scars from infarcts might facilitate the development of complex 3-
dimensional re-entry circuits.
20
 Histological examination of myocardial specimens 
from patients with chronic MI and medically refractory VT has revealed isolated 
bundles of surviving myocytes interwoven with strands of fibrous tissue at the 
apparent arrhythmic focus. These data implicate a heterogeneous zone between the 
scar and the viable tissue i.e. the grey zone, in the pathogenesis of ventricular 
arrhythmias by providing a substrate for development of re-entrant VT. 
The above evidence lends support to approaches for identifying the grey zone as a 
“potentially arrhythmic heterogeneous zone of viable and non-viable myocardium”. 
CMR imaging allows assessment of the grey zone by quantifying the extent of infarct 
tissue heterogeneity.
21
 Importantly, clinical studies have demonstrated a correlation 
between the grey zone size characterised by CMR and clinical outcome data including 
mortality, ventricular arrhythmia inducibility and appropriate ICD discharge.
2-4
 These 
studies support the notion that MRI characterisation of the grey zone can provide 
unique and valuable information which can be used as a prognostic predictor for VT 
and sudden cardiac death incremental to that offered by current selection criteria for 
ICD therapy. Clinical electrophysiology studies have found that fractionated and 
isolated electrograms are more commonly seen in this heterogeneous grey zone which 
correlates to the propensity for VT.
22,23
 Varying degree of the grey zone size may 
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explain why some patients with myocardial infarction are more prone to VT than the 
others despite similar sized infarcts.
24
 Indeed, areas of grey zone appear to represent 
critical components of the re-entrant VT circuit and have been targeted during VT 
ablation with successful long-term outcomes.
25
 
Currently left ventricular ejection fraction (LVEF) is used as the main clinical criteria 
in deciding ICD implantation for primary prevention of sudden cardiac death in post-
MI patients. This is based on data from the Multicentre Automated Defibrillator 
Implantation Trial (MADIT II) and Sudden Cardiac Death in Heart Failure Trial 
(SCD-HeFT) which demonstrated that implantable cardioverter-defibrillator (ICD) 
reduced mortality rates in patients with evidence of ischaemic heart disease and 
reduced LVEF <30%, and NYHA class I and LVEF < 35% and NYHA class II or III, 
respectively.
26,27
 Post hoc analysis of the MADIT II study population showed that 
only 35% of the patients who received an ICD developed ventricular arrhythmia 
requiring ICD therapy during a 3-year follow up.
28
 In 2004, the number of ICDs 
(including ICDs combined with cardiac resynchronisation pacemakers) per million 
capita was approximately 100 in Western Europe compared with 550 in the USA.
29
 
MAVERIC registry study estimated that UK ICD implant rate would rise to at 18 per 
million of the population, costing the National Health Service £24.1 million per 
annum.
30
  In addition to the financial cost to innovative health care service delivery, 
there is also a human cost. There is significant incidence of inappropriate shocks 
delivered which has an adverse effect on patient’s quality of life.31-33 Hence there is a 
need for more refined selection criteria for ICD implantation. 
Previous studies of grey zone quantification and risks of arrhythmia have only been 
performed in the ischaemic patient population. Non-ischaemic dilated 
cardiomyopathy (NICM) patients have been shown to have prognostic benefit from 
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ICD therapy and account for a significant proportion (20% to 40%) of the ICD/CRT-
D (ICD with cardiac resynchronisation therapy) patient population.
34-36
 Although 
there is evidence supporting ICD implant in these NICM patients for primary and 
secondary prevention of sudden cardiac death, a clear risk stratification method in 
terms of ventricular arrhythmia risk prediction remains problematic. Though LV 
ejection fraction is used for risk stratification for ICD therapy, it is poor at predicting 
appropriate ICD therapy and therapy outcome. Histological studies have demonstrated 
varying degrees of fibrosis in NICM although the significance in terms of predicting 
ventricular arrhythmia is unclear.
37,38
 Assomoll et al have demonstrated that mid-wall 
fibrosis detected with conventional MRI is associated with a poor clinical outcome in 
terms of heart failure hospitalisation and ventricular arrhythmia/sudden cardiac 
death.
39
 Iles et al found that 50% of NICM patients had regional fibrosis detected by 
late gadolinium enhancement and that this was associated with a higher incidence of 
ventricular arrhythmia resulting in appropriate ICD therapy.
40
 Nazarian et al  
demonstrated that fibrosis in NICM detected by DE-MR provided additional 
predictive value over the ejection fraction in VT inducibility.
41
 These data 
demonstrate that regional fibrosis exist in a significant proportion of cardiomyopathy 
with non-ischaemic aetiology and support the notion that tissue heterogeneity 
characterisation may also be an important risk predictor for ventricular arrhythmia in 
patients with NICM.  
 
2.6 Relevance of myocardial scar to cardiac resynchronisation therapy response 
Since the first reported case of cardiac resynchronisation therapy (CRT) two decades 
ago, it has established its effectiveness, improving morbidity and mortality in 
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selective heart failure patients with evidence of dyssynchrony. 
42,43
 Prolonged QRS 
duration (QRSd), usually manifests as left bundle branch block (LBBB) are the 
recommended criteria in patient selection for CRT.
44,45
 However responder rates vary 
between half to two-thirds in reported cohorts, with left ventricular remodeling 
response (LV RR) rate being much lower than clinical response rate. 
46,47
 One 
explanation for this high non-response rate may be the presence of focal and diffuse 
interstitial myocardial fibrosis, which can disrupt the concordance between 
mechanical and electrical dyssynchrony mediated through lines of structural and 
functional block thus attenuating the effect of CRT. 
48-52
 
Heart failure patients with ischemic etiology tend to benefit less from CRT than 
patients with DCM.
53-55
 Prior studies have demonstrated that total scar burden 
(without differentiating between scar core and grey zone) is lower in CRT responders 
defined by clinical functional status rather than LV volumetric response.
50,56
 Long-
term prognosis after CRT has been shown to correlate with LV RR rather than clinical 
symptomatic response.
57
 Prior studies that assessed LV volumetric responses to CRT 
have focused on scar burden at the LV lead pacing site.
49,51,58
 
The presence of diffuse fibrosis is overlooked in routine clinical CMR studies due to 
the inherent limitation of conventional LGE CMR technique. It requires the nulling of 
apparently “normal” myocardium in order to provide a contrast in image signal 
intensities to highlight the region of focal scar represented by gadolinium 
enhancement. The degree of transmurality in LGE has been shown to correlate with 
contractile improvement after revascularisation suggesting that the greater proportion 
of surviving myocardium the greater the capacity for the myocardium to recover.
59
 





There is no clear consensus on the definition of a positive response to CRT. Prior 
studies have used different definitions that derived from clinical symptoms parameters, 
echocardiographic parameters and composite of the two.
62
 Furthermore, the follow-up 
duration following CRT at which the response is measured also varied greatly. It is 
generally considered that the response rate measured by clinical criteria is higher than 
that measured by echocardiographic parameters. It is not surprising that there is little 
correlation between the two. 
62
 Echocardiographic parameters are susceptible to 
operator dependence. Whilst MLHFQ scores provide additional validity to the 
subjective NHYA class scores, a poor correlation has been found between NYHA 
class and some objective measures of cardiac function, such as peak oxygen 
consumption and 6-minute walk.
63
 
The lack of universal definition of response to CRT is also a reflection of uncertainty 
regarding the effects of CRT.   
QRS duration being a primary selection parameter for CRT yet is not used as a 
measure of response to CRT. It is mainly because it has been shown to be a relatively 
specific but not sensitive predictor of CRT response and there is a lack of 
standardisation in measuring QRS duration in CRT patients. 
64
. A consistent feature of 
electrophysiological remodelling in heart failure is ventricular action potential 
duration (APD) prolongation.
65
  However, the effect of reverse remodelling on APD 
during cardiac resynchronisation therapy (CRT) has not been determined in these 
patients.  
Recently, the MultiCenter Automatic Defibrillator Implantation Trial with Cardiac 
Resynchronisation Therapy (MADIT-CRT) trial, the Resynchronisation Reverse 
Remodelling in Systolic Left Ventricular Dysfunction (REVERSE) trial and the 
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Resychronisation-Defribrillation for Ambulatory Heart Failure Trial (RAFT) trial 
have demonstrated that CRT provided an incremental overall survival benefit to ICD 
therapy alone in heart failure patients.
66-68
 However, earlier studies showed that the 
incidence of arrhythmia and sudden death continues to be high despite CRT inferring 
the possible need for additional protection from implantable cardioverter defibrillator  
(ICD).
36,43
    
These observations highlighted a need to further elucidate the effect of CRT on 
electrophysiology. Given the potential impact of regional or diffuse fibrosis that may 
impact on the electrical conduction through lines of structure or functional block 
during CRT pacing, quantitative scar assessment using CMR may add predictive 





Chapter 3 General Methods 
 
Where methods are applicable to more than one of the following chapters, the details 
are given below to avoid repetition. However, the individual study protocols are 
described within the respective chapters.  
 
3.1 Ethics  
Local institute ethics committee (Guy’s and St Thomas’ Hospital) approved the 
studies involving human subjects. All study participants gave written informed 
consent prior to participation.  
 
3.2 Patient selection 
ICD patients 
All patients undergoing ICD implantation for primary and secondary preventions as 
per guidelines (ESC guideline 2012) at local institution between May 2011 to January 
2013 to participate.
69
 Ischemic etiology was defined as the presence of any epicardial 
coronary artery stenosis with more than 75% or any history of myocardial infarction 
or coronary revascularisation with a scar pattern consistent with myocardial infarction 
on CMR. Non-ischemic etiology was defined as the absence of the above criteria. 
Patients undergoing implantation of ICD for catecholaminergic VT, Brugada 





Patients undergoing CRT pre-assessment clinic in local institution and fulfilling Class 
I and II recommendation for CRT were prospectively invited to participate in the 




Heart failure with New York Heart Association (NYHA) Class III-IV symptoms 
 Patients should be on optimal medical therapy 
 Have significantly impaired LV function (ejection fraction <35%) 
 QRS duration >150ms on ECG or QRS duration between120 and 149ms with 
evidence of dyssynchrony on echocardiography. 
 Age > 18 years 
Exclusion criteria 
 Contra-indication to CMR scan 
 Significant renal impairment (eGFR<30ml/min/1.73m2) 
 
3.3 Cardiac magnetic resonance imaging 
3.3.1 CMR protocol 
CMR imaging was performed using a 1.5T scanner with a 32–channel coil (Philips 
Healthcare, Best, Netherlands). After standardised patient-specific planning, a stack 
of breath-hold short axis balanced steady-state free precession cine slices covering the 
LV was acquired for quantification of volume, mass and EF. Following a Look-
Locker scan to find the optimum inversion time, a stack of short axis slices of an 
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inversion-recovery gradient-echo sequence (repetition time/echo time = 3.4/2.0ms, 
flip angle = 25 degrees, voxel size = 1.8x1.8x8mm, ECG triggered to end-diastole 
with a patient-adapted pre-pulse delay) were acquired 10-15 minutes post contrast 
injection (gadobutrol, 0.2mmol/kg body weight) for CE-CMR scar assessment. A 
single mid-ventricular short axis slice (in the same geometry as the mid CE-CMR 
slice) using modified Look-Locker inversion recovery sequence (MOLLI) with 11 
phases (3+3+5) was acquired for T1 mapping (repetition time/echo time = 3.3/1.5ms, 
a flip angle = 50 degrees, voxel size = 1.8x1.8x8mm, with heart rate adapted trigger 
delay, and adiabatic pre-pulse to achieve a complete inversion) both before and after 
the administration of contrast. 
3.3.2 Image analysis 
Ventricular volumes, function and mass were analyzed using dedicated software 
(ViewForum, Philips Healthcare, Best, Netherland) and were indexed to body surface 
area. LGE-CMR images were visually assessed by two independent CMR experts 
blinded to the study outcome. In case of discrepancy, the data were jointly reviewed 
by these experts to reach a consensus. Quantitative analysis of LGE was performed 
using CMR42 (Circle Cardiovascular Imaging Inc., Calgary, Canada). The extent of 
LGE was quantified using both the 2-standard deviation method (Scar
_2sd
, defined as 





defined as the region with SI above the 50% of 
the maximal SI of the enhanced area). The extent of grey zone was quantified using 
the Greyzone
_2sd-FWHM





), and the Greyzone
_2sd-3sd 
method (defined as the region with SI between 2 
and 3 SD above the remote reference myocardium). Each of these indices was 
expressed as a percentage of the LV mass (%LV).  
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T1 relaxation maps were processed using a customised software plugin, incorporating 
motion correction with open source software (Osirix environment, Pixmeo, Geneva, 
Switzerland). Motion correction was performed by applying a multi-resolution 
BSpline deformable registration, as implemented in the Insight Toolkit.
71
 Due to the 
potential susceptibility of high T1 values to the effects of heart rate during image 
acquisition, we performed linear regression analysis of the measured native non-
contrast T1 (T1
_native
) values on heart rate and applied heart rate correction using a 
function of the mean heart rate of our study population to the non-contrast T1 values 
as previously described.
9
 The T1 associated derivative, extracellular volume index 




A region of interest (ROI) in the septum was chosen for estimation of non-contrast T1 
(T1
_native
), post-contrast T1 (T1
_contrast
) and ECV, as previously described.
72
 Care was 
taken to avoid the endocardium/blood pool interface. If regional enhancement was 
seen in the septum on the LGE image a septal ROI was chosen adjacent to the 
enhanced region for T1 mapping analysis. The geometry of the mid-ventricular T1 




Transthoracic echocardiography was performed using a GE Vivid 7 scanner (General 
Electric-Vingmed, Milwaukee, WI, USA) to acquire standard 2D images of left 
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ventricular (LV) dimensions and ejection fractions (EF) during breath-hold in 
standard apical 2-chamber and 4-chamber views. LVEF and dimensions were 
measured using the 2-dimentional modified biplane Simpson’s method. Analysis was 
done on EchoPac 6.0.1 (General Electric-Vingmed). 
Echocardiographic evidence of inter- and/or intra-ventricular dyssynchrony was 
deemed present if any of the following criteria were fulfilled:
73
 
 LV pre-ejection period  > 140ms 
 Interventricular mechanical delay (LV minus RV pre-ejection period) > 40ms 
(Pulsed wave Doppler was used with the measurement made from the LV outflow 
tract (LVOT) in an apical 5-chamber view. The RV outflow tract (RVOT) was viewed 
in a parasternal short axis view. The pre-ejection period was defined as the time from 
the QRS onset on the ECG to the onset of flow.  
 Septal to lateral wall motion delay (by tissue Doppler imaging, TDI) > 60ms 
(The difference between septal to lateral peak velocity within the aortic valve opening 
and closing times) 
 
3.5 Activation recovery interval measurement 
LV unipolar electrogram (UEG) signal was made via the device programmer (Merlin 
Patient Care System, Model 3650, St Jude Medical). In order to eliminate the 
influence of variable heart rate on ARI. UEG recordings were made after at least 2 
minutes of pacing at a constant rate of 10 beats above the patient’s intrinsic heart rate. 
The 30 second LV UEG recordings were analysed off-line using a software script 
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developed by our group within the MATLAB environment (MathWorks, 
Massachusetts, USA) to derive the activation recovery interval (ARI). 
74
 ARIs were 
measured using conventional validated criteria from dv/dt min of the QRS of the UEG 
to dv/dt max of the local T wave.
75-79
An example showing the measurement and the 
stability of recordings is illustrated in Figure 3.1. 
 
Figure 3- 1 An example of LV unipolar electrogram raw data recording demonstrating 
activation recovery interval (ARI). 
 
3.6 Statistics 
The baseline characteristics of the participants were studied in detail; continuous 
variables are reported as mean ± sd and categorical variables as number (and 
percentage) of participants. Between-group comparisons were made using the t-test 
for normally distributed continuous variables, otherwise the Mann-Whitney U or 
Wilcoxon tests were used, or the Chi-squared test (for categorical variables), with a 
two-tailed p-value < 0.05 indicating statistically significant differences between 
groups.  
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(Where applicable) The first episode of appropriate ICD therapy or sustained VT was 
considered as the event of interest for quantifying various associations.  
Kaplan-Meier survival curves were plotted to study the cumulative event rates 
between groups of participant, with the log-rank test providing further evidence 
regarding any significant differences between them.  
The univariate association between pre-specified variables of interest and the primary 
endpoint was examined using Cox proportional hazards regression models. For 
multivariable-adjusted analyses, a forward selection process using variables 
significantly associated with the outcome of interest in univariate analyses (at p 




Chapter 4 Exploring T1 mapping for scar assessment 
 
The clinical application of T1 mapping in myocardial tissue characterisation was in its 
infancy when this exploratory study was conducted. The aim of the study is to explore 
its application as a useful clinical tool for myocardial scar characterisation. Given the 
established experience with the use of LGE CMR for detection of regional myocardial 
scar, the study focused on comparing the quantitative assessment of regional scar, in 
particular the grey zone by T1 mapping with that by LGE CMR in the ischemic 
cohort population.  
 
4.1 Abstract 
Background: In ischaemic cardiomyopathy, grey zone is a strong predictor of 
ventricular arrhythmia. T1 relaxation-time mapping allows quantitative myocardium 
characterisation. We explored whether T1 measurements using images generated by a 
modified Look-Locker inversion-recovery (MOLLI) sequence can differentiate grey 
zone from healthy myocardium and scar core.  
Methods: Twenty-one patients with a history of myocardial infarction underwent scar 
assessment with standard inversion-recovery gradient-echo sequence post-contrast 
(gadobutrol, 0.2mmol/kg) on a 1.5T scanner (Philips, Netherlands). Signal-intensity-
based tissue heterogeneity assessment identified regions of remote healthy 
myocardium, scar core, and grey zone. These corresponding regions-of-interest were 
identified on the pre- and 20-minutes post-contrast MOLLI images. T1, R1 (1/T1) and 
relative ΔR1 (r ΔR1) values (Pre-contrast R1 – Post-contrast R1/ Pre-contrast R1) 
values for each region were analyzed.  
 49 
Results: The mean T1 relaxation-times or R1 values for remote healthy myocardium, 
grey zone and scar core  (n=63, respectively) were different on the pre- (p<0.001) and 
the post-contrast T1 maps (p<0.001). ROC analysis showed that r ΔR1 provided the 
best distinction between remote healthy myocardium, grey zone and scar core in 
comparison to either pre- or post-contrast R1 alone.  Pre-contrast R1 is just as good at 
distinguishing the remote healthy myocardium from scar core and grey zone, but not 
as good at distinguishing the grey zone from scar core.  
Conclusion: Using measurements derived from T1 mapping, pre-contrast R1 value 
can reliably distinguish healthy myocardium from scar and grey zone. However, rΔR1 
provides a better distinction for grey zone from scar core and healthy myocardium 
than either pre- or post-contrast R1 alone.  
Key words: grey zone, T1 mapping, late gadolinium enhancement 
 
4.2 Introduction 
Late gadolinium enhanced (LGE) inversion-recovery imaging in cardiac magnetic 
resonance (CMR) imaging is the standard approach to visualise regional myocardial 
fibrosis.
80,81
 Studies have shown that the presence of regional fibrosis by LGE is an 
important prognostic indicator in both patients with ischaemic cardiomyopathy and 
patients with non-ischaemic cardiomyopathy.
39,59,82,83
 With improvements in spatial 
resolution and contrast-to-noise ratio, it is now possible to perform a more detailed 
characterisation of the degree of scarring in the infarct border zone, where there is an 
admixture of fibrosis and surviving myocytes.
21
 This area is referred to as the grey 
zone, because of the intermediate signal intensity (SI) between the hyper-enhanced 
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scar core and the nulled non-infarct myocardium seen on the LGE images. Studies 
based on semi-quantitative SI-based scar segmentation methods have demonstrated 
that the grey zone is an independent prognostic indicator of mortality and ventricular 
arrhythmia in post-infarct patients.
2-4
  
Despite the wide adoption of the standard LGE-CMR imaging for regional 
myocardial fibrosis assessment, it is not without limitations such as inaccurate 
inversion-time selection and therefore suppression of diffuse fibrosis.  An alternative 
method of characterizing the myocardium by assessing the tissue longitudinal 
relaxation time, T1 mapping, would eliminate the influence of imprecise inversion 
time selection during image acquisition and allow true quantitative signal 
quantification on a standardised scale of each image voxel to characterise tissue 
heterogeneity. One of the best described methods of generating T1 map of the 
myocardium is the modified Look-Locker inversion-recovery (MOLLI) sequence, 
which has been optimised and validated in patients with ischaemic 
cardiomyopathy.
7,9,84
 MOLLI provides high resolution T1 maps within a single breath-
hold.  
We hypothesised that the change in longitudinal relaxation times derived from pre- 
and post-contrast T1 measurements acquired using MOLLI sequence would be best at 
characterizing the myocardium and differentiating between regions of healthy 





(See Chapter 3.2 for General patient selection criteria) 
Patients with a known history of ischaemic cardiomyopathy and under assessment for 
implantable cardioverter defibrillator (ICD) for primary or secondary preventions 
were invited to participate in the study prior to their routine clinical CMR. Additional 
inclusion criteria included a history of myocardial infarction(s) at least > 3 months 
prior to CMR 
Cardiovascular magnetic resonance imaging 
(See Chapter 3.3.1 for General CMR methods protocol) 
For left ventricular (LV) scar assessment, LGE-CMR was performed by full short axis 
coverage of LV 10-15 minutes post contrast injection
85
 (gadobutrol, 0.2mmol/kg body 
weight).  
Breath-hold MOLLI sequence was used for T1 mapping.
84
 Three separate gapless 
short-axis slices of MOLLI T1 mapping images were acquired pre- and 20 minutes 
post-contrast in the same corresponding three mid-ventricular short-axis slices as the 
LGE images. 
In order to maintain reasonable scanning duration, functional images were routinely 
acquired post contrast injection and we were limited to three MOLLI image slices per 
patient. Rather than having different MOLLI slices geometries for different patients, 
we decided to standardise the scanning protocol to three mid-ventricular slices. This 
allowed direct comparison with LGE scar images in the same slice geometry and 
maximised the likelihood of image acquisition of scar and grey zone, as in our 
experience nearly all patients with ischaemic cardiomyopathy have scars that extends 
to the mid-ventricular levels as demonstrated by our cohort.  
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Data analysis 
Tissue sub-types selection  
For the study, three mid-ventricular LGE short axis images with regional scar 
coverage were cross-referenced with the corresponding T1 mapping images of the 
same geometry and analyzed using open source software OsiriX (Pixmeo, Geneva, 
Switzerland). Signal intensity (SI) based tissue heterogeneity assessment on the LGE 
images were analyzed with additional dedicated software plug-in for OsiriX as 
previously described.
86
 On each LGE short-axis slice, we manually delineated the LV 
endocardial, epicardial borders and the border of a region of non-enhanced 
myocardium which was defined as the region of remote healthy myocardium. The 
maximum SI within the whole myocardium was automatically determined.  
Using the full-width-half maximum method all pixels with SI values up to half of the 
maximum SI were automatically characterised as scar core.
87
 Pixels with SI higher 
than 2 standard-deviation of the SI of the manually selected remote healthy 
myocardium but below the SI of the scar core were automatically assigned as being 
grey zone. The manually identified endocardial and epicardial borders and the three 
areas of region-of-interest (ROI), i.e. manually selected remote healthy myocardium, 
automatically segmented grey zone and scar core, were transferred to the 
corresponding pre- and post-contrast T1 mapping images, as illustrated in Figure 1.  
Motion correction 
Though selective acquisitions at fixed points of the cardiac cycle in end-diastole and 
single breath holding would have largely suppressed the influence of cardiac and 
respiratory motion. The MOLLI sequence required eleven images to obtain the final 
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T1 map which led to a relatively long breath-hold and therefore sometimes undesired 
residual respiratory motion. This would have resulted inaccurate T1 value estimation 
for the ROI. We therefore applied manual motion correction using the endocardial 
and epicardial borders to adjust for in-plane respiratory motion between the eleven 
images used to construct the final T1 map.  
T1 relaxation time analysis 
The T1 values for each of the three ROIs were calculated from the eleven pre- and 
post-contrast images by fitting a three parameter exponential model to the average 
voxel value of the measured data from each ROI, i.e. “ROI-by-ROI” method, and 
applying Look-Locker correction as previously described.
88
 Due to the potential 
susceptibility of high T1 values to the influence of heart rate during image acquisition, 
we also performed linear regression analysis on the measured pre-contrast T1 values 
against heart rate and applied heart rate correction using a function of the mean heart 





Figure 4- 1 Transposition of region of interest (ROI) from late-gadolinium-enhanced (LGE) 
image to modified Look-Locker inversion-recovery image for T1 longitudinal relaxation time 
analysis. 
ROI = region of interest; MOLLI = modified Look-Locker inversion-recovery; LGE = late 
gadolinium enhancement; SD = standard deviation; FWHM = full-width-half-maximum. 
 
The final T1 value for each region of interest (ROI) is generated from curve fitting 
from the mean voxel data points gathered from eleven images, each acquired at 
different inversion-recovery time, with the MOLLI sequence. The error bars 
demonstrate the variance of voxel data points within selected ROI. 
 
R1 and relative ΔR1 (rΔR1) 
In addition, R1 values (
1
/T1) and rΔR1 (
(Pre-contrast R1 – post-contrast R1)
/ pre-contrast R1) for the 
respective ROI were also calculated.  
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T1 longitudinal relaxation times were expressed as R1 values, to allow a direct 
comparison of the post-contrast R1 values (R1,post) with native pre-contrast R1 values 
(R1,pre). The relationship between R1,pre, R1,post and the contrast agent concentration C 
and its relaxivity r1 is expressed by the function:
18 
 
R1,post  = R1,pre + C 
.
 r1 
The proposed quantity rΔR1 takes into account the difference between R1post and R1pre 
which is then normalised against R1pre: 
rΔR1  =  ΔR1 /R1pre = (R1,post – R1,pre) / R1pre  =  (C 
.
 r1) / R1,pre 
Expressing the relative change in tissue T1 longitudinal relaxation time pre- and post-
contrast as rΔR1 takes advantage of rΔR1 being linearly proportional to the contrast 
agent concentration and its relaxivity constant.  rΔR1 is inversely proportional to pre-
contrast R1 as shown in the above equation, thus any difference in pre-contrast T1 or 
R1 between different ROI would be taken into account; and any changes in T1 or R1 
values post contrast would potentially be magnified allowing greater separation of 
rΔR1 between different ROI on a quantitative scale. 
4.3.1 Statistics 
(See Chapter 3.6 for General statistical methods) 
Receiver-operating characteristics (ROC) analysis was used to identify the cut-off 
values with the best comparable sensitivity and specificity to discriminate different 
ROI. The predictive ability of pre-contrast R1, post-contrast R1 and rΔR1 to identify 
each ROI was summarised using the area under curve (AUC). The best cut-off values 
derived from the ROC curve analysis for the distinction of remote healthy 
myocardium from scar and grey zone and that for the distinction of scar core from 
grey zone and healthy myocardium were then used as threshold values for the grey 
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zone. These different threshold values were retrospectively tested on the observed 
data to assess their predictability of the grey zone. The AUCs for pre-contrast R1, 
post-contrast R1 and rΔR1 for each ROI (remote healthy myocardium, grey zone and 
scar core) were compared. Where a significant difference in the AUCs was detected 
between the three measures, pairwise comparisons were conducted using a Bonferroni 
correction (i.e. p<0.05/3=0.016 were considered statistically significant; the 
correction adjusts for multiple comparisons). 
Analysis of the variables was conducted on a per-short axis slice basis. To assess the 
impact of including three short axis slices from each patient as independent data 
points on the final results estimation, a linear mixed effects model was used to adjust 
for within patient correlation and data analysis repeated using randomly selected 
single slice from each patients and compared with the final results. All statistics were 





Twenty-one patients were included in the study (nineteen males). The mean age was 
61 ± 16 years. The baseline patient characteristics are outlined in Table 1. All patients 




Characteristics Patient, n = 21 (100%) 
Male 19 (90%) 
Hypertension 3 (14%) 
Diabetes 2 (10%) 
Renal impairment (estimated glomerular 




Indication for Implantable defibrillator therapy Primary prevention: 16 (76%) 
Secondary prevention: 5 (24%) 
Duration of last infarct to CMR, months 40±29 
Left ventricular ejection fraction, % 35±10 
Left ventricular end-diastolic volume, ml 232±49 
Number of segments with evidence of late 
gadolinium enhancement / patient 
7±3 
Number of patient with evidence of late 
gadolinium enhancement at mid-ventricular 
level 
21 (100%) 
Culprit coronary artery territory of infarct LAD: 11 (52%) 
Cx: 5 (24%) 
RCA: 13 (61%) 
Scar transmurality at mid-ventricular levels:  
(per total scarred segment analyzed, n=180)  
<25%: 0 (0%)            25-50%: 15 
(8%)  
50-75%: 51(28%)     >75%: 114 
(64%) 
 
Table 4- 1 Baseline patient clinical characteristics 
Data are expressed as n ± standard deviation, (%); LAD: left anterior descending artery, Cx: 
circumflex artery, RCA: right coronary artery.  Left ventricular segments are classified 





All of the three mid-ventricular LGE scar images and the corresponding pre-contrast, 
20 minutes post-contrast T1 mapping images contained scar were suitable for ROI 
segmentation. The mean number of LV segments (American Heart Association 16-
segment model) with enhancement on the LGE images were 7±3 per patient, with 
64% of the enhanced segments having >75% transmural scar at the mid- ventricular 
level.  T1 values, R1 values and respective rΔR1 from a total of 189 ROIs identified 
from the LGE images; remote healthy myocardium (n=63), grey zone (n=63) and scar 
core (n=63); were analyzed.  
To account for the impact of including three short axis slices from each patient as 
independent data points on the final results estimation, a linear mixed effects model 
was used to compare the values between remote health myocardium, grey zone and 
scar core to adjust for within patient correlation. The mean T1 relaxation times and R1 
values for each region, healthy myocardium, grey zone and scar core, were 











Grey zone  Scar core P 
values 




971 ± 44 ms 
1.03±0.05 
1067 ± 57 ms 
0.94±0.05  








419 ± 51 ms 
2.42±0.28 
348 ± 36 ms  
2.90±0.30 




rΔR1 1.35 ± 0.30 2.10 ± 0.38 3.68 ± 0.79 < 0.001 
 
Table 4- 2 Pre-contrast T1 relaxation time, post-contrast T1 relaxation time, R1 values (1/T1) 
and the relative changes expressed by rΔR1 (
R1,pre - R1,post
/R1,pre) for regions of remote healthy 
myocardium, grey zone and scar core; n=63, respectively. 
Data are expressed as mean ± standard deviation. 
  
At 20 minutes post-contrast, the T1 values were significantly reduced in all regions 
with the greatest reduction seen in scar core. The distribution of R1 and rΔR1 for each 
region are plotted in Figure 4-2. 
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Figure 4- 2 Box plot demonstration of the distribution of pre-contrast R1 (1/T1 relaxation time), post-contrast R1 and rΔR1 (R1,pre - R1,post/R1,pre) for 
each region of interest: remote healthy (green), grey zone (grey) and scar core (red). 
Box: median, interquartile ranges. Wiskers: minimum, maximum ranges. Different R1 scales are used on the pre- and post-contrasts graphs because of the 
effect of gadolinium on R1 
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ROC curve analysis, Figure 3, showed that the native pre-contrast R1 (AUC: 0.96; 
95% Confidence interval (CI): 0.93-0.97) and rΔR1 (AUC: 0.97; 95% CI: 0.95-0.99) 
both provided a better distinction for healthy myocardium from scar core and grey 
zone than post-contrast R1 value (AUC:0.94; 95% CI:0.91-9.97); rΔR1 (AUC: 0.99; 
95% CI: 0.98-1.00) and post-contrast R1 value (AUC: 0.98; 95% CI: 0.96-0.99) 
provided a better distinction for scar core from grey zone and healthy myocardium 
than pre-contrast R1 value (AUC: 0.92; 95% CI: 0.88-0.96).  rΔR1 (AUC: 0.98; 95% 
CI: 0.95-1.00) provided the best distinction for grey zone from scar core, with post-
contrast R1 also providing good differentiation (AUC: 0.95; 95% CI: 0.92-0.99), and 




Figure 4- 3 ROC curve analysis of remote healthy myocardium, scar core and grey zone assessment by pre-contrast R1 (blue), post-contrast R1 (red) and 
rΔR1 (green); n = 63, respectively. 
a: differentiation for remote healthy myocardium from scar core and grey zone; b: differentiation for scar core from grey zone and healthy myocardium; c: 
differentiation for grey zone from scar core. 
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A cut-off of pre-contrast R1 x10
3
 value of ≥0.986 provided a good distinction for 
healthy myocardium from scar core and grey zone with a sensitivity of 0.92 and 
specificity of 0.90 as did a cut-off rΔR1 value of ≤1.78 with a sensitivity of 0.95 and 
specificity of 0.89; a rΔR1 value of ≥2.68 provided the best distinction for the scar 
core from grey zone and healthy myocardium with a sensitivity of 0.92 and specificity 
0.99. Using cut-off values for scar core and remote healthy myocardium derived from 
the ROC analysis as threshold values for grey zone, a rΔR1 value between 1.78 and 
2.68 provided the best prediction for the grey zone with a sensitivity of 0.75 and 

























(sens 0.92; spec 0.90) 
(ppv 0.83; npv0.96) 
(diag. accuracy 91%) 
≤2677 
(sens 0.81; spec 0.91) 
(ppv 0.82; npv 0.91) 
(diag. accuracy 88%) 
≤1.78 
(sens 0.95; spec 0.89) 
(ppv 0.80; npv 0.97) 
(diag. accuracy 90%) 
Scar core ≤923 
(sens 0.87; spec 0.80) 
(ppv 0.69; npv 0.93) 
(diag. accuracy 83%) 
≥3226 
(sens 0.91; spec 0.94) 
(ppv 0.93; npv 0.95) 
(diag. accuracy 95%) 
≥2.68 
(sens 0.92; spec 0.99) 
(ppv 0.98; npv 0.96) 
(diag. accuracy 97%) 
Grey zone 923 < 986 
(sens 0.46; spec 0.90) 
(ppv 0.71; npv0.77) 
(diag. accuracy 76%) 
2677 < 3226 
(sens 0.78; spec 0.86) 
(ppv 0.73; npv 0.89) 
(diag. accuracy 83%) 
1.78 < 2.68 
(sens 0.75; spec 0.94) 
(ppv 0.85; npv 0.88) 
(diag. accuracy 87%) 
 
Table 4- 3 Prediction of Grey zone using pre-contrast R1, post-contrast R1 and rΔR1 
sens. = sensitivity; spec. = specificity; ppv = positive predictive value; npv =  negative 
predictive value; diag. = diagnostic 
 
For prediction of remote healthy myocardium from scar core and grey zone, the AUC 
of pre-contrast R1 was not significantly different from the AUCs of post-contrast R1 
(p=0.377) and rΔR1 (p=0.459). For prediction of grey zone from scar core, the AUC 
of rΔR1 was significantly larger than the AUC of pre-contrast R1 (p<0.001), but not 
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significantly different from the AUC of post-contrast R1 (p=0.076); the AUC of post-
contrast R1 was also significantly larger than the AUC of pre-contrast R1 (p=0.007). 
Linear regression model analysis suggested within subject correlation may be a 
potential source of bias. To assess the impact of this correlation, data analysis was 
repeated using only one randomly selected image slice from each patient. The pre- 
and post-contrast T1 for each ROI using a randomly selected single slice from each 
patient (see Table 4-4) were in good agreement with the final results shown above 
(see Table 4-2) encompassing all three short axis images from each patient.  






Grey zone  Scar core P 
values 
Pre-contrast T1 969 ± 48 ms 1066 ± 59 ms 1191 ± 107 
ms 
< 0.001 
Post-contrast T1  416 ± 53 ms 350 ± 35 ms  262 ± 36 ms < 0.001 
 
Table 4- 4 T1 values for each ROI derived from a randomly selected single short axis 
slice of MOLLI images from each patient. 
 
Using data derived from randomly selected single slice of short axis images from each 
patient, repeated ROC analysis showed the same numbers for AUCs for remote 
healthy myocardium from scar core and grey zone using pre-contrast R1 (AUC: 0.96, 
95% CI 0.91-1.00); and in prediction for scar core from grey zone and remote healthy 




Our findings revealed that the pre-contrast and post-contrast T1 maps derived from 
MOLLI and more specifically the R1 (
1
/T1) and rΔR1 (
R1,pre - R1,post
/R1,pre) values  can be 
used for characterisation of different myocardial tissue sub-types in patients with 
ischaemic cardiomyopathy. We realise that the “healthy” non-enhancing areas in our 
conventional LGE images are not necessarily normal myocardium. There is some 
suggestions that patients with ischaemic cardiomyopathy may develop interstitial 
fibrosis in the remaining non-infarct region as the LV remodels, although histological 
study has not conclusively demonstrated this.
89,90
 Conventional LGE images would 
have not been able to detect this as this region is nulled. Thus the T1 longitudinal 
relaxation times for the remote “healthy” myocardium should be taken as delineating 
an area which is not scar core or grey zone but not necessarily normal myocardium. 
Further studies in healthy volunteers would be needed to characterise the true T1 
values for healthy myocardium.  
For T1 quantification, motion correction between the multiple images used to build 
the T1 map is crucial to ensure accuracy. We applied manual in-plane motion 
correction to the 11 images for each slice by aligning the endocardial and epicardial 
borders. In addition, we adopted a more robust technique to calculate the ROI T1 
value of by using the mean signal intensity within the ROI using the “ROI-by-ROI” 
method as apposed to the “pixel-by-pixel” method that is less influenced by small 
amount of residual motion between the 11 images needed for T1 mapping. 
We used the term T1 in the introduction, discussion and R1 (
1
/T1) in the methods and 
results, as R1 better represents the relationship between the pre- and post-contrast 
values, with post-contrast R1 being a linear function of contrast concentration.  
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4.5.1 Pre-contrast T1 values 
We observed that the remote non-infarcted myocardium had a mean T1 value that was 
significantly different from the grey zone and scar core. ROC analysis demonstrated 
pre-contrast R1 value was just as good as post-contrast R1 and rΔR1 at distinguishing 
remote nulled myocardium from grey zone and scar seen on LGE images. This lends 
support to the suggestion that “healthy” myocardium could be reliably distinguished 
from abnormal myocardium (either grey zone or scar) without the need for contrast 
enhancement.  
Messsroghli et al. also observed differences between pre-contrast T1 values of 
“healthy” myocardium and areas of late enhancement in both patients with acute and 
chronic myocardial infarction.
7
 They however did not assess the predictive values of 
T1 mapping in identifying the different regions. The T1 values for “healthy” 
myocardium in patients with chronic infarcts from both studies are comparable, 
however the T1 values for scar were lower in the Messroghli’s study than our values 
for scar core. This may be explained by our study’s additional differentiation between 
grey zone and scar core.   
The prevailing hypothesis for the difference in the native T1 values between healthy 
myocardium and scar is that there is an increase in the extracellular matrix volume 
and loss of vasculature within the scar region, whilst healthy myocardium is packed 
with closely adherent parenchymal cells.
91
 In addition, fibrillar type III and type I 
collagens are laid down substituting the loss of parenchymal cells in the scarred 
region.
92
 These long-term histological changes in the infarcted myocardium are the 
likely explanation for the increase in native pre-contrast tissue longitudinal relaxation 
that we see in this study.   
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4.5.2 Post-contrast T1 values 
There was a significant drop in T1 values in all regions in the 20 minutes post-contrast 
scans. Similar to the pre-contrast T1 values, the post-contrast T1 values for the 
different tissue regions were also significantly different. Our post-contrast T1 values 
were lower than those observed by Messroghli et al.
7
 This could be explained by the 
difference in our study protocol where post-contrast T1 values were taken at 20 
minutes post contrast administration rather than 10-15 minutes; and the higher 
concentration of gadolinium (0.2mmol/kg) used in our study.  
Gadobutrol, used in our study, is an extracellular contrast agent. As a result of the 
disappearance of normal parenchymal cellular architecture and decreased capillary 
density within scarred myocardial regions, it preferentially distributes and 
accumulates for longer in the larger extracellular space, resulting in a reduction in the 
T1 relaxation time in these regions.
91,92
 The reduction in T1 values in the scar borders 
zones with a mixture of scar and “healthy” myocardium will be less. Iles et al. have 
demonstrated that T1 values, using images taken with a sequence similar to MOLLI 
fifteen minutes post-contrast, correlated with collagen volume fraction seen from 
biopsy samples in patients with heart failure with mixed aetiology.
93
 Flett et al. have 
also demonstrated that regional myocardial T1 values, taken after a slow infusion of 
contrast agent, correlated strongly with collagen volume fraction from biopsy results 
in patients with severe aortic stenosis.
11
 Both these studies support the potential of 
using post contrast T1 values to quantitatively assess the degree of collagen density 
within different myocardial regions.   
We used LGE as a gold standard in our study as it has been validated in studies 
against histology for differentiating between “healthy” myocardium, scar core and 
infarct border zone i.e. grey zone.
21,87 
We have demonstrated that each of the three 
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regions of “healthy” myocardium, grey zone and scar core with varying degrees of 
signal intensity seen in LGE have distinct post contrast T1 and therefore R1 values, 
presumably due to different levels of collagen volume fraction. We have also showed 
that post-contrast R1 is much better than pre-contrast R1 in distinguishing between 
grey zone and scar core with a greater degree of separation in post-contrast R1 values 
(x 10
3
) than pre-contrast R1 values (x 10
3
); 1.03 ± 0.51 vs. 0.09 ± 0.07. The observed 
non-linear differences in post-contrast R1 between scar core, grey zone and remote 
“healthy myocardium” may be due to the non-linear differences in the regional 
contrast kinetics, which may vary depending on the regional tissue and microvascular 
constituents within each of the three ROIs.   
4.5.3 Combining Pre-and Post-contrast T1 values 
We have shown the superiority of the simple index rΔR1 (
R1,pre - R1,post
/R1,pre) to 
differentiating the three ROIs in patients with ischaemic cardiomyopathy. Though the 
difference between the AUCs of rΔR1 and post-contrast R1 were not statistically 
significant, there was a trend to suggest rΔR1 being superior at distinguishing grey 
zone from scar core with higher specificity and diagnostic accuracy.  
Expressing the relative T1 values changes as rΔR1, allows a measure that is linearly 
proportional to contrast agent concentration in the tissue and takes into account the 
differences in the pre-contrast R1 values. This is important because when ΔR1 is 
normalised against the pre-contrast R1 values, represented by rΔR1, there is a greater 
separation between the tissue subtypes on a quantitative scale (“healthy” remote 
myocardium has higher R1 than scar core pre-contrast), thus allowing better 
distinction between regions of healthy myocardium, grey zone and scar core.  This is 
due to the opposite orders in which scar-core and remote myocardium sits on the pre- 
and post-contrast R1 quantitative scale. Indeed, retrospective analysis using different 
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cut-off thresholds for the grey zone derived from the ROC curve analysis showed 
rΔR1 provided the best prediction for grey zone from the remote healthy myocardium 
and scar core with improved specificity and diagnostic value.  
With conventional inversion-recovery LGE, tissue heterogeneity assessment is based 
on semi-quantitative signal intensity quantification on an arbitrary scale that can only 
differentiate between different tissue sub-types in contrast to a region of nulled 
myocardium. In comparison, T1 mapping enables direct myocardial signal 
quantification on a standardised scale. It overcomes the inherent limitation of 
conventional inversion-recovery LGE imaging where the optimal imaging of different 
tissue sub-types requires the precise identification of the inversion time so that the 
“healthy” myocardium can be nulled. Therefore, T1 mapping could also be a useful 
tool for assessing diffuse micro-fibrosis seen in other types of cardiomyopathy where 
myocardium fibrosis or scars are more homogeneous.  
Several studies showed that myocardial extracellular volume fraction (Ve) provides a 
surrogate quantitative measure of myocardial collagen volume fraction.
11,94-96
 Ve 
estimation is based on a calculation combining pre-and post-contrast T1 value 
measurements and relies on prerequisite of an achieved steady state between the 
myocardial and blood pool contrast concentration.  In addition, an assumption is made 
that there is a constant myocardial plasma volume fraction (reflecting capillary 
density) in regions of myocardium. After achieving an equilibrium following slow 
intravenous contrast infusion, Flett et al showed a close correlation between measured 
Ve and collagen volume fraction from histology. Schelbert et al. recently has 
demonstrated that a single bolus injection of gadolinium contrast at 0.2mmol/kg can 
also achieve this steady state 12-50 minutes post injection.
96
 However their study 
involved a population of >50% subjects healthy volunteers, and only analyzed regions 
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of homogenous myocardium where there was no late gadolinium enhancement. This 
difference in study populations compared with ours meant that we could not 
extrapolate their observation to our study. In addition, in ischaemic cardiomyopathy 
there is a loss of vasculature in the infarct scar region,
91
 therefore an assumption of 
normal myocardial capillary density or myocardial plasma volume fraction cannot be 
made. The heterogeneity between the different ROIs within the myocardium would 
influence the local contrast kinetics and timing of achieving contrast equilibrium 
between the scar core, grey zone, remote “healthy” myocardium and blood pool.  
Further studies comparing bolus injection and slow infusion to achieve contrast 
equilibrium state in the ischaemic cardiomyopathy patients are needed before we can 
apply Ve estimation in such selective patient population with myocardial tissue 
heterogeneity.  In addition, the purpose of this study is to assess the ability of utilizing 
pre- and post-contrast T1 values to separate scar core, grey zone and remote “healthy” 
myocardium. Variables such as blood pool pre and post-contrast R1 values and 
hematocrit levels would be the same for the three ROIs within individual patient, thus 
removing the impact of these variables in distinguishing one ROI from the  other. Our 
index, rΔR1 (
R1,pre - R1,post
/R1,pre), takes into account of the pre-contrast R1 value, which 
is different for the different ROI in heterogeneous myocardial tissue. It would 
therefore add additional predictive value in characterizing different myocardial 
subtypes. Although we used LGE as the gold standard in this study of patients with 
ischaemic cardiomyopathy, future studies that compare the two techniques against a 
histological gold standard will be of great interest. rΔR1 can potentially be 
incorporated into an automated clustering tool that can quantitatively segment the 




4.5.4 Study Limitations  
One limitation is the relatively small number of patients in our study. However, we 
were still able to demonstrate the ability of pre-contrast R1, post-contrast R1 and rΔR1 
at differentiating the different tissue sub-types. As with many previous studies,
84,98
 
multiple images, three separate short axis slices in our study, from each patient were 
used as independent data points which potentially introduces bias because of the intra-
class correlation between the slices from the same individual. However, we found 
little difference in the T1 values when we used a randomly selected single slice from 
each patient. In addition, the AUC for prediction of ROI from ROC analysis were also 
almost identical. Inaccurate manual endocardial border delineation may have 
introduced contamination of blood pool in the sub-endocardial scar regions due to 
similarity in signal intensity seen on the LGE images. All of our patients had close to 
or more than 50% transmural infarcts, thus minimizing the effect of blood pool 
contamination. Post-contrast T1 or R1 values also depend on individual 
pharmacokinetics and vary across a population as seen in the standard deviation of 
our values. A slow infusion technique that allows steady state between tissue and 
blood contrast concentrations proposed by Flett et al. that may overcome this issue, 
but is more time consuming.
11
 There is however, some evidence to suggest that at 20 
minutes following a bolus injection, relative steady state in tissue contrast 
concentration is reached within scarred myocardium,
98
 we therefore acquired our 
post-contrast T1 values 20 minutes post injection.   
 
4.6 Conclusion 
Using pre- and post-contrast T1 measurements acquired with single-breath hold 
MOLLI sequence, rΔR1 was best at distinguishing different tissue sub-types in 
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ischaemic cardiomyopathy. Pre-contrast R1 was able to reliably distinguish “healthy 






Chapter 5 Improving respiratory navigator efficiency 
during high-resolution 3D delayed-enhancement CMR and 
its impact on myocardial scar assessment 
 
One criticism of grey zone quantification by LGE CMR is the impact of imaging 
resolution on the quantification of LGE image signals. The quantification is semi-
quantitative and is based on the signal intensities from the LGE images, therefore 
susceptible to partial volume effect of signal strength within each imaging voxel. 
With higher resolution LGE CMR, it is perceived that grey zone can be more 
accurately quantified with smaller voxel size. However this high-resolution data 
acquisition is at the cost of longer scanning time requiring patients to perform 
multiple long breath-holds. This is time consuming and laborious for the patients, 
especially to those with severely impaired LV function. One way of overcoming this 
is to acquire high-resolution 3-dimesional data with CMR sequence during free-
breathing. This requires respiratory navigation with a selected window of interest for 
data acquisition during the respiratory phase (usually end-expiratory). However, 
patients with severely impaired LV function often have irregular breathing patterns, 
resulting in poor navigator efficiency and prolonging the scan time again. This 
chapter describes the work that explores a new technique to improve the navigator 




Background: Myocardial scar characterisation and quantification by delayed-
enhancement cardiac magnetic resonance imaging (DE-CMR) improves arrhythmia 
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risk stratification in patients with severely impaired left ventricular ejection function 
(LVEF). However, often the long breathhold required for routine multi-slice 2-
dimensional (M2D) scar imaging are challenging for many of these patients, and 
irregular breathing resulting in prolonged free-breathing 3-dimensional (3D) scar 
imaging time. We proposed to combine high-resolution 3D DE-CMR with a more 
efficient respiratory-gating approach (HybridPAWS)
 
to improve scan efficiency and 
asses its clinical efficacy in patients with significantly impaired LVEF who are being 
considered for defibrillator device therapy.  
Methods: Breath-holding M2D and free-breathing high-resolution 3D DE-CMR were 
performed in 44 consecutive patients. During 3D data acquisition, the navigator 
efficiency (NE) for HybridPAWS and a standard respiratory-gated acquisition scheme 
were compared. Scar quality and quantification analyses were compared between the 
M2D and 3D images in short- and long-axis orientations, using a multi-planar 
reformatting tool.  
Results: The mean LVEF of the study cohort was 30±12%. The mean respiratory NE 
was 47±15% with HybridPAWS vs. 39±18% with the standard respiratory-gated 
Cartesian scheme (p <0.01). HybridPAWS made the greatest impact in patients with 
NE <40%, achieving a mean improvement of 55±68% in NE. 3D scar image quality 
was comparable to M2D images and without any compromise when reformed to any 
clinically important image orientations to study region of interest. Quantitative 
delayed-contrast enhancement analyses showed that given similar in-plane resolutions, 
M2D and 3D images produced similar scar core and grey zone sizes. Increasing 
through-plane slice thickness did impact on the scar quantification beyond a thickness 
of 8mm.  
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Conclusion: HybridPAWS can improve respiratory NE and shorten scan time during 
high-resolution isotropic 3D DE-CMR. Isotropic 3D scar image has a potential for 
improving the accuracy of scar border zone quantification and allowing retrospective 
multi-plane reformatting for optimal myocardial scar assessment. Increasing through-
plane slice thickness during 3D scar imaging may potentially shorten acquisition time 
without a significant impact on scar quantification.  
 
Key words: high-resolution CMR, respiratory navigation, HybridPAWS 
 
5.2 Introduction  
Delayed-enhancement cardiac magnetic resonance imaging (DE-CMR) is the standard 
approach for visualising myocardial fibrosis.
80,81
 The presence of myocardial fibrosis 
is an important prognostic indicator in patients with both ischemic and non-ischemic 
cardiomyopathies.
39,59,82,83
 Signal intensity (SI) based analysis on regions of 
enhancement allows further characterisation of the scar region, separating the scar 
core and the scar border zone (often referred to as grey zone due to its intermediate 
signal intensity with a mixture of fibrosis and myocytes). This has been shown to 
improve patient arrhythmic risk stratification and assist cardiac arrhythmia ablation 
procedure.
4,24,99,100
 Small areas of myocardial scar need to be characterised in high 
spatial resolution in order to detect complex arrhythmogenic substrates beyond the 
simple binary detection of scar. Conventional DE-CMR yields myocardial scar 
images by acquiring multiple two-dimensional (M2D) image slices over several 
breath-holds in order to give sufficient coverage of the whole ventricle. This image 
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acquisition process can be strenuous for some patients, particularly those with 
significantly impaired left ventricular (LV) function who often cannot hold their 
breath long enough for each image acquisition. Furthermore breathholds are often not 
reproducible resulting in misalignment of slices along the slice selection direction. 
Whilst the in-plane resolution of the image slice is sufficient for excellent 
visualisation of the ventricular myocardial scar, the slice thickness is much larger 
(resulting in an one order of magnitude lower through-plane resolution than the in-
plane resolution). High-resolution three-dimensional (3D) free-breathing DE-CMR 
has been proposed to overcome these limitations and to allow for accurate depiction 
of scar tissue independent of the scan orientation.
5
 However, the acquisition requires 
long scan time requiring compensation of cardiac and respiratory motions. Whilst 
cardiac motion is synchronised by electrocardiography (ECG) triggering, respiratory 
gating is commonly applied during the free breathing scan. For such scans, data are 
only accepted if a respiratory motion surrogate such as the position of the right 
diaphragm is within a pre-defined narrow gating window. This approach can be 
problematic especially in patients with impaired ventricular function who often have 
irregular breathing patterns leading to prolonged image acquisition times as a result of 
poor respiratory gating efficiency.
101-103
 
In order to improve respiratory navigator efficiency (NE), a CMR data acquisition 
scheme called Phase ordering with Automatic Window Selection (PAWS) has been 
proposed to improve respiratory gating efficiency in non-contrast enhanced coronary 
magnetic resonance angiography.
104
 Recently a Radial Phase Encoding (RPE)-PAWS 
approach for non-contrast enhanced 3D-MRI has been proposed, which is more 
efficient as it allows better under-sampling properties.
105
 However, RPE usually 
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requires advanced image reconstruction techniques making its clinical translation 
cumbersome.  
Here, a modified RPE-PAWS approach is proposed that acquires all phase encoding 
steps in a radial order but on a rectilinear grid. This allows immediate data 
reconstruction on the scanner platform allowing direct clinical assessment at the 
scanner. This method is referred to as HybridPAWS. The purpose of this study is to 
assess HybridPAWS in patients with impaired LVEF who are likely to have irregular 
breathing patterns resulting in poor navigation efficiency and evaluate the respiratory 
NE and image quality of high resolution isotropic 3D DE-CMR acquired. 
Furthermore, the study aims to assess the impact of the required through-plane slice 
thickness on the quantification of scar core and grey zone.  
 
5.3 Methods  
5.3.1 HybridPAWS combined with a 3D DE-CMR inversion-recovery (IR) 
sequence 
In HybridPAWS all phase encoding steps are acquired in a radial order but located on 
a rectilinear grid allowing straightforward application of standard parallel imaging 
techniques and thus fast image reconstruction. Instead of defining the gating window 
at the beginning of the scan, PAWS is determining the most probable respiratory 
motion state during the acquisition ensuring a high NE over the complete scan. For 
this the data was obtained at multiple respiratory windows (referred to as bins) 
covering the entire amplitude of the respiratory signal. In each respiratory bin, data 
are radially distributed and thus cover both low and high spatial frequencies 
homogeneously. In addition, the proposed ordering scheme ensures that data 
acquisitions in two adjacent respiratory bins are complementary. Therefore the scan is 
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successfully finished if two neighboring bins can be combined for the reconstruction 
of a 3D image (Figure 5-1a). The acquisition scheme was combined with inversion 
recovery (IR) pre-pulse for late-enhancement MRI. The electrocardiograph (ECG) -
triggered acquisition scheme and behavior of the longitudinal magnetisation for 
healthy and fibrotic myocardium post contrast enhancement is shown in Figure 5-1b.  
 
Figure 5- 13D DE-MR sequence combined with HybridPAWS. 
 (a) HybridPAWS acquires data in multiple respiratory bins (red/blue bars) covering the entire 
amplitude of diaphragm movement. An interleaved phase encoding scheme is used which 
allows for the combination of data from two adjacent bins. Data acquisition is successfully 
finished when one combination of two adjacent bins leads to a completely filled k-space 
allowing reconstruction of DE-3D images. (b) Data acquisition is cardiac triggered with the 
trigger delay (TD). An inversion recovery (IR) pre-pulse inverts the longitudinal 
magnetisation. Signal at the location of the respiratory navigator (NAV) is restored (RES). 
Data is obtained after an inversion time TI which is selected to optimally null healthy 
myocardium. IR inverts the longitudinal magnetisation Mz. The administered contrast agent 
leads to a shortening of the T1 time of scar tissue. Therefore, Mz of scar tissue (red) recovers 
faster than the longitudinal magnetisation of viable myocardium (blue). The inversion time TI 




Patient selection  
(See Chapter 3.2 for General patient selection criteria) 
Cardiovascular magnetic resonance imaging 
(See Chapter 3.3.1 for General CMR methods protocol) 
For scar imaging, standard M2D DE-CMR was performed in the same views 10-15 
minutes post contrast injection (gadobutrol, 0.2mmol/kg body weight), using a 
standard IR gradient echo sequence with repetition time/echo time of 3.4/2.0ms; flip 
angle 25 degrees; voxel size 1.8x1.8x8mm
3
 and a field of view (FOV) of 
approximately 300x300x8mm
3
; ECG triggered to end-diastole. Patient-specific 
inversion time (TI) for the IR sequences was selected individually based on a Look-
Locker scan to ensure nulling of the myocardium just prior to the M2D DE-CMR 
imaging.
106
 Immediately after M2D scar image acquisition, high-resolution 3D DE-
CMR data was acquired using HybridPAWS with isotropic voxel size of 
1.7x1.7x1.7mm
3
, FOV approximately 300x300x100mm
3
, repetition time/echo time of 
5.4/2.6ms and flip angle 25 degrees. Parallel imaging was used in two directions with 
SENSE factors of 2 and 1.3 in phase and slice encoding direction, respectively. For 
respiratory gating of the 3D IR acquisition, a combination of a pencil beam navigator 
with a preceding restore pulse was applied.
107
 Again, patient-specific TI was selected 
from a repeated Look-Locker scan. 
Respiratory navigator efficiency (NE) 
Respiratory navigator efficiency (NE) was defined as the number of accepted data 
points in the two bins divided by the overall obtained data points in all bins.  During 
the acquisition of high-resolution 3D DE-CMR data, the NE was calculated for 
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HybridPAWS. All respiratory signals were stored to calculate the NE for a standard 
respiratory-gated Cartesian acquisition scheme (Std-gated Cartesian scheme), thus 
allowing a direct comparison of NE from the same respiratory motion information.  
Image analysis 
The scar images were compared between the conventionally acquired M2D and 3D 
DE-CMR images. In order to make comparison, the higher resolution 3D datasets 
were reformatted to the same slice thickness as that of the M2D datasets with a multi-
planar reformatting tool (mean SI slabs with a thickness of 8mm), using OsiriX 
Imaging Software, version 3.9.2 (Geneva, Switzerland). The in-plane resolution 
between the two datasets was comparable, 1.7x1.7mm vs. 1.8x1.8mm, and was 
therefore not modified, as we expected the gain in image quality with 3D DE-CMR to 
be mainly in the slice direction. Two experienced observers blinded to the image 
acquisition methods visually scored each dataset to assess the quality of the scar 
images in short- and long-axis on a scale between 0 and 4:  0 = non-interpretable, 1 = 
poor quality, 2 = medium quality, 3 = good quality, and 4 = excellent quality. The 
scar signal noise ratio (SNR) was measured by the mean SI from the region of 
contrast enhanced region divided by the standard deviation (SD) of the SI in the lung 
field away from the myocardium. The scar_myocardium and scar_blood contrast 
noise ratios (CNR) were measured as the difference between the scar SNR and the 
respective remote normal myocardium SNR or blood pool SNR. 3D mages with the 
best visual quality score (i.e. score 4) were selected for further SI based scar 
quantification analysis. Scar core was defined by the full-width-half-maximum 
(FWHM) method; and the grey zone was defined by the region with SI above that 
defined by FWHM but below that defined by that of two standard deviation (2SD) 
from remote presumed normal myocardium (2SD – FWHM method). Scar 
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quantification analyses were also repeated with varying reformatted though-plane 
slice thickness (1mm, 2mm, 4mm, 8mm, 16mm) in order to assess its impact on the 
in-plane image scar quantification using 3D DE-CMR images. 
5.3.2 Statistics 
(See Chapter 3.6 for General statistical methods) 
Between-group comparisons were made using the t-test or the Chi-squared test (for 
categorical variables), or the one-way ANOVA test (for more than two groups 
comparison), with a two-tailed p-value < 0.05 indicating statistically significant 
differences between groups. All statistics were performed using computer software 
Prism Version 6 (GraphPad Software, Inc. CA, USA) 
 
5.4 Results 
In total, 44 patients were enrolled in the study prior to CMR as part of their clinical 
assessment before ICD implantation. The mean LVEF was 30±12%.  Of the cohort, 
30 (68%) patients subsequently received combined cardiac resynchronisation therapy 
(CRT) with a defibrillator device. All patients completed standard M2D and high-
resolution 3D DE-CMR with HybridPAWS implemented during data acquisition. The 







Characteristics Patient, n = 44 (100%) 
Age (years) 
Female 
65 ± 12 
11 (25) 
Hypertension 8 (18) 
Diabetes 6 (14) 
Atrial fibrillation 5 (11) 
COPD 9 (20) 





NYHA class I/II/III/IV 5/12/23/4 
ICM / NICM 30 (68)/14 (32) 
Indications for ICD: primary/secondary 32/12 
Combined cardiac resynchronisation therapy 30 
CMR findings  
LV ejection fraction, % 30 ± 12 
V end-diastolic volume index, ml/m
2
 127 ± 40 
LV mass index, g/m
2
 72 ± 15 
Culprit territories of infarct in ischemic 
cardiomyopathy (n=30), LAD/Cx/RCA 
14 (47)/10 (33)/19 (63) 




Table 5- 1 Baseline patient and CMR characteristics 
COPD indicates chronic obstructive pulmonary disease; eGFR, estimated glomerular 
filtration rate; NYHA, New York Heart Association; ICM, Ischemic cardiomyopathy; NICM, 
non-ischemic cardiomyopathy; ICD, implantable cardioverter defibrillator; LV, left 




5.4.1Respiratory navigator efficiency (NE) and scan time 
Patients with significantly impaired LV function have irregular breathing patterns, 
resulting in poor respiratory navigator efficiency. Figure 5-2 illustrates the breathing 
patterns with examples of high NE and low NE based on diaphragm positions. 
 
Figure 5- 2 Diaphragm positions recorded during 3D DE-CMR data acquisition 
 
The mean respiratory NE was 47±15% (median: 47%; inter-quartile range IQR: 37-
55%) with HybridPAWS compared to 39±18% (median 39%; IQR: 27-52%) with 
Std-gated Cartesian scheme, p < 0.01. Data acquisition with HybridPAWS led to a 
mean relative improvement of 36±59% in NE per individual patient.  
The greatest improvement was achieved in patients with low NE, i.e. <40%, using 
Std-gated Cartesian scheme.  In this group, HybridPAWS improved the overall NE 
from 27±8% to 38±9%, p <0.01; achieving a mean relative improvement of 55±68% 
in NE per individual patient.  In the group with NE ≥40%, HybridPAWS improved 
overall NE from 58±12% to 61±11%; achieving a mean relative improvement of 
6±7% in NE per individual patient; as illustrated in Figure 5-3. 
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Figure 5- 3 Scatter plot of navigator efficiency (NE) achieved with HybridPAWS versus 
standard Cartesian respiratory gating sampling scheme.   
 
HybridPaws significantly improves the NE for subjects with low NE using a standard 
gating scheme. (The respiratory patterns for subjects are illustrated in Figure 5-2) 
 
The average nominal scan time for high-resolution 3D DE-CMR data acquisition was 
4:09±1:30 minutes assuming an average heart rate of 70 beats per minute and a 
respiratory NE of 100%. HybridPAWS led to an average total scan time of 9:44±5:15 
minutes with mean NE of 47±15%. M2D DE-CMR data acquisition took an average 
time of 9:59±2:02. (This included a SAX stack with 11-13 slices, a LAX slice in 
standard 4-, 3- and 2- chambers and any repeat slices needed to improve image 
quality). There was no significant difference in scan times between the total M2D data 
and the 3D data acquisition.  
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5.4.2 Image quality and scar quantification 
One of the limitations of single slice 2D LAX images in standard orientations is that it 
does not always highlight areas of clinical interest. Two examples are illustrated in 
Figure 5-4. The top panel illustrates images from 2D single slices in standard 
orientations. The bottom panel illustrates retrospectively reformatted 3D images in 
orientations that best highlight areas of clinical interest such mural thrombus, complex 














Subject 1 is a patient with subendocardial scar from right coronary artery infarct (white 
arrow in inferior wall) with additional epicardial scar (white arrow in the lateral wall) from 
secondary post infarct pericarditis which are not demonstrated in standard LAX views. 
 
 
Subject 2 is a patient with extensive left anterior descending artery and circumflex artery 
territory infarct, the 3D image allows the freedom of assessing the complex scar structures in 
any orientations without a reduction in image quality. Surviving myocardium is interwoven 
within the infarct zone (white and black arrows), providing potential substrate for re-entrant 
ventricular tachycardia. 
Figure 5- 4 Two examples of M2D scar images (top panel) in standard long axis (LAX) 2-, 3-, 
4- chambers “missing” clinical regions of interest compared with 3D scar images (lower 




In order to make a like-with-like comparison, we also reformatted the M2D SAX and 
3D stacks to LAX in the same orientations that best illustrate regions of clinical 
interest such as complex scars and thrombus. The 3D images were reformatted to the 
same slice thickness as that of the M2D slices in the same orientation. 5 examples of 
M2D and 3D images in SAX and LAX orientations are shown in Figure 5-5, 
illustrating that the 3D data allowed the freedom of retrospective assessment in any 
orientations without a reduction in image quality of clinical regions of interest. 
Subjects 1-3 demonstrate the detections of fine structures such as thrombus, papillary 
muscle scar, the strands/islands of surviving myocardium within complex scar 
structure and at the infarct border zone in three ICM patients with previous histories 
of ventricular tachycardia.  Subjects 4-5 demonstrate the different scar patterns that 
are more commonly associated with NICM. Subjective image quality from two 
independent experienced assessors were 3.4±0.6 for M2D images versus 2.8±1.0 for 
3D images in SAX (p<0.01); 1.8±0.7 for M2D images versus 2.9±0.9 for 3D images 














Figure 5- 5 M2D and 3D DE-CMR images  
 
Subject 1: Left anterior descending artery infarct with complex scar structures surround 
islands/strands of surviving myocardium (white arrow) and thrombus in the antero-septal wall 
(black arrow). 
 
Subject 2: Right coronary artery territory infarct with a partial infarction of the inferior-
posterior papillary muscle (white arrows). 
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Subject 3: Left anterior descending artery and right coronary artery region infarct. The infarct 
border zone, the “grey zone”, (white arrow) appears larger and the apical thrombus (black 
arrow) appears less sharp with larger voxel size due to the partial volume effect. 
 
Subject 4: Non-ischemic dilated cardiomyopathy with island of focal fibrosis (white arrow) 
and strands of myocardium (black arrow) in regions of diffuse fibrosis.  
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Subject 5: “Burnt-out” hypertrophic cardiomyopathy with complex diffuse patchy scars and 
regional scars involving the ventricular myocardium and the papillary muscles. 
 
Scar quantification analysis on six reformatted 3D SAX images of 2mm, 4mm, 8mm 
and 16mm slice thickness showed that these changes did impact on scar quantification 
with a significant overestimation observed only when the slice thickness was 
increased than larger than 8mm, shown in Figure 5-6. This suggested an influence of 
partial volume effect with increasing slice thickness on scar core and grey zone 
definitions. The infarct border zone appeared to enlarge as the slice thickness is 
doubled with reducing SI.  
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Figure 5- 6 Quantitative scar assessment with scar core (FWHM method) and grey zone 
(2SD – FWHM method) with varying slice thickness 
3D image resolution: (acquired in-plane) 1.7mm x 1.7mm x (varying reformatted through-
plane) 1mm/2mm/4mm/8mm/16mm; FWHM=full-width-half-maximum; SD=standard 
deviation. 
 
The respective scar SNR, the scar_myocardium CNR and scar_blood CNR for 
patients with a previous history of myocardial infarction are illustrated in Table 5-2.  
n = 30 2D 3D P values 
Scar SNR 21±5 43±11 P<0.01 
Scar_Myocardium CNR 20±5 39±10 P<0.01 
Scar_Blood CNR 4±2 16±7 P<0.01 
 
Table 5- 2 Signal noise ratio (SNR) and contrast noise ratio (CNR) 
 
5.5 Discussion  
The current study, involving a cohort of patients with severely impaired LV systolic 
function, demonstrates that the implementation of HybridPAWS can reliably improve 
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NE and shortens scan time for the acquisition of high-resolution isotropic 3D DE-
CMR with immediate image post process reconstruction. The technique is particularly 
effective in patients with poor respiratory breathing patterns, in whom the standard 
respiratory-gated Cartesian acquisition scheme would normally achieve less than 40% 
NE. Furthermore, qualitative and quantitative scar assessments show that isotropic 3D 
data allow post-scan multi-plane reformatting of optimal image planes without a 
compromise in image quality; and a higher resolution 3D image has the potential to 
improve the accuracy of scar quantification. 
5.5.1 Navigator efficiency and scan time 
Despite the implementation of HybridPAWS, which has the benefit of immediate 
reconstruction of the 3D data, the acquisition time is comparable with the time needed 
for M2D data acquisition. This however is coupled with the benefit of acquiring 
isotropic high-resolution image data. The relatively long acquisition time with both 
M2D and 3D image data is a reflection of clinical difficulties faced when scanning 
patients with severely impaired LV function, including difficulties in achieving long 
breath-holds and the need to rest between multiple breath-holds. The lengthy 
acquisition time of high-resolution 3D DE-CMR has hindered its routine clinical 
application. In addition, the long scan time makes the scar image quality more 
susceptible to the influence of contrast agent kinetics, thus the initially determined 
optimal inversion time (TI) for nulling of the myocardium to give the greatest signal 
contrast between scar and healthy myocardium will be incorrect by the end of the scan, 
causing image artifacts. By shortening the 3D DE-CMR scan time through improved 
NE, we can potentially limit the impact of inaccurate nulling due to changes in 
contrast kinetics during a prolonged scan. An additional advantage of the 3D 
HybridPAWS phase encoding scheme compared with standard PAWS is that, for an 
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IR pre-pulse, the TI is ensured for both phase encoding directions, i.e. for the central 
portion of the k-space (disc shape), therefore further minimise the influence of 
contrast kinetics on regional DE-CMR image quality during a prolonged scan.  
5.5.2 Image quality 
The 3D scar images were consistently acquired after 20 minutes of bolus injection 
whereas the M2D images were acquired between 10-20 minutes in this study. There is 
evidence to suggest that at 20 minutes following a bolus injection of gadolinium 
contrast, a relative steady state in tissue contrast concentration is reached within 
scarred myocardium in ICM.
98
 The scar SNR was doubled for 3D scar images with an 
acquired voxel resolution of 1.7x1.7x1.7mm
3
 when compared with the M2D images 
with a resolution of 1.8x1.8x8mm
3
. The reason for the doubling of SNR for the 3D 
images is the additional phase encoding along the slice direction resulting in 
additional averaging and compensates for the thinner slice thickness. The 
scar_myocardium CNR was also 2-fold higher and the scar_blood CNR was 4-fold 
higher with the 3D compared with the M2D images. The additional increase in 
scar_blood CNR originates from a higher blood signal in the 2D images due to inflow 
effects.  
Despite the higher SNR and CNR, the mean in-plane SAX subjective scar image 
quality score was lower for the reformatted 3D images than for the M2D images. The 
image quality achieved with HybridPAWS should be less dependent on the breathing 
pattern than with the original PAWS because it potentially suppresses residual motion 
artifacts by distributing them evenly along both phase directions rather than along one 
encoding direction. However, one reason for the reduction in image quality could be 
due to the residual motion artifacts introduced during the continuous 3D data 
acquisition scan which can affect all slices of 3D image without the benefit of 
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immediate correction. In contrast to that, a failing breath-hold would usually impact 
only those M2D slices when motion occurred. This suboptimal M2D image was 
immediately repeated during the clinical study and the improved image slices were 
used for the image qualitative score assessment. Furthermore, the 3D images were 
reformatted to the same slice thickness as that of the M2D SAX images for image 
quality score assessment, effectively reducing the acquired resolution.  
SI-based assessment on regions of delayed contrast enhancement with further scar 
characterisation demonstrated a potential of influence of acquired voxel resolution on 
the accuracy of scar core and grey zone quantification. A major criticism of the 
quantification of the grey zone is the effect of partial volume given the relative large 
voxel size of the standard M2D scar images. Schelbert et al have demonstrated this 
using reformatting the ultra-high resolution at cellular level in ex-vivo rat heart scar 
images.
12
 Peters et al have demonstrated that a reduction in voxel size (a reduction in 
in-plane as well as through-plane resolutions) that is more relevant to standard clinical 
in vivo human scans can produce a larger peri-infarct zone in heterogeneous scar and 
conversely a smaller peri-infarct zone in homogenous scar.
 5
The current study has 
however found that when the in-plane (SAX) resolutions are comparable, the slice 
thickness in the slice encoding direction only has a significant impact on the analyses 
when it is multiple orders of magnitude of the in-plane resolution. 
5.5.3 Clinical relevance 
The 3D DE-CMR enables a greater degree of freedom to visualise scar structure by 
allowing multi-plane reformatting of the images without compromising image quality. 
Post-acquisition multi-plane analysis of 3D images with isotropic voxel is therefore 
helpful in characterising complex heterogeneous scar structure in different 
orientations. This is important because there is a growing need to achieve better scar 
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characterisation at a higher resolution other than simply binary detection of the 
presence of scar. Fused displays of myocardial scar images with other imaging 
modalities such as fluoroscopy and electro-anatomical mapping have been shown to 
aid therapeutic decisions during cardiac resynchronisation therapy and ventricular 
tachycardia ablative therapy.
99,108-110
 The high spatial resolution 3D DE-CMR is 
capable of providing structural information in regions of tissue heterogeneity, 
potentially exceeding the resolution that can be achieved with contact electrode 
mapping.
111
 Scar quantifications have demonstrated additional clinical prognostic 
benefit in terms of assessing arrhythmia risk in both ischemic and non-ischemic 
cardiomyopathy.
2-4,112,113 
In order to reduce free-breathing 3D data acquisition time in 
patients who are unable to hold sufficiently long breathhold, the through-plane 
acquisition resolution can be further reduced without significantly impacting on the 
scar quantification assessment provided the in-plane resolution of scar imaging 
remains sufficient high.  
5.5.4 Study limitation 
The study is limited by a relative small number of patients. Although it is the largest 
study to-date that focused on a patient population with severely impaired LV function 
and irregular breathing patterns. Though we reformatted the high-resolution 3D data 
to the lower resolution of the M2D images for “like-with-like” comparison, it could 
have introduced a systemic bias favoring the image quality assessment of the 3D 
images. The 3D dataset was acquired 5-10 minutes after the first M2D scar images 
due to constraints of the clinical protocol. This would have resulted in a systemic bias 
on the image quality by potentially giving additional time for the contrast kinetics to 
reach an equilibrium state during 3D data acquisition. Randomising both scan types 
would avoid this. 
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5.6 Conclusions 
This study has shown for the first time that HybridPAWS can reliably improve 
respiratory navigator efficiency and shorten scan time during high-resolution isotropic 
3D DE-CMR. The technique is particularly effective at improving the poor navigator 
efficiencies in patients with irregular respiratory patterns. Isotropic 3D DE-CMR 
acquired with the assistance of HybridPAWS has the additional advantage of allowing 
multi-plane characterisation of myocardial scar without compromising image quality 
and the potential to improve the accuracy of scar quantification assessment. However 
suboptimal motion compensation may still affect the image quality without the 
freedom of real-time correction. Non-isotropic 3D imaging with sufficient high in 




Chapter 6. Exploring the association between scar 
heterogeneity using cardiac magnetic resonance imaging 
with ventricular tachycardia substrate – a clinical and 
computer modeling approach 
 
Computational modelling of cardiac arrhythmogenesis and arrhythmia maintenance 
has made a signiﬁcant contribution to the understanding of the underlying 
mechanisms of arrhythmia. In collaboration with biomedical engineers from Inria, 
Asclepios Team, Sophia Antipolis, France, we sought to explore the relationship 
between the myocardial scar heterogeneity detected by CMR with VT arrhythmia 
substrate through a combined clinical and computer modelling approach. The 
following chapter describes the work involved in a clinical pilot validation study of a 
biophysical model to predict VT inducibility and circuit morphology.  
 
6.1 Abstract 
Background: Computational modelling of cardiac arrhythmogenesis and arrhythmia 
maintenance has made a signiﬁcant contribution to the understanding of the 
underlying mechanisms of arrhythmia. We hypothesised that cardiac model using 
personalised electro-anatomical parameters can represent the underlying VT substrate 
and predict re-entrant VT circuits.  We used a combined modelling and clinical 
approach in order to validate the concept. 
Methods: Non-contact electroanatomic mapping studies were performed in seven 
patients (5 ICM, 2 NICM). Three ICM patients underwent a clinical VT stimulation 
study. Anatomical information was obtained from cardiac magnetic resonance 
imaging (CMR) including high-resolution scar imaging. A simpliﬁed biophysical 
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mono-domain action potential model personalised with the patients’ anatomical and 
electrical information was used to perform in silico VT stimulation studies for 
comparison.  
Results: The personalised in silico VT stimulations were able to predict VT 
inducibility as well as the macroscopic characteristics of the VT circuits in patients 
who had clinical VT stimulation studies.  Patients 1 and 2 with positive clinical VT 
stimulation studies had wider distribution of APD-RC slopes and APDs than Patient 3 
with a negative VT stimulation study. The exit points of re-entrant VT circuits 
encompassed a higher percentage of the maximum APD-RC slope compared to the 
scar and non-scar areas, 32%, 4% and 0.2% respectively.  
Conclusions: VT stimulation studies can be simulated in silico using a personalised 
biophysical cardiac model. Myocardial spatial heterogeneity of APD restitution 
properties and conductivity may help predict the location of crucial entry/exit points 
of re-entrant VT circuits.  
Keywords: Ventricular tachycardia; computer modelling; APD restitution; 
conductivity; cardiac magnetic resonance imaging. 
 
6.2 Introduction 
Implantable cardioverter defibrillator (ICD) shocks are a cause of substantial 
morbidity in patients with ventricular arrhythmias.
114 
Radiofrequency ablation is 
increasingly used to treat ventricular tachycardia (VT) to reduce ICD discharges and 
improve patient quality of life and mortality.
 
The current arrhythmia risk stratification 
strategy is imperfect and is determined largely on left ventricular (LV) function with 
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not all high-risk patients receiving an ICD, and those who received ICDs never 
experiencing appropriate therapies. Similarly ablation of VT is technically 
challenging with a recurrence rate of up to 40% with a lack of clinical consensus on 
the optimal ablation strategy.
1152
 Better risk stratification and higher ablation success 
rates would potentially improve patient outcomes. There is therefore a need to 
identify individuals at high risk of developing ventricular arrhythmia and the 
arrhythmia substrate in order to guide the optimal ablation strategy.  
 
Computational modelling of cardiac arrhythmogenesis and arrhythmia maintenance 
can be used to contribute to the understanding of the underlying mechanisms of 
arrhythmia.
 
Image-based computational models have incorporated cardiac structural 
information such as heterogeneity of scars into such simulations.
1163
 However, the 
heterogeneity in action potential duration (APD) restitution, the adaptation of APD as 
a function of the cardiac cycle length, has a crucial role in arrhythmogenesis.
117,118
 
The integration of both personalised structural and functional data has not previously 
been performed.  
 
We hypothesised that, using personalised electrophysiological mapping data and 
structural anatomical data acquired respectively from electrophysiology studies and 
high-resolution cardiac magnetic resonance imaging (CMR) we could develop a 
patient-specific biophysical model to perform in silico VT stimulation studies to 





(See Chapter 3.2 for General patient selection criteria) 
Patients under consideration for primary prevention ICD on the basis of their LV 
function were prospectively invited to participate in the study following local research 
ethics committee approval. Seven patients, 5 with ischaemic cardiomyopathy (ICM) 
and 2 with non-ischaemic dilated cardiomyopathy (NICM) gave written consent prior 
to study inclusion.  
 
CMR Acquisition and Image Processing 
(See Chapter 3.3.1 for General CMR methods protocol) 
CMR was performed on a Philips Achieva 1.5T scanner using a 32 channel cardiac 
coil. All 7 patients completed CMR morphological and volumetric assessment as well 
as high-resolution scar characterisation by late-gadolinium-enhanced (LGE) imaging 
with acquired voxel size 1.3x1.3x2.6mm
3
. A personalised 3D model of the ventricles 
was derived from the CMR images: a tetrahedral mesh was generated from the binary 
mask of the ventricles. The LV myocardial scar distribution was segmented using 
signal intensity (SI) based analysis from the high-resolution LGE images to 
distinguish between scar core and grey zone. Each element of the mesh was labelled 
(healthy/scar core/grey zone).  
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6.3.1 Invasive Electrophysiological Study with Electroanatomic Mapping and 
Signal Processing 
LV electroanatomic mapping (EAM) was performed using a multi-electrode array 
catheter (EnSite Velocity System, St Jude Medical, MN, USA) in all 7 patients. The 
chamber geometry was reconstructed using locator signals from a steerable 
electrophysiological catheter. Three patients (patients 1-3) with ICM underwent a 
simultaneous VT stimulation study according to the Wellens protocol during the 
mapping study.
119 Unipolar electrograms (UEG) derived were ﬁltered with a band-
pass ﬁlter (10Hz/300Hz and 0.5Hz/30Hz) to optimise QRS complex and T wave 
detections. The depolarisation times were detected within the QRS window and 
derived from the zero crossings of the laplacian of the measured UEGs, the 
repolarisation times were detected within the ST window for the signals.
117
 The 
difference between the depolarisation and repolarisation times was used to estimate 
the activation recovery time (ARI) which is used as a surrogate marker for APD. The 
APD restitution curve (APD-RC) was estimated from steady-state RV pacing (500ms) 
with sensed pacing extras at progressively shorter coupling interval at a decrement of 
20ms till 200ms or refractory period. The APD-RC was represented by a non-linear 
equation using a least-squares fit to the mono-exponential function as previously 
detailed on experimental and clinical data: a single APD-RC was fitted for each 
measured point from the EAM and the maximum APD was estimated as the 
asymptotic APD of the APD-RC when the diastolic interval tends to infinity.
120,121
  
6.3.2 Construction of Personalised 3D Cardiac Model 
Building on the framework that we have previously described and validated, the 
anatomical mesh was registered with the electrical information offline and used to 
generate a personalised 3D cardiac model, which combines the benefits of an Eikonal 
(EK) model (fast and robust for conduction velocity (CV) personalisation) and those 
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of a simplified biophysical mono-domain action potential Mitchell-Schaeffer (MS) 
model (well suited for personalising APD restitution properties).
120-122
 The MS model 
was personalised with the apparent conductivity (AC) values derived from the 
patient’s CV computed from the EAM data. AC is the diffusion coefficient that 
represents an intrinsic parameter of the cardiac tissue electrical conductivity in the 




) is proportional to the product of the 
square of CV and a time constant parameter in the model.
121
 AC is used as an 
independent estimation of the intrinsic biophysical electrical conductivity property of 
the tissue rather than CV which could be dependent on the activation sequence and 
the shape of the propagation wave front. The process of building the models from the 
CMR and EAM data is illustrated in Figure 6-1.  
(The estimation of the electrical parameters and computer modelling is described in 




Figure 6- 1(A) high-resolution contrast-enhanced CMR scar images; (B) whole heart model 
segmented from 3D steady-state free precession (SSFP) CMR with scar (core and grey zone) 
in violet; (C) low voltage areas from electroanatomical mapping. Lower panel: (D) model 
personalisation and in silico VT stimulation study procedure workflow. 
 
6.3.3 In silico VT Stimulation Study 
In three patients (patients 1-3) with ICM, the personalised cardiac model was used to 
simulate a clinical VT stimulation study in silico in order to predict the initiation and 
maintenance of ventricular arrhythmia induced during clinical study. The simulated 
study was performed in accordance with the clinical study protocols that were carried 
out: the pacing stimuli were applied from the RV apex following the Wellens protocol. 
We also simulated the study from alternate pacing sites in the RV and LV that 
encompassed the basal and apical freewall/lateral/septum/anterior and inferior walls. 
The exit points identified from the clinical VT stimulation studies and the in silico 
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simulations were characterised in terms of the spatial heterogeneities of the AC, APD 
restitution properties. 
 
6.3.4 Statistical analysis 
The electrical parameters consisted of multiple data points, each corresponding to a 
different location within the LV of an individual patient. The data were expressed by 
median and inter-quartile range (IQR) or mean and standard deviation. Continuous 
variables were compared using Median test. A p value < 0.05 was considered to be 
statistically significant. All statistics were performed using computer software SPSS 
Statistics, version 21, SPSS Inc., IBM, USA. 
 
6.4 Results 
Baseline patient characteristics and CMR findings are summarised in Table 1. During 
the clinical VT stimulation studies, patients 1 and 2 developed sustained 
monomorphic VT; patient 3 was non-inducible. All 7 patients were implanted with 
ICDs for primary prevention following clinical assessment. During a median follow-
up period of 22months, IQR 9 months, patient 2 received appropriate ICD therapy for 






Patient 1 2 3 4 5 6 7 
Condition ICM ICM ICM ICM ICM NICM NICM 
Gender M M M M F M M 
Age  73 69 64 60 65 75 81 
Co-morbidities HTN None HTN, 
AF 
DM None AF PAF 
B-blocker Yes Yes Yes Yes Yes Yes Yes 
ACE-I/ARB Yes Yes Yes Yes Yes Yes Yes 
Statins Yes Yes Yes Yes Yes No Yes 
LVEF, % 27 35 35 25 31 36 17 
LVEDV, ml 199 292 245 304 185 196 285 
LV mass, g 129 172 147 182 118 89 206 
Scar on CMR Yes Yes Yes Yes Yes Yes Yes 
Scar core, g 8 22 20 12 16 7 12 
Grey zone, g 12 26 4 19 7 8 5 
 
Table 6- 1 Baseline patient characteristics and CMR findings. 
ACE-I= angiotensin converting enzyme inhibitor; AF= atrial fibrillation; ARB= angiotensin 
receptor blocker; CMR= cardiac magnetic resonance imaging; EDV= end-diastolic volume; 
EF= ejection fraction; ICM= ischaemic cardiomyopathy; LV= left ventricle/ventricular; 
NICM= non-ischaemic dilated cardiomyopathy; PAF= paroxysmal atrial fibrillation. 
 
6.4.1 Heterogeneities in Apparent Conductivity (AC) and APD Restitution 
Properties  
The IQRs of AC and APD restitution data representing the heterogeneities of these 
electrical parameters were calculated for each patient, shown in Figure 2. The range 
of AC across the LV was comparable across the 7 patients. “Apparent Conductivity” 






) is proportional to the product of the square of CV and a time constant 
parameter in the model. In brief, the observed conduction velocity (CV) is responsible 
for the estimation of the intrinsic electrical parameters of the cardiac tissue. A simple 
Eikonal (EK) model is used to measure the electrical apparent conductivity (AC) 
parameters, which are then used to set the parameters of a biophysical model, the 
Mitchell-Schaeffer (MS) model. Contrary to CV, AC is independent of the 
propagation direction and curvature. As only endocardial data is measured, the 
acquired parameters are extrapolated through the myocardium using a diffusion-like 
process and global measurements such as the QRS durations are used to control this 
extrapolation. The MS model intrinsically incorporated CV restitution parameters 
adjusted according to AC. In the present study, a greater emphasis is placed on the 
impact of APD restitution, as in our experience CV restitution has a greater impact on 
propagation at much higher pacing frequencies. The AC range across the tissues 
subtypes (healthy, grey zone and scar) between patients with inducible VT and 

























 (scar core). 
The median APD-RC slopes and maximum asymptotic APD for NICM patients was 
lower than that for ICM patients (p<0.01). Amongst the 3 patients who underwent a 
clinical VT stimulation study, patients 1 and 2 with positive clinical VT stimulation 
studies had APD-RC slopes IQRs of 1.50 and 1.02; and maximum asymptotic APD 
IQRs of 123ms and 66ms. These IQRs were greater than that of patient 3 with a 
negative clinical VT stimulation study; in whom the APD-RC slope IQR and APD 





Figure 6- 2 Box-whiskers plots of (A) spatial heterogeneity of apparent conductivity; (B) 
maximum APD-RC slope; and (C) maximum (asymptotic) APD for each of the patients. 
 Box = median and quartile ranges; whiskers = total range. Data range values for each of the 
boxplots are shown at the bottom of each box-plot. Colour coding shows the range varies 
from the largest (darker brown) and the smallest (lighter brown) for each parameter. 
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The APD-RC properties and ACs are also illustrated with LV polar plots to provide a 
qualitative assessment of the spatial heterogeneity of these parameters across the LV 
in Figure 6-3.  
 
Figure 6- 3 LV polar plot representation of the spatial distribution of the maximum slope for 
APD-RCs, maximum asymptotic APD and AC. 
Scars identified by LGE CMR with its border zone (highlighted by grey contours) and 
clinically observed exit points (highlighted in Patient 1 and 2 by fang-shaped* white contours 
during re-entrant VT are overlaid to the polar plots.  
*Fang-shaped due to unfolding of 3D volume surface to 2D polar plot) 
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There appeared to be the same broad spatial heterogeneity in AC in all the study 
patients including the 2 patients with NICM who also had regions of low AC in areas 
without scars seen on CMR. However, there was a wide variation in the spatial 
heterogeneity of APD-RC properties across the cohort, with patients 1 and 2 showing 
the most heterogeneity.  
 
Visually, the VT exit points that were observed during the clinical VT stimulation 
studies in patients 1 and 2 appear to be at the neighbouring regions with varying 
degree of APD-RC properties and AC. These VT exit points were in the scar border 
zone/grey zone as determined by the LGE CMR scans. In order to explore the role of 
local spatial heterogeneity of electrical properties play in arrhythmogenesis we 
assessed the differences in AC, APD and APD-RC between neighbouring regions in 
LV (each region ≈ 3mm3) by evaluating the gradient of the parameters in polar 
coordinates in Figure 3. The gradient amplitude reflects how smooth or abrupt the 
transition is between values in the spatial domain. Using a definition of “high gradient” 
being greater than the 90th percentile of the gradient range, the proportion of LV 
regions with high gradients was analysed for each patient. For each of the electrical 
parameters, AC, APD and APD-RC, there was no statistically significant difference in 
the number of elements with high gradients (≥ 90 percentile) between patients. 
However, patient (1 and 2) with inducible VT had a combined greater heterogeneity 
of both AC and APD-RC, shown in Figure 4. 
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Figure 6- 4 Percentages of LV spatial domains with high gradient (> 90th percentile of the 
gradient range) as a representation of spatial differences between neighbouring regions in 
terms of AC and APD-RC slope for each patient (P1-P7). 
The separating line with a maximal margin was computed here using the Support Vector 
Machine algorithm. 
 
6.4.2 Induction of VT and Clinically Observed Monomorphic VT Exit Points  
Patient 1 had induced sustained monomorphic VT (SMVT) with a cycle length (CL) 
of 275ms at Wellens’ stage 11. Patient 2 had induced SMVT with a cycle length of 
245ms at Wellens’ stage 4. The patterns of activation for both re-entrant VT circuits 
are illustrated in Figure 5. Analysis of the UEG recording from the EAM showed a 
higher percentage of maximum APD-RC slope that is 2 standard deviation (SD) above 
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the mean LV APD-RC slope at the observed exit points (32%) compared to the scar 
(4%) and non-scar regions (0.2%). The absolute values in APD and tissue 
conductivity between the three areas were not as distinct although the exit point 



























). It is possible that it is the heterogeneity in 
regional tissue electrical properties distributions rather than the absolute value (mean 
or median) that may allow us to identify the exit points from other regions of the 
myocardium.  
 
Figure 6- 5 Isochrones mapping during re-entrant VT. 
 (A) Patient 1 with VT cycle length 275ms; (B) Patient 2 with VT cycle length 245ms.  
 
In Patient 1, the sustained VT self-terminated 42 seconds after failed attempts of 
 113 
overdrive pacing given due to patient’s stable hemodynamic response. In Patient 2, 
the sustained VT required DC-cardioversion due to patient’s unfavorable 
hemodynamic response. The 3D VT isochrones with exit points (red) in relation with 
scar core (white) and grey zone (grey) are shown in the left panels. Unipolar 
electrograms recording during VT are shown in the middle panels. LV polar plots of 
VT isochrones illustrating the direction of activation pattern are shown in the right 
panels.  In Patient 1, the endocardial activation recorded from EAM showed the re-
entrant VT circuit initiating from the LV lateral wall, spreading anteriorly and then 
posteriorly before returning to the lateral wall. In Patient 2, the re-entrant VT circuit 
exited from the LV infero-lateral wall, spreading antero-laterally and then towards the 
septum, before returning to the infero-lateral wall. 
 
6.4.3 Comparison of Model-Predicted and Clinically-Observed Induced VT 
Sustained monomorphic VT was induced in silico at stage 7 of the virtual Wellens 
protocol for Patient 1 and stage 5 for patient 2. Sustained VT was not inducible in 
silico for patient 3. LV polar plots of the clinical and virtual VT isochrones are 
illustrated in Figure 6 for comparison. Both macroscopic re-entrant VT circuit and 




Figure 6- 6 VT isochrones of induced re-entrant VT during clinical VT stimulation study (left 
panel) and during in silico VT stimulation study (right panel). 
 
The arrows point towards the directions of propagation. Scars (core and grey zone) 
are superimposed to the LV shell shown in darkened regions. The personalised model 
of patient 1 predicted a sustained re-entrant VT circuit with a cycle length of 260ms 
compared with the clinically observed cycle length of 275ms with a macroscopically 
similar activation pattern and a predicted exit point that matched with the observed 
clinical one. The personalised model of patient 2 also predicted a positive VT 
stimulation study with a cycle length of 250ms compared with 245ms for the clinical 
VT. The induced VT was sustained and the re-entrant pathway stable. Notably the 
direction of the activation pattern during the predicted re-entrant VT was reversed 
from that observed clinically; however, the predicted exit point correlated with the 
clinically observed one. 
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6.4.4 Three-Dimensional VT Circuit Visualisation 
By taking into account the 3D geometric information including transmural scar core 
and grey zone across the LV wall, the computer model enabled the prediction of a 3D 
VT circuit as opposed to the 2D VT activation pattern observed by endocardial EAM. 
Computational simulation allowed this additional insight to the wave propagation 
within the myocardium. For patient 2, the activation wave front of the re-entrant VT is 
shown propagating in the region of the grey zone. The estimated wave front path 
surrounds the scar core and lies within the scar border zone, entering from the 
endocardial surface, meandering within the ventricular wall, and exiting via the 
epicardial surface, shown in Figure 6-7.  
 




Estimated endocardial 2D geodesic path between the entry and exit points from 
electroanatomical study during clinical VT stimulation study is demonstrated by the 
isochrones map.  Estimated intra-myocardial 3D geodesic path (red line) takes into 
account of the scar heterogeneity from the high-resolution CMR images. The entry 
and exit points are illustrated by the graded colours on the 3D path with blue denoting 
late activation and red denoting early activation. The activation wave front of the re-
entrant VT propagates in the region of the grey zone. The estimated wave front path 
surrounds the scar core and lies within the scar border zone, entering from the 
endocardial surface, meandering within the ventricular wall, and exiting via the 
epicardial surface. 
A comparison of clinically observed and predicted exits points in terms of anatomic 
location were made. We defined the exit region compassing anatomical points with an 
activation time within 10ms of the earliest activation. The distance between the 
clinically observed and simulated exit points was defined as the 3D Euclidean 
distance between the centres of both exit regions. A difference of 7mm and 8mm were 
found, respectively, for patients 1 and 2.  
 
6.4.5 Simulated VT Stimulation from Additional Sites 
VT stimulation study was also performed in silico by pacing from other sites than the 
RV apex used during the clinical study for patients 1 and 2. Different VT circuits with 
three additional exit points were observed in both patients. The exit points were 
located on the boundary of scar in the region of the grey zones from the CMR LGE 
images. Similar to the clinically observed exit points, they were mostly in the region 
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of maximum APD-RC slope. The composite of different exit points are plotted in 
Figure 6-8 in terms of their APD restitution properties and AC.  
 
Figure 6- 8 Correlation of predicted exits points with structural heterogeneity and functional 
heterogeneity. 
A = Patient 1. B = Patient 2. The left panel shows the isochrones for the three predicted VT 
circuits with fangs of white lines denoting the exit points. The middle panel demonstrates the 
LV scar distribution with black region denoting healthy myocardium, white region denoting 
the scar core and the grey region denoting the grey zone/scar boarder zone with overlying 
composite exit points (fanged green lines). The right panel demonstrates the electrical 
properties with overlying composite exit points (fanged green lines). 
 
6.5 Discussion 
The present study provides new insights into the prediction of VT circuits using a 
biophysical model. The principal findings of our study are as follows: 1) the location 
of scar border zone (grey zone) on high-resolution CMR correlates with areas of 
abnormal measured and model derived electrical properties; 2) the VT exit points 
have a substantially higher percentage of tissue with steep APD-RC slopes compared 
to surrounding tissues; and combined tissues heterogeneity in APD-RC and CV may 
underlie the substrate for the inducibility of VT; 3) in silico VT stimulation studies 
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were able to predict inducibility of VT in patients at risk of ventricular arrhythmia; 4) 
the characteristics of the modeled VT circuits correlated well with the clinically 
observed circuits in terms of cycle length, macroscopic activation patterns and VT 
exit sites. 
 
6.5.1 Tissue Heterogeneity (admixture of scar and myocardium) co-location with 
Heterogeneity in APD Restitution Properties and Tissue Conductivity 
A correlation between the spatial heterogeneity in APD, APD-RC slopes and AC and 
the location of grey zone detected on high-resolution CMR supports the notion that 
myocardial scars can alter the regional restitution properties and provide potential 
substrate for arrhythmia.
61
 Data from the two patients who developed sustained VT 
suggest that VT exit points are co-located with heterogeneous APD-RC slopes. 
Ciaccio et al. has demonstrated potential mechanisms using a geometric model that 
could account for this co-location between exit zones and conducting channels in 
terms of tissue conductivity.
123
 The presence of clumps of fibroblasts, although 
electrically non-excitable, results in a slowing of the electrical wave front propagation 
in the myocardial tissue in which they are embedded. Fibroblasts can modulate 
cellular ion channel remodelling and therefore tissue electrical properties through a 
variety of mechanisms including mechano-electric feedback via stretch-activated ion 
channels, close coupling of nearby cardiac myocytes via connexin, and by altering 
surrounding myocardial fibres anisotrope.
61,124
 Some of these mechanisms have been 
shown in vitro, but remains speculative in vivo. The suggested relationship between 
the degree of heterogeneity demonstrated by the electrical gradients between 
neighbouring tissue domains and the propensity for sustained ventricular arrhythmia 
is therefore likely be non-linear as observed in the present study. The present study 
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supports the notion that potential successful ablation sites for VT lie in areas of 
heterogeneous tissue zones that can be identified with CMR.
99,125 
 
Heterogeneity in electrical properties have been observed in LV.
117,118
 Computation 
modellings  have demonstrated that theoretically APD-RC slope >1 is needed to result 
in electrical instability and initiate ventricular arrhythmia.
126
 In keeping with the 
observed tissue functional heterogeneity at the VT exit points in the present study, 
others have also demonstrated that the heterogeneity in APD-RC slopes is needed for 
the initiation and stability of re-entry VT.
118,126,127
 These prior studies did not have the 
benefit of high-resolution CMR scar information, and so could not explain the 
anatomical cause of this. Nash et al. speculated that regional stretch strain pattern 
resulting from ischemia might have led to electrical remodelling through mechano-
electric feedback.
118
 It may well have been that these regions had areas of grey zone 
as they correlated to the territories of the diseased coronary arteries.  
 
Restitution hypothesis has suggested that electrical alternans was a dynamic 
consequence of the slope of the APD restitution curve and if the slope of was ≥ 1, 
then APD alternans was possible.
128,129
 However, in-vivo studies (Nash et al 2006 and 
Orini et al 2016) have found a large region of normal left ventricle tissue express 
APD restitution properties > 1, in accordance with our finding.
118,130
 There are also 
significant regional heterogeneities observed within the LV (basal vs. apical; 
epicardial vs. endocardial). This suggests the importance of restitution parameters 
other than slope per se in the mechanisms underlying arrhythmogenesis. It is reflected 
in our result that it is the spatial heterogeneity and heterogeneity in the neighbouring 
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tissue that provide substrate for ventricular arrhythmia. APD restitution property is a 
function of both activation and repolarization. Orini et al has recently demonstrated 
the relationship in a systematic assessment of these parameters in a human whole 
heart in vivo study.
130
 At shorter cycle length, conduction delay significantly 
increases the APD slope by interacting with the diastolic interval; and ARI restitution 
slope does not depend on baseline APD, but more dependent on the activation time 
than the repolarization time. In the present study, the exact correlation was not made. 
However significant heterogeneity in terms of APD slopes and conductivity were 
observed at the re-entrant arrhythmia exit zone. Further correlation of the these 
parameters would be of great interest in exploring the mechanism by which these 




6.5.2 In silico VT stimulation studies in patients 
Encouragingly the personalised cardiac models encompassing both anatomical and 
electrical properties were able to predict not only the inducibility of VT, but also the 
re-entrant VT circuit properties and anatomical locations of the substrate. The present 
study is unique in that, as well as anatomical and scar information it incorporated 
personalised functional data including APD-RC properties and tissue conductivities 
into the patient-specific cardiac models. Previously, Arevalo H et al. suggested that 
VT dynamics were primarily governed by the geometric parameters of the scar-core 
and border zone using image-based computational VT modelling work.
131
 The present 
study highlighted the advantage of incorporating detailed geometric information 
gained from CMR, demonstrating the possibility of using high-resolution 3D scar data 
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to help predict potential critical isthmus on the epicardial surface.  This is important, 
as conventional mapping techniques used during ablative therapy are limited to two-
dimensional geometry when the substrate of the VT circuit could be on the opposite 
side of the mapping surface.  
 
Whilst we realise that CMR can provide important scar geometry that governs the 
substrate of re-entrant VT, we also recognise that the resolution of the current 
standard clinical CMR technique is limited (common voxel size 2x2x8mm
3
) in 
providing the level of spatial geometry details that we would like to see at the border 
zone. We believe that additional knowledge and understanding of patient-specific 
heterogeneities in local electrical parameters would assist in predicting the likely 
culprit conduction channels/isthmus, and not the bystanders, that is critical to the 
clinical VT. We have performed additional sensitivity analysis using empirical 
electrical parameters instead of personalised patient-specific electrical data in the two 
patients with positive clinical VT stimulation studies and found that using combined 
personalised electrical and image data can potentially improve the accuracy of VT 
inducibility and predictions regarding the location of exit zones predictions. (See 
Supplemental Material: Personalised vs. non-personalised empirical electrical 
parameter)  
Given the interaction between activation and repolarization wave front, Taggart et al 
has proposed a re-entry vulnerability index (RVI) which may predict the susceptibility 
of re-entry in tissue.
132
 Coronel et al demonstrated that the critical parameter for 
differentiating between the occurrence of reentry and the mere occurrence of a line of 
activation block between the two myocardial regions was not the magnitude of the 
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repolarization gradient but the timing of arrival of the premature activation wave at 
the distal side of the line of activation block relative to the repolarization time of the 
premature beat proximal to the line of block.
78
 Thus during electrophysiology study, 
by evoking an extra simulation and then measuring the local unipolar electrograms at 
different points within the ventricle, one can calculate the activation time and 
repolarization at those points. With the additional anatomical information in terms of 
distance between neighboring points, an algorithm is created to allow identification of 
sites of block and subsequent reentry. Such analysis can potentially be retrospectively 
applied to the dataset in the present study. However the inherent limitation of NCM 
with T wave morphologies may potentially impact on the analysis. 
 
 
6.5.3 Clinical application: Potential for Circuit Prediction using Personalised 
Computer Models to Guide Ablation 
Whilst cardiac modelling has been an active research area for decades, personalised 
cardiac modelling using patient-specific clinical data is in its infancy. In silico 
personalised models may offer significant clinical benefit in predicting the risk of 
ventricular arrhythmia in patients and guiding treatments including ICD implantation 
and VT ablation. Successful VT termination through ablation may be achieved when 
the critical isthmus is successfully interrupted with ablation lesions. If VT exit points 
can be predicted with biophysical models then this information may be used to guide 
ablation. Such models also offer additional ﬂexibility as the model can simulate any 
combination of paced stimuli from different locations with varying pacing cycle 
lengths, which may not be feasible in clinical practice. Predicted VT exit points could 
be Recently, Ashikaga et al. presented a retrospective study that found a good 
 123 
correlation between the predicted ablation sites and the actual target VT ablation sites 
at the scar border zone.
133
 We have indeed demonstrated that additional exit points 
can be induced from in silico VT stimulation studies which could be potential targets 
for ablation. Our results suggest that patient-speciﬁc cardiac models may offer 
incremental clinical benefit in terms of ventricular arrhythmia risk stratification and in 
the planning and delivery of ablation strategies for re-entrant ventricular arrhythmias. 
Non-invasive body surface mapping could be incorporated to routine simple 
electrophysiology study to gain such personalised whole heart electroanatomic data in 





Arevalo H et al. suggested that VT dynamics were primarily governed by the 
geometric parameters of the scar-core and border zone using image-based 
computational VT modeling work with scar data acquired from high-resolution CMR 
of ex-vivo canine heart (reconstructed voxel size 200um3) and empirical ionic cell 
parameters.
131
 Recently, Ashikaga et al. elegantly demonstrated that such image-based 
simulation can estimate ablation target site in a retrospective study in patients who 
underwent catheter ablation of VT.
133
 Others previously have shown that conducting 
channels of viable myocardium between the scars detected with CMR, in regions of 
scar border zone, have correlated with potential ablation sites for reentrant VT.
99,125
  
Whilst we realize that contrast-enhanced CMR provides important scar geometry that 
governs the substrate of reentrant VT, we also recognize that the resolution of current 
standard clinical CMR imaging technique is limited (common voxel size 
2x2x10mm3) in providing the level of spatial geometry details that we would like to 
 124 
see at the border zone. Thus the term “gray zone” reflecting the spectrum of 
intermediate signal intensity seen on CMR scar images at the scar border zone was 
originated.  
We therefore adopted a slightly different computational approach to the simulated VT 
model by incorporating not only a higher resolution than standard CMR scar images 
to obtain the geometry information in our study but also patient-specific endocardial 
electrical parameters from endocardial non-contact electrical mapping. We believe 
that at the current standard resolution achieved with clinical CMR scar images, 
additional personalized electrical parameters would assist in predicting the likely 
culprit conduction channels/isthmus that is critical to the clinical VT and not the 
bystanders.  
 
6.5.4 Study limitations 
Given the invasive nature of the study precludes analysis of a large number of patients, 
the study is limited by the small number of patients included with only a subset of 
patients undergoing a VT stimulation procedure. The electro-anatomical data are 
derived from non-contact mapping with the inherent limitations of this type of 
mapping. It was chosen for its ability to provide ‘beat-to-beat’ mapping in the setting 
of rapid and unstable VT circuits. The cardiac model also made several 
simplifications in particular for the Purkinje network and pathological changes of 
cardiac fibre orientations. With any personalisation of computational physiology 
model, there is a degree of uncertainty due to the limitations in acquired temporal and 
spatial resolution clinical data. Extending computational methods used in the study to 
incorporate an efficient Bayesian inference method could account the uncertainties in 
the application of the model.
13520 
The action potential duration (APD) restitution 
 125 
represents the APD as a function of the preceding diastolic interval or local cycle 
length. The curve produced when APD is plotted against cycle length is not linear and 
is usually flatter for longer cycle length and steeper for shorter cycle length. The 
estimation accuracy of restitution curve using a mono-exponential function will be 
dependent on the range of the cycle length tested. Its inaccuracy increases over the 
shorter cycle length range and with fewer sampling intervals, giving an 
over/underestimation of the restitution curve where the restitution curve is usually 
steeper. In the present study, the MS model was used. It is a simplified ionic model 
for fast simulation and personalization using clinical data, thus limited parameter was 
used. A bi- (or higher) exponential function may allow more degree of freedom in 
estimating the shape of the restitution curve as others have found a secondary peak 
and plateau in the shape of APD restitution curve. 
6.6 Conclusion 
Patient-speciﬁc spatial heterogeneity of restitution properties were the distinguishing 
features of ventricular arrhythmogenicity, with re-entrant VT exit points present in 
regions of higher maximum APD-RC slopes compared with the surrounding tissue. 
These regions were within the grey zone identified by LGE CMR. Personalised 
biophysical model was able to predict macroscopic VT circuits and exit point 






6.7 Supplementary material 
Rocio Cabrera-lozoya PhD and Jatin Relan PhD
 
(Inria, Asclepios Team, Sophia 
Antipolis, France) under the guidance of Maxime Sermesant PhD. carried out the 
following computational work. 
6.7.1 Computer Modeling 
The present study used a coupled personalisation framework that was previously 
evaluated in details.
120,121
 It combines the benefits of two different kinds of 
mathematical models while keeping the computational complexity tractable. The 
Eikonal (EK) model was used to estimate the conductivity parameters over the 
ventricle derived from non-contac diffusion-like process t mapping of the ventricular 
endocardial surface potential, which were then used to set the parameters for the 
Mitchell-Schaeffer (MS) model. Additionally, the MS model is able to hold the 
memory of one preceding cycle and has restitution properties, thus is able to simulate 
arrhythmias macroscopically. Both models are computed on the whole 3D 
myocardium. This personalisation framework has already been detailed in a previous 
publication and the predictive power of such personalised model was evaluated on 
experimental data. 
120,121
 A summary on the personalisation of each of the models is 
included in the following sections.  
 
Cardiac Electrophysiology Models 
 
Eikonal (EK) Model  
The EK model simulates the propagation of the depolarisation wave in cardiac tissue 
by computing the local activation time. It is governed by the eikonal-diffusion 
equation and solved using the fast marching method. It can be written as: 
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𝑐𝑜√𝑑𝐸𝐾 (√∇𝑇(𝑥)𝑡𝑀∇𝑇(𝑥)) − ∇ ∙ (𝑑𝐸𝐾𝑀∇𝑇(𝑥)) = 𝜏(𝑥) 
 
Where: 
𝑐𝑜 – is a dimensionless constant (=2.5) 
𝜏(𝑥) – is the cell membrane time constant (=0.003s) 
𝑑𝐸𝐾 – is the square of the tissue space constant along the fiber and is related to the 
specific conductivity of the tissue in the fiber direction, it has units of m
2 
𝑀 = 𝑑𝑖𝑎𝑔(1, 𝜌, 𝜌) – is a diffusion tensor that incorporates the tissue anisotropy into 
the model 
𝜌 = 1/2.52 – is the anisotropy ratio between longitudinal and transverse diffusion. 
This value is given to have a conduction velocity (CV) 2.5 times faster in the fiber 
direction 
  





Mitchell Schaeffer (MS) Model  
The MS model is a simplified biophysical model derived from the Fenton Karma 
ionic model.
122,137
 It models the trans-membrane potential as the sum of a passive 
diffusive current and several active reactive currents including combination of all 
inward and outward phenomenological ionic currents. This is described in the MS 



















   𝑖𝑓  𝑢 <  𝑢𝑔𝑎𝑡𝑒
−𝑧
𝜏𝑐𝑙𝑜𝑠𝑒





𝑢 – is a normalised transmembrane potential variable 
𝑧 – is a gating variable which depicts the depolarisation and repolarisation phases by 




 – represents the inward currents (primarily Na+ and Ca2+) which raise 




 – represents the outward currents that decrease the action potential 
voltage (mainly K
+
), describing repolarisation  
𝐽𝑠𝑡𝑖𝑚 – is the stimulation current at the pacing location 
𝜏𝑖𝑛, 𝜏𝑜𝑢𝑡, 𝜏𝑜𝑝𝑒𝑛, 𝜏𝑐𝑙𝑜𝑠𝑒 – have units of seconds 
𝑀 – is a diffusion tensor that controls the diffusion term in the model  
 
This model incorporates both APD and CV restitution effects, and the restitution 
curves can be written in an analytical formulation, which can be used to estimate 
restitution parameters. 
 
Depolarisation and Repolarisation time extraction 
The electrical data was collected with high pass filter settings for prominent QRS 
detection and with low pass filter for T-Wave detection. The depolarisation times 
were detected within the QRS window and were derived from the zero crossings of 
the laplacian of the measured unipolar electrograms. The repolarisation times were 




alternative method has repolarisation times derived from 𝑑𝑉/𝑑𝑡𝑚𝑎𝑥 for the negative 
T-wave, at the 𝑑𝑉/𝑑𝑡𝑚𝑖𝑛  for the positive T-wave, and the mean time between 




Apparent Conductivity Parameter Estimation 
The apparent conductivity (AC) of tissue can be measured by the parameter 𝑑𝐸𝐾 in 
the EK model. It is initially estimated on the endocardial surface as a global value 
using a bisection method that matches the average conduction velocity of the 
measured depolarisation time (DT) isochrones to the simulated ones. It is used as an 
initial estimate in an adaptive multi-level domain decomposition algorithm, which 
minimises the mean-squared difference of the simulated and measured DT 
isochrones.
1387
 One particular aim of this step is to estimate areas with high 
conduction velocity, which can represent parts of the Purkinje network. 
 
Extrapolation of myocardial volumetric parameters from endocardial data, imaging 
and body surface ECG 
In order to propagate the estimated parameters to the whole myocardium, the present 
approach uses a diffusion-like process that smoothly extrapolates the estimated 
endocardial parameters. This estimation is based on the model using the anatomical 
3D information from the CMR scar images and the global electrical information 
(ECG). The transmural AC value is estimated in order to fit the measured QRS 
duration, by a one-dimensional minimisation of the following cost function: (mean-
squared difference of simulated and measured isochrones at endocardium + squared 
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difference of simulated and measured QRS duration). The simulated QRS duration is 
calculated as the difference between the maximum and the minimum depolarisation 
times in the biventricular mesh and the measured QRS duration is estimated from the 





 as previously described.
139
 Such estimation method has been 




Due to the absence of transmural electrical propagation information, no variation is 
assumed across the healthy left ventricular myocardium, excluding the LV 
endocardium which was personalised as described in the previous paragraphs and the 
scar personalised from imaging, see below. 
 
Coupling of EK and MS Model Parameters 
 
The AC parameter for EK model 𝑑𝐸𝐾  is a scale for the diffusion speed of the 
depolarisation wave front in the tissue. In 3D, the model Conduction Velocity (CV) is 
related to 𝑑𝐸𝐾 as  
 
𝑐𝐸𝐾 = 𝛼𝐸𝐾√𝑑𝐸𝐾 + 𝛽𝐸𝐾 
 
where the constants 𝛼𝐸𝐾 and 𝛽𝐸𝐾 are introduced to take into account the discretisation 
errors (in particular of the curvature) in 3D.  
The corresponding conductivity parameter for MS model, 𝑑𝑀𝑆 is also a scale for the 
wave diffusion speed in the tissue. The model CV here is related to  𝑑𝑀𝑆 as: 
𝑐𝑀𝑆 = 𝛼𝑀𝑆√𝑑𝑀𝑆 + 𝛽𝑀𝑆 
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where the constants 𝛼𝑀𝑆 and 𝛽𝑀𝑆 are introduced for the same reasons as of EK model, 
while 𝜏𝑖𝑛 is kept as a constant. The estimated AC parameter 𝑑𝐸𝐾 can then be used to 




To represent the volumetric heterogeneity of the border zone, the intensity values 
derived from the 3D LGE CMR images were used to modulate the spatial variation in 
the AC values of scar border zone (the higher the signal intensity seen on LGE-CMR 
images, the lower the tissue conductivity). AC values were assigned to zero in the scar 
core, to reflect the paucity of viable cardiac myocytes. 
 
APD Restitution Curves 
APD restitution is an electrophysiological property of the cardiac tissue and defines 
the adaptation of APD as a function of the heart rate. Its slope has a heterogeneous 
spatial distribution. The APD restitution curve (APD-RC) defines the relationship 
between the diastolic interval (DI) of one cardiac cycle and the APD of the 
subsequent cardiac cycle. The slope of these RCs is controlled by a model parameter 
𝜏𝑜𝑝𝑒𝑛 of the MS model and depicts the APD heterogeneity present at multiple heart 
rates. APD-RC for MS model is explicitly derived as: 
 
𝐴𝑃𝐷𝑛+1 = 𝑓(𝐷𝐼𝑛) =  𝜏𝑐𝑙𝑜𝑠𝑒 ln(





where ℎ𝑚𝑖𝑛 = 4(𝜏𝑖𝑛/𝜏𝑜𝑢𝑡) and n is the cycle number. The maximum value of APD is 








CV Restitution Curves 
 
In the current study, a greater emphasis is placed on the impact of APD restitution, as 
in our experience CV restitution has a greater impact on propagation at a much higher 
pacing frequencies than our sampling pacing range. If deemed relevant, CV restitution 
can also be personalised, as the parameters to adjust CV restitution are also present in 
the Mitchell-Schaeffer model. Its mathematical formulation is described in the 
















However, these parameters also impact the APD restitution formula, so a slightly 





6.7.2 Personalised vs. Non-Personalised Empirical Electrical parameters 
VT simulation with patient-specific personalised parameters 
The personalised model was finally used to predict VT circuits, using an in silico 
programmed ventricular stimulation study from RV apex with Wellens protocol. Each 
stage for the VT stimulation in silico was simulated in parallel on a cluster of 
computers, and tested for induced VT. Simulated induced VT cycle isochrones were 
computed to locate the earliest activation time site, which corresponded to the exit 




VT simulation with non-personalised parameters 
A sensitivity analysis where the performance of a model constructed using non-
personalised empirical electrical parameters was compared to that using personalised 
patient-specific electrical data. For all cases, patient anatomy and scar geometry was 
preserved. The VT simulation procedure was performed as described in the previous 
sections.  
 
The personalised mesh was divided into three different types of tissue, guided by the 
LGE CMR imaging information: healthy myocardium, grey zone and scar core. 
Nodes within the scar core tissue were set to have zero apparent conductivity values. 
Conduction and restitution parameters in the healthy myocardium tissue were set to 
the average value computed from the personalised models across patients. This 




 for the apparent conductivity and Tau close = 180ms, tau in = 
0.3ms, tau out = 6ms, tau open = 160 ms for the restitution model parameters. 
According to the described values of conduction velocity and restitution parameters in 
the literature, model parameters were modified in the grey zone areas.
19,140
 
Conduction velocity parameters were reduced by 90% with respect to those in the 
healthy myocardium. Restitution parameter values in the grey zone regions were set 
to have 25% longer action potential duration (increase in tau close parameter) and 
31% slower upstroke velocity (increase in the tau in parameter) than those in the 
healthy myocardium.  
 
Using non-personalised empirical electrical parameters, VT was not inducible in 
Patient 1. It also induced a different macroscopic VT circuit morphology from the one 
seen during the clinical study in Patient 2. The Euclidean distance between the centre 
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of the clinical exit region and that predicted using non-personalised electrical 





Chapter 7 Myocardial tissue characterisation by cardiac 
magnetic resonance imaging using T1 mapping predicts 
ventricular arrhythmia in ischemic and non-ischemic 
cardiomyopathy patients with implantable cardioverter 
defibrillators 
 
This chapter describes the work of a prospective clinical study that assessed the 
prognostic value of quantitative scar assessment using CMR in predicting ventricular 
arrhythmia in both patients with ischaemic and non-ischaemic cardiomyopathies. This 
included scar quantification using conventional late gadolinium enhancement images 
and T1 mappings with its associated derived index such as extracellular volume index 
(ECV). The analyses also demonstrated how results of the present study would have 




Background: Diffuse myocardial fibrosis may provide substrate for the initiation and 
maintenance of ventricular arrhythmia. T1 mapping overcomes the limitations of the 
conventional delayed contrast-enhanced cardiac magnetic resonance imaging (CE-
CMR) technique by allowing quantification of diffuse fibrosis. We assessed whether 
myocardial tissue characterisation using T1 mapping would predict ventricular 
arrhythmia in ischemic and non-ischemic cardiomyopathy.  
Methods: A prospective longitudinal study of consecutive patients receiving 
implantable cardioverter defibrillators (ICD) in a tertiary cardiac center. Participants 
underwent CMR myocardial tissue characterisation using T1 mapping and 
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conventional CE-CMR scar assessment prior to device implantation. The primary 
endpoint was appropriate ICD therapy or documented sustained ventricular 
arrhythmia.  
Results: One hundred and thirty patients (71 ischemic; 59 non-ischemic) were 
included with a mean follow-up period of 430±185 days (median: 425 days; IQR: 293 
days). At follow-up, 23 (18%) patients experienced the primary endpoint. In 
multivariable-adjusted analyses, the following factors showed a significant 
association with the primary endpoint: secondary prevention (hazard ratio [HR] 1.70, 
confidence interval [CI] 1.01-1.91), non-contrast T1
_Native
 for every 10ms increment in 
value (HR 1.10, CI 1.04-1.16; 90ms difference between the endpoint positive and 
negative groups), and greyzone
_2sd-3sd
 for every 1% LV increment in value (HR 1.36, 
CI 1.15-1.61; 4% difference between the endpoint positive and negative groups). 






 were also 




Conclusions: Quantitative myocardial tissue assessment using T1 mapping is an 
independent predictor of ventricular arrhythmia in both ischemic and non-ischemic 
cardiomyopathies. 
Key words: ventricular arrhythmia; T1 mapping; grey zone; defibrillator 
 
7.2 Introduction 
Ventricular arrhythmia is a major cause of sudden cardiac death in patients with 
impaired left ventricular (LV) function. Implantable cardioverter defibrillators (ICDs) 
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are effective in reducing mortality but are associated with both peri-operative 
complications and post-implant morbidity including inappropriate therapies.
26,27
 Risk 
stratification is therefore critical to select patients most likely to benefit from ICD 
therapy. Although LV ejection fraction (LVEF) plays a central role in patient 
selection, there is considerable risk heterogeneity amongst patients with impaired 
LVEF.
141
 Myocardial fibrosis provides potential substrate for the initiation and 
maintenance of re-entrant ventricular arrhythmia circuits, which propagate around 
localised regions of scars and along zones of slow conduction containing a mixture of 
scar and “healthy” myocardial tissue (grey zone). Cardiac magnetic resonance 
imaging techniques using late contrast enhancement (CE-CMR) are considered the 
gold standard for the non-invasive assessment of myocardial regional fibrosis, with a 
growing body of evidence showing the presence and the magnitude of the region of 
delayed contrast enhancement predict arrhythmia in ischemic and non-ischemic 
cardiomyopathies (ICM, NICM).
112,113,142,143
 Diffuse LV fibrosis has also been shown 
to be arrhythmogenic by affecting electrical propagation between individual myocytes, 
which might provide evidence of increased risk for ventricular arrhythmia.
144,145
 
Assessment of diffuse fibrosis as seen in patients with NICM is not possible with 
conventional CE-CMR techniques since they rely on an arbitrary scale of relative 
signal intensity (SI) difference detected between regions of dense scar and regions of 
user-defined “normal” tissue. Even in patients with ICM, the non-infarct regions of 
the LV seen as “normal” myocardium on CE-CMR may contain diffuse interstitial 
fibrosis as a result of adverse remodeling.
60,146
 Myocardial tissue characterisation 
using T1 mapping has emerged as a new CMR application, which has the potential to 
overcome the limitations of conventional CE-CMR techniques and allows 
characterisation of diffuse fibrosis, providing a reliable quantitative assessment of 
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myocardial tissue on a standardised scale. Several studies have shown a good 
correlation between measured T1 values and its associated derivative, extracellular 
volume index (ECV), with quantitative histological measures of fibrosis.
11,93,147
 
We therefore hypothesised that T1 mapping techniques, which enable better 
assessment of diffuse myocardial fibrosis, would help predict the occurrence of 
ventricular arrhythmia in patients with ischemic or non-ischemic cardiomyopathy 




(See Chapter 3.2 for General patient selection criteria) 
We prospectively invited all patients undergoing ICD implantation for primary and 
secondary preventions as per guidelines at our institution between May 2011 to 
January 2013 to participate.
148
 Over 90% of patients gave written informed consent 
and were recruited to the study. All study participants underwent CMR assessment 
and coronary angiography prior to device implant. Patients undergoing implantation 
of ICD for catecholaminergic VT, Brugada syndrome or long QT syndromes with 
normal CMR findings were not included in the final analysis.  
Cardiac magnetic resonance imaging protocol 
(See Chapter 3.3.1 for General CMR methods protocol) 
Image analysis 
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Ventricular volumes, function and mass were analyzed using dedicated software 
(ViewForum, Philips Healthcare, Best, Netherland) and were indexed to body surface 
area. CE-CMR images were visually assessed by two independent CMR experts 
blinded to the study outcome (RR and AC). In case of discrepancy, the data were 
jointly reviewed by these experts to reach a consensus. Quantitative analysis of late 
gadolinium enhancement (LGE) was performed using CMR42 (Circle Cardiovascular 
Imaging Inc., Calgary, Canada). The extent of LGE was quantified using both the 2-
standard deviation method (Scar
_2sd
, defined as the region with SI 2sd above the 




defined as the region with SI above the 50% of the maximal SI of the enhanced area). 
The extent of grey zone was quantified using the Greyzone
_2sd-FWHM
 method (defined 




), and the Greyzone
_2sd-3sd 
method (defined as the region with SI between 2 and 3 SD above the remote reference 
myocardium). Each of these indices was expressed as a percentage of the LV mass 
(%LV).  
T1 relaxation maps were processed using a customised software plugin, incorporating 
motion correction with open source software (Osirix environment, Pixmeo, Geneva, 
Switzerland). We performed motion correction by applying a multi-resolution 
BSpline deformable registration, as implemented in the Insight Toolkit.
71
 Due to the 
potential susceptibility of high T1 values to the effects of heart rate during image 
acquisition, we performed linear regression analysis of the measured native non-
contrast T1 (T1
_native
) values on heart rate and applied heart rate correction using a 
function of the mean heart rate of our study population to the non-contrast T1 values 
as previously described.
9
 The T1 associated derivative, extracellular volume index 





We chose a region of interest (ROI) in the septum for estimation of non-contrast T1 
(T1
_native
), post-contrast T1 (T1
_contrast
) and ECV, as previously described.
72
 Care was 
taken to avoid the endocardium/blood pool interface. If regional enhancement was 
seen in the septum on the LGE image a septal ROI was chosen adjacent to the 
enhanced region for T1 mapping analysis. The geometry of the mid-ventricular T1 
map slice was the same as that of the mid-ventricular LGE images to allow for this 
comparison.  
7.3.1 Follow-up and endpoint 
All patients were implanted with an ICD or an ICD combined with cardiac 
resynchronisation therapy device (CRTD) capable of storing electrograms that met the 
criteria for detection. A standardised programme for ventricular arrhythmia detection 
and therapy was employed: ventricular arrhythmias > 170 bpm were detected 
(detection count: 16 intervals) and treated with anti-tachyarrhythmia pacing (ATP) 
and then shock therapy if ATP failed. Ventricular arrhythmias > 210bpm were 
detected (detection count: 24/30 intervals) and were treated with shock therapy as the 
first line. Standard supraventricular tachycardia detection discriminators were enabled 
according to device manufactures’ recommendations. (St Jude Medical, St. Paul, 
Minnesota; Medtronic, Minneapolis, Minnesota. Onset: 81% for Medtronic devices, 
18% for St Jude devices; stability: 40ms for both types of devices; morphology: 
passive.) These settings were altered only if clinically indicated. Patients were 
followed up at three-monthly intervals. At each follow-up visit, the device was 
interrogated for system integrity and any recorded events were reviewed by an 
experienced device physiologist and trained electrophysiologist who were blinded to 
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the CMR data. The primary endpoint for our study was the delivery of appropriate 
ICD therapy for VT or VF, or documented sustained VT greater than 30-second 
duration as documented by the device. Multiple therapies may occur in a single 
triggered event and we defined any additional appropriate therapy five minutes apart 
from the preceding therapy to be a separate episode of therapy.  
7.3.2. Statistical analysis 
(See Chapter 3.6 for General statistical methods) 
The first episode of appropriate ICD therapy or sustained VT was considered as the 
event of interest for quantifying various associations. Kaplan-Meier survival curves 
were plotted to study the cumulative event rates between groups of participant, with 
the log-rank test providing further evidence regarding any significant differences 
between them. The univariate association between pre-specified variables of interest 
and the primary endpoint was examined using Cox proportional hazards regression 
models. For multivariable-adjusted analyses, a forward selection process using 
variables significantly associated with the outcome of interest in univariate analyses 
(at p <0.05) was employed to further determine any independent predictors of the 
primary endpoint. All reported associations in this study are hazard ratios (HR) and 
their corresponding 95% confidence intervals (CI). To overcome limitations of 
missing data, only patients who had complete information on CE-CMR derived 
indices and T1 mapping derived indices were included in our multivariate analysis. 
Moreover, to avoid spurious associations due to the inclusion of correlated variables 
in a single Cox model, the multivariate analysis studied each of the CE-CMR indices 
separately. Receiver-operating characteristic (ROC) curves were plotted to identify 
variable cut-off points with 90% sensitivity to discriminate the primary endpoint. The 
estimated cut-off values for the chosen scar index and T1 index to predict the primary 
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endpoint was retrospectively used to re-classify and dichotomise the study subjects 
into high and low risk categories. All data analyses were performed using SPSS 
statistical software (version 21, IBM, New York, USA). 
 
7.4 Results 
7.4.1 Study population  
A total of 138 patients agreed to participate in the study, of whom, 3 did not complete 
the CMR protocol due to claustrophobia and 2 additional participants were lost to 
follow-up. Three patients with Brugada or long QT syndromes were excluded from 
the analysis, leaving a total of 130 patients for further analysis. Of these, 71 patients 
had ICM and 59 had NICM (1 sarcoidosis, 5 hypertrophic cardiomyopathy, 53 dilated 
cardiomyopathy). One hundred study participants underwent T1 myocardial tissue 
characterisations and of this subset, 95 paired native and post-contrast T1 mapping 
images were suitable for analysis, 5 T1 mapping images were not suitable for analysis 
due to image corruption due to excessive motion artifacts. Table 7-1 shows the 








 ICM NICM P 
N (%) 71(100) 59(100)  
Age 66±10 58±18 n/s 
Female 14 (20) 12 (20) n/s 
ICD 34 (48) 25 (42) n/s 
CRTD 37 (52) 34 (57) n/s 
1°
 
prevention 48 (68) 44 (75) n/s 
2°
 
prevention 23 (32) 15 (25) n/s 
COPD 10 (14) 10 (17) n/s 
Diabetes 14 (20) 7 (12) n/s 
Hypertension 25 (35) 20 (34) n/s 
CVA 6 (8) 2 (3) n/s 
AF  14 (20) 19 (32) n/s 
eGFR<60mls/min/1.73m2 25 (35) 15 (25) n/s 
    
LVEF, % 26±11 35±18 n/s 
QRS, ms 123±25 124±30 n/s 
Pre-implant NSVT  
(1° prevention) 
13 (27) 17(38) n/s 
    
Aspirin/Clopidgrel* 65 (92) 28 (47) <0.001 
B-blocker 70 (99) 53 (90) n/s 
Ca-antagonist 2 (3) 3 (5) n/s 
ACEi/ARB 69 (97) 57 (97) n/s 
Statins* 65 (92) 37 (63) <0.001 
Amiodarone* 12 (17) 3 (5) 0.036 
Digoxin 7 (10) 6 (10) n/s 
Loop diuretic 27 (38) 30 (51) n/s 
K-sparing diuretic 33(45) 25 (42) n/s 
 
Table 7- 1 Baseline patient characteristics 
ICD = implantable cardioverter defibrillator; CRTD = cardiac resynchronisation therapy with 
defibrillator; COPD = chronic obstructive pulmonary disease; AF = atrial fibrillation; CVA = 
cerebral vascular accident; LVEF = left ventricular ejection fraction; NSVT = non-sustained 
ventricular tachycardia.  
* = Variable with a statistical significant difference between groups. 
 
7.4.2 Primary endpoint   
During a mean follow-up of 430±185 days (median: 425 days; IQR: 293 days), 23 
(18%) patients experienced appropriate ICD therapy.  Three patients experienced 
 144 
more than one episode of appropriate ICD therapy. The median time to first ICD 
therapy was 178 days, IQR 420 days. Of the 4 cardiovascular deaths (3 in ICM and 1 
in NICM; 1 died of primary heart failure, 3 died of heart failure following sepsis), 
only 1 patient had experienced appropriate ICD therapy following implant and before 
death. There was a greater proportion of appropriate ICD therapy in the secondary 
[11/38 (29%)] versus primary prevention [12/92 (13%)] group (p = 0.031), as was the 
cumulative event rate for the primary endpoint (p=0.033, Figure 7-1A). The 
cumulative event rate was similar, however, between the ICM and NICM cohorts 


















Figure 7- 1 Kaplan-Meier survival curves of appropriate ICD therapy for primary vs. 
secondary prevention (A); and for ICM vs. NICM (B). 
ICD = implantable cardioverter defibrillator; ICM = ischemic cardiomyopathy; NICM = non-
ischemic cardiomyopathy. 
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7.4.3 CE-CMR and T1 myocardial tissue characteristics 
When patients were dichotomised into endpoint +ve and endpoint –ve groups, there 
were significant differences in the CE-CMR derived indices with both scar and grey 
zone being significantly higher in the endpoint +ve group. In addition, non-contrast 
native T1 value was significantly higher in the endpoint +ve group (Table 7-2). 
 Endpoint -ve  Endpoint +ve  P 
 ICM NICM  ICM NICM  
LV EF, %;  32±15  30±12 0.893 
 28±10 36±19  31±13 30±12  
LV mass, g 151±42  155±34 0.588 
 146±35 155±49  162±33 144±36  
Scar
_2sd
*, %LV 18±11  30±11 <0.001 
 23±8 13±12  33±9 26±13  
Scar
_FWHM
*, %LV 11±7  18±8 <0.001 
 14±6 7±8  19±7 15±9  
Greyzone
_2sd-FWHM
*, %LV 8±5  12±7 0.006 
 9±4 6±6  14±7 11±7  
Greyzone
_2sd-3sd
*, %LV 5±3  9±3 <0.001 
 5±2 5±4  8±2 9±5  
T1
_native
*†, ms 1033±65  1123±80 0.029 
 1031±70 1035±59  1088±63 1158±93  
T1
_contrast†, ms 421±72  415±43
 
 0.592 
 418±56 425±87  421±34 408±56  
ECV† 0.29±0.06  0.31±0.05 0.262 
 0.29±0.06 0.29±0.06  0.31±0.04 0.32±0.07  
 
Table 7- 2 CMR derived indices  
EF = ejection fraction; FWHM = full-width half-maximum; ECV = extracellular volume 
index; LV = left ventricular; +ve = positive; -ve = negative 
 (T1
_native 
<1000ms were considered to be the normal reference in our institution. 1.5T 
scanner with a 32–channel coil, Philips Healthcare, Best, Netherlands. There were no 
significant differences, p > 0.05, in age, gender distribution, comorbidities such as 
hypertension/diabetes/renal impairment and patient heart rate during image acquisition 
between the Endpoint-ve and Endpoint+ve groups.) 
* Variable with a statistical significant difference between groups  
† T1 derived indices, n = 95 
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7.4.4 Predictors of ICD therapy  
Univariate analysis showed that secondary prevention, CE-CMR derived indices of 
scar and grey zone (n = 130), and non-contrast native T1 values (n=95) were 
significantly associated with appropriate ICD therapy (Table 7-3).  In multivariable-
adjusted analysis, secondary prevention, CE-CMR derived indices of scar and grey 
zone and non-contrast native T1 values were all significantly associated with ICD 
therapy (Table 7-3). To overcome limitations of missing data, only patients who had 
complete information on CE-CMR derived indices and T1 mapping derived indices 
were included in our multivariate analysis. The HR of secondary prevention was 1.70, 
a mean difference of 4% in Greyzone
_2sd-3sd
 between the endpoint +ve and endpoint –
ve groups gave a 2.4-fold excess risk of the primary outcome. Similarly, for non-
contrast native T1, a mean difference of 90ms between the end-point +ve and –ve 
groups was associated with a 1.4-fold excess risk of the primary outcome. The 











Univariate analyses    
Variables Hazard ratio Confidence intervals    P 
Age, + 1year 0.99 0.96-1.03 n/s 
Female 1.53 0.45-5.16 n/s 
COPD 2.16 0.84-5.55 n/s 
Diabetes 2.23 0.87-5.68 n/s 
Hypertension 1.89 0.83-4.29 n/s 
CVA 2.84 0.83-9.69 n/s 
AF 1.48 0.61-3.59 n/s 
eGFR<60mls/min/1.73m2 1.37 0.75-2.24 n/s 
QRS ≥120ms 1.18 0.51-2.73 n/s 
2° prevention 1.59 1.04-1.82 0.039 
LVEF, +1% 0.99 0.96-1.02 n/s 
LV mass, +1g 1.01 0.99-1.01 n/s 
Scar
_2sd
, +1%LV 1.09 1.05-1.14 <0.001 
Scar
_FWHM
, +1%LV 1.09 1.04-1.15 0.001 
Greyzone
_2sd-FWHM
, +1%LV 1.14 1.08-1.22 <0.001 
Greyzone
_2sd-3sd
, +1%LV 1.31 1.17-1.47 <0.001 
T1
_native
, +10ms 1.06 1.01-1.11 0.021 
T1
_contrast
, -10ms 1.03 0.98-1.09 n/s 
ECV, +1% 1.01 0.94-1.11 n/s 




   
Variables Hazard ratio Confidence intervals      P 
QRS ≥120ms   n/s 
2° prevention 1.70 1.01-1.91 0.048 
LVEF≤35%   n/s 
Scar
_2sd
, +1%LV 1.10 1.04-1.15 <0.001 
Scar
_FWHM
, +1%LV 1.11 1.05-1.19 0.001 
Greyzone
_2sd-FWHM
, +1%LV 1.13 1.05-1.22 0.001 
Greyzone
_2sd-3sd
, +1%LV 1.36 1.15-1.61 <0.001 
T1
_native
, +10ms 1.10 1.04-1.16 0.001 
 
Table 7- 3 Findings from univariate and multivariate Cox regression analyses 
EF = ejection fraction; FWHM = full-width half-maximum; ECV = extracellular volume 
index; LV = left ventricular; n/s = non-significant; +ve = positive; -ve = negative. For 
multivariable-adjusted analyses, each of the factors listed in the table has been mutually 
adjusted for all the other factors mentioned for the corresponding regression analysis. 
* To overcome limitations of missing data, only patients who had complete information on 
CE-CMR derived indices and T1 mapping derived indices were included in our multivariate 
analysis, n = 95. 
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† To avoid spurious associations due to the inclusion of correlated variables in a single Cox 
model, the multivariate analysis studied each of the scar or grey zone indices separately, i.e. 
for the analysis of Scar
_2sd
 +1%LV, the adjustment included QRS ≥120ms, 2° prevention, 
LVEF≤35% and T1_native +10ms; for analysis of Scar_FWHM +1%LV, the adjustment included 
QRS ≥120ms, 2° prevention, LVEF≤35% and T1_native +10ms; for the analysis of 
Greyzone
_2sd-FWHM
 +1%LV, the adjustment included QRS ≥120ms, 2° prevention, 
LVEF≤35% and T1_native +10ms; for the analysis of Greyzone_2sd-3sd +1%LV, the adjustment 
included QRS ≥120ms, 2° prevention, LVEF≤35% and T1_native +10ms. 
 
7.4.5 Risk re-classification 




 values that 
allowed 90% sensitivity for detecting the primary endpoint. Based on ROC analyses, 
a cut-off value of ≥1015ms was used for T1_native and a value of ≥5.5% of the LV 
mass was used for Greyzone
_2sd-3sd
 to dichotomise the study participants into high-risk 
(i.e. those requiring an ICD) and low-risk (i.e. those not requiring an ICD) groups. In 
the primary prevention group, 50 of the 80 participants (62.5%) who had an ICD 
implanted but who never experienced the endpoint were correctly reclassified into the 
low risk category based on Greyzone
_2sd-3sd
 data, whilst none of the participants 
experiencing a positive endpoint were mistakenly reclassified into the low risk group. 
By comparison, 25 of the 57 participants (43.9%) with a primary prevention ICD and 
a negative endpoint were correctly reclassified to low risk group based on T1
_native
 
measures, whilst none of the patients with a positive endpoint were mistakenly 
reclassified into the low risk group. The net reclassification improvement (NRI) was 
62.5% and 26.3%, respectively, compared with original clinical risk classification. 





 was effective in risk re-classification (NRI 26.3% and -7.9%, respectively, 
Figure 7-2A). The value of using risk reclassification is illustrated in Figure 7-2B 






 value to high or low risk categories resulted in 
significantly different cumulative event rates in the primary prevention cohort but not 


















Figure 7-2A. Risk reclassification with Greyzone
_2sd-3sd
 (high risk ≥5.5% LVmass) or 
T1
_native
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Net reclassification improvement = 43.9% 
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Net reclassification improvement =-7.9% 
* denotes changes affected by risk reclassification.  
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Figure 7-2B Kaplan-Meier curves for the reclassified high and low risk categories 
 
Figure 7- 2 Risk reclassification with Greyzone
_2sd-3sd
 (high risk ≥5.5% LVmass) or T1_native 
(high risk ≥1015ms) in the primary prevention and secondary prevention cohort (A), with 
corresponding Kaplan-Meier curves for the reclassified high and low risk categories (B).  
 
7.4.6 Reproducibility of T1 measurement 
T1 measurements were repeated in a subgroup of randomly selected patients from the 
study cohort (10 ICM and 10 NICM). For T1
_native
 measurement, the intra-observer 
average difference in values was 5±3ms, coefficient of variation (COV) was 
0.3±0.2%; the inter-observer average differences in values were 6±5ms and COV was 
0.4±0.3%. For T1
_contrast
 measurement, the intra-observer average difference in values 
was 5±4ms and COV was 0.8±0.6%; the inter-observer average differences in values 
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were 5±4ms and COV was 0.9±0.7%. There were good agreements in inter and intra-
measurements of native T1 and contrast T1 (Pearson’s r  = 0.99; p≤0.01). 
 
7.5 Discussion 
The current study is the first to demonstrate that non-contrast native T1 estimated 
with T1 mapping is an independent predictor of ventricular arrhythmia in patients 
with ICM and NICM.  It also provides further confirmation that the extents of scar 
and grey zone derived from CE-CMR are independently associated with ventricular 
arrhythmia, and highlights the importance of grey zone in patients with NICM.  
7.5.1 Diffuse fibrosis and ventricular arrhythmia  
It has long been recognised that diffuse interstitial fibrosis occurs at various stages in 
the pathological progression of cardiomyopathies of different etiologies. 
60,89,93,146,149
 
Fibroblasts are not electrically “inert” and can modulate cellular ion channel 
remodelling, thereby affecting tissue electrical properties through a variety of 
mechanisms including mechano-electrical feedback mediated via stretch activated ion 
channels; gap junctions via connexin with close coupling of nearby cardiac myocytes; 
and altering the orientation of cardiac fibres. Collectively, these effects can provide a 
substrate for ventricular arrhythmia.
61,124
 Electroanatomical mapping study suggests 
that diffuse interstitial fibrosis plays a critical role in the maintenance of re-entrant VT 
and propensity to degenerate to VF.
150
 Studies using myocardial biopsy specimens to 
look for diffuse fibrosis in patients with deemed normal hearts and those with 
hypertrophic cardiomyopathy have also shown a strong association between 




T1 mapping of the myocardium provides a true quantitative assessment of the voxel 
SI and is used to detect regions of diffuse interstitial fibrosis with higher native T1 
values than normal myocardium.  In comparison, conventional CE-CMR techniques 
require an arbitrary reference “normal” myocardium to generate an image with a 
signal contrast between fibrotic and apparently non-fibrotic regions. It is therefore less 
discriminative in “highlighting” the diffuse fibrosis that affects the myocardium in a 
more homogeneous way. Native T1 values reflecting the presence of diffuse 
interstitial fibrosis, not detectable by conventional CE-CMR, have been found to be 
higher in myocardial regions free of delayed contrast enhancement in a number of 
different cardiomyopathies.
153,154
 The current study is the first to show that native 
myocardial T1 is independently associated with ventricular arrhythmia in patients 
with advanced cardiomyopathies of both ischemic and non-ischemic etiologies.  
T1 values have also been measured following the administration of gadolinium 
contrast agents and in addition to the patients’ hematocrit levels can be used to 
calculate ECV. Several studies have demonstrated a close correlation between ECV 
and histological measures of fibrosis in cardiomyopathies of various etiologies.
155-157
 
Others have demonstrated a correlation between ECV and mortality.
16,158,159
 Accurate 
ECV assessment depends on the time delay of T1 mapping after contrast injection, the 
haematocrit level which affects the partition coefficient of the gadolinium contrast 
agent, the contrast kinetics between regions of fibrosis and normal myocardium and 
the contrast wash-out rate which is influenced by the renal clearance rate. In the 
current study, ECV was not a significant independent predictor of ventricular 
arrhythmia which may be explained by several factors including the fact that the time 
delay after contrast injection for post-contrast T1 mapping varied between 10 and 25 
minutes and that the hematocrit levels were measured using blood samples taken from 
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a time range within 24hrs before and after the time of image acquisition due to 
clinical constraints. It is known that hematocrit levels may vary significantly 
depending on the time of the day, posture, physical activity and post-prandial state.
160
 
Similarly the formula from which ECV is derived holds true when the extracellular 
contrast concentration in the blood and myocardium reaches equilibrium and there are 
uncertainties whether this equilibrium is achievable with the bolus technique we used 
rather than the slow contrast infusion technique.
16134
 Finally, in our cohort of 
advanced cardiomyopathies, variations in diuretic therapy and varying degrees of 
renal function are likely to have an impact on renal clearance of gadolinium and 
therefore contrast kinetics.  
7.5.2 Regional fibrosis and ventricular arrhythmia 
Regional fibrosis provides an important substrate for ventricular arrhythmias and is an 
independent predictor of ventricular arrhythmia in both ICM and NICM with several 
electroanatomical mapping studies demonstrating that scar border zone (grey zone) is 
important in the initiation and maintenance of ventricular arrhythmia.
99,125
  Further 
characterisation of the enhanced region with intermediate SI to further differentiate 
the grey zone from the scar core has provided incremental prediction of ventricular 
arrhythmia in ICM but has not been studied so far in NICM.
3,4
  
A criticism of grey zone assessment is the effect of partial volume and image 
acquisition voxel size which may influence its quantification. Furthermore the 
multitude of SI-based quantitative methods used in various studies makes direct 
comparison of the predictive value of each index difficult. To overcome these 
limitations, an automated computer analysis was used to improve the reproducibility 
of the quantification by standardizing the SI-based assessment; and comparison was 






). This study systematically tested the predictive values of each 
index expressed as a percentage of LV mass and found both to be independent 
predictors of ventricular arrhythmia in a multivariate model that included adjustments 
for established variables used for arrhythmia risk stratification. Greyzone
_2sd-3sd
 gave 
the highest HR for every 1% LV mass increment compared to other indices, although 
ROC analysis showed the areas under the curve were not significantly different 
between the grey zone and other scar indices. This study is the largest cohort to date 
to demonstrate the incremental value of grey zone quantification for arrhythmia 
prediction and to highlight the potential of arrhythmia prediction by grey zone in 
patients with NICM. 
7.5.3 Clinical relevance 
Native T1 removes the dependence on contrast kinetics and makes its potential 
translation to routine clinical application attractive. In addition, it allows myocardial 
tissue characterisation free of the potential risk associated gadolinium contrast in 





 values for risk re-stratification, additional risk 
assessment based on the cut-off values derived from this study could correctly re-
classify primary prevention patients from high risk to the low risk category. In the 
secondary prevention group, some patients were wrongly risk stratified to the low risk 




 alone, however the 
specificity may be improved if both indices were considered simultaneously. These 
results are in line with others that showed scar quantification with CE-CMR as the 
only independent predictor of adverse ventricular arrhythmia outcome in the patients 




7.5.4 Study limitations 
This study is limited by a relatively short follow-up and use of a surrogate end point 
(i.e. appropriate ICD therapy) which does not necessarily equate to sudden arrhythmic 
death. The absolute T1 values of interest can be influenced by a number of technical 
parameters including magnetic field strength and acquisition sequence as well as post-
acquisition image processing including motion correction and image registration. T1-
mapping was limited to just a single slice of myocardium and an assumption made 
that diffuse fibrosis imaged is truly diffuse/uniform in the remote myocardium. 
Conducting a single center study allowed standardisation of the imaging protocol 
across the entire cohort, however it may have introduced systematic bias including the 
timing of post-contrast T1 measurement. Only one type of sequence was used for T1 
image acquisition. A shorter T1 mapping acquisition sequence with shorter 
breathholds during image acquisition may potentially reduce motion artifact and 
impact on the post-contrast T1 value analysis. In light of the results from MADI-RIT 
study, optimzd ICD programming aimed at reducing ICD therapy could have 
potentially reduced the event rate of the study.
163
 However by standardizing the ICD 
programming within our cohort, it is unlikely that our programming asset up would 
have introduced any systemic bias in the associations studied. This study included a 
heterogeneous patient population, though diffuse fibrosis may be present in advanced 
cardiomyopathies of various etiologies, a more homogenous population group would 
have improved the power of detection of suggested association. A multicenter study 






The study has shown for first time that quantitative myocardial tissue assessment 
using T1 mapping is an independent predictor of ventricular arrhythmia with a hazard 
ratio comparable to scar or grey zone quantification detected by conventional CE-
CMR in both ischemic and non-ischemic cardiomyopathies. Our results suggest a 
potential for the use of myocardial tissue characterisation using CMR to refine the 
current risk stratification decisions regarding ICD implantation especially in the 







Chapter 8. Exploring electrical remodeling in response to 
cardiac resynchronisation therapy 
 
This chapter describes the work that assessed the impact of CRT on LV electrical 
remodeling in terms of action potential duration (APD) changes between responders 
and non-responders.  The findings may provide explanation to the persistent high 
incidence of arrhythmias in some patients with CRT and the additional mortality 
benefit observed in responders of CRT. 
 
8.1 Abstract 
Background: A consistent feature of electrophysiological remodelling in heart failure 
is ventricular action potential duration (APD) prolongation.  However, the effect of 
reverse remodelling on APD during cardiac resynchronisation therapy (CRT) has not 
been determined in these patients. We hypothesised (1) CRT may alter APD and (2) 
that the effect of CRT on APD may be different in patients who exhibit a good 
haemodynamic response to CRT compared to those with a poor response.  
Methods: LV activation recovery intervals (ARI), as a surrogate for action potential 
duration, were measured from the LV epicardium in thirteen patients at day 0, 6 
weeks and 6 months following CRT implant. Responders to CRT were defined as 
those demonstrating a ≥15% reduction in LV end-systolic volume at 6 months.  
Results: The responder group had a significant reduction in LVARI  (mean: -
13ms±12ms; median: -16ms, IQR -2ms to -19ms) during RV pacing at 6 months 
(p<0.05). Conversely the non-responders showed a significant increase in ARI (mean: 
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+22ms±16; median: 17ms, IQR 8ms to 35ms) (p<0.05). (One patient in each group 
was on Amiodarone.)   
Conclusions: In patients with heart failure left ventricular epicardial APD (ARI) 
altered during CRT. The effect on APD was opposite in patients showing a good 
haemodynamic response compared to non-responders. The findings may provide 
explanation for the persistent high incidence of arrhythmias in some patients with 
CRT and the additional mortality benefit observed in responders of CRT. 
 
Key words: 
action potential duration; activation recovery interval; cardiac resynchronisation 
therapy; mechano-electrical feedback. 
 
8.2 Introduction 
A consistent feature of electrophysiological remodelling in heart failure is ventricular 
action potential duration (APD) prolongation.
65
 The effect of cardiac 
resynchronisation therapy (CRT) and reverse remodelling on APD duration has not 
been determined in these patients.  
Cardiac resynchronisation therapy (CRT) in patients with heart failure has been 
shown to be beneficial in terms of symptomatic improvement and overall mortality
.
 
Recently, the MultiCenter Automatic Defibrillator Implantation Trial with Cardiac 
Resynchronisation Therapy (MADIT-CRT) trial, the Resynchronisation Reverse 
Remodelling in Systolic Left Ventricular Dysfunction (REVERSE) trial and the 
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Resychronisation-Defribrillation for Ambulatory Heart Failure Trial (RAFT) trial 
have demonstrated that CRT provided an incremental overall survival benefit to ICD 
therapy alone in heart failure patients.
66-68
 However, earlier studies showed that the 
incidence of arrhythmia and sudden death continues to be high despite CRT inferring 
the possible need for additional protection from implantable cardoverter defibrillator  
(ICD).
36,43
   These observations highlighted a need to further elucidate the effect of 
CRT on electrophysiology. 
CRT is associated with anatomical and electrical remodelling and evidence suggests 
these two processes are linked.
164-166
 The effect of CRT on APD has been studied in a 
canine heart failure model which showed APD shortening in cells from the lateral LV 
wall.
16710
 However, evidence suggests that the electrophysiological effects of CRT 
may vary according to the anatomic and haemodynamic profiles,
168-171
 underlining the 
need to obtain information directly from the hearts of patients with heart failure. 
We hypothesised that APD may be modified during CRT, and the effect on APD may 
vary in patients who exhibit a beneficial response to CRT compared to those with a 
poor response. To assess this we set out to record activation recovery intervals (ARI) 
as a surrogate measure of APD from the left ventricular epicardial lead of a CRT 
device at intervals over the first 6 months following implantation. ARI has been 
theoretically and experimentally validated as a reliable surrogate marker of regional 
action potential duration.
75-79
 It has advantages over other measures of repolarisation 
including enabling analysis of regional electrical properties, unlike the QT interval 
which is a more global measurement. It also avoids the need for long pacing protocols 
required for effective refractory period (ERP) and the pro-arrhythmic risk of 





8.3.1 Study population and protocol  
(See Chapter 3.2 for General patient selection criteria) 
Thirteen patients who fulfilled the standard criteria for CRT were prospectively 
recruited to the study prior to their device implant. The selection criteria included 
drug refractory symptomatic heart failure with New York Heart Association (NYHA) 
class II-IV, impaired left ventricular ejection fraction (LVEF) ≤ 35% with a QRS 
duration ≥ 120ms.  
Clinical status according to NYHA class and Minnesota heart failure questionnaires 
and echocardiographic measures of LV function were assessed at baseline (day 0) and 
6 months post device implant.  
 
Transthoracic echocardiography was performed at baseline and 6 months post implant 
to acquire standard 2D images of left ventricular (LV) dimensions and ejection 
fractions (EF) during breath-hold in standard apical 2-chamber and 4-chamber views. 
LVEF and dimensions were measured using the 2-dimentional modified biplane 
Simpson’s method.  
(See Chapter 3.4 for General echocardiography methods) 
 
All thirteen patients were implanted with the Quartet Model 1458Q LV pacing lead 
(St. Jude Medical, Minnesota, USA) via the coronary sinus in conjunction with a 
Unify Quadra CD 3251-40Q generator (St. Jude Medical, Minnesota, USA). The 
atrial-ventricular (AV) and ventricular-ventricular (VV) delays were empirically set at 
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120ms and LV 30ms ahead of RV at implant. CRT device optimisation was 
performed at 6 weeks post-implant per our institute’s standard clinical care protocol. 
At this time the AV and VV delays were adjusted under echocardiographic guidance 
using mitral valve inflow Doppler signals and aortic valve outflow velocity-time-
intervals to achieve the best haemodynamic benefit. There were no changes in the LV 
pacing vectors and output stimulus strength in the patients over the 6 months period. 
The LV pacing output strength was 2.0V at 0.5ms pulse width for all patients. 
 
At day 0 post-implant, a 30 second recording of the LV unipolar electrogram (UEG) 
signal was made via the device programmer (Merlin Patient Care System, Model 
3650, St Jude Medical) during DDD-RV or VVI-RV pacing, depending on whether 
the patient was in sinus rhythm or in atrial fibrillation. This enabled comparisons 
between patients with sinus rhythm and those with atrial fibrillation at identical heart 
rate, in order to eliminate the influence of heart rate on ARI. This study protocol is 
also clinically relevant in that during CRT, in addition to LV pacing, the RV is also 
paced which would change the regional ARI when patient is in intrinsic ventricular 
rhythm.
172
 In order to eliminate the influence of variable heart rate on ARI. UEG 
recordings were made after at least 2 minutes of pacing at a constant rate of 10 beats 
above the patient’s intrinsic heart rate. The same recordings were repeated 6 weeks 
and 6 months post implant at the same heart rate. The 30 second LV UEG recordings 
were analysed off-line using a software script developed by our group within the 
MATLAB environment (MathWorks, Massachusetts, USA) to derive the activation 
recovery interval (ARI).
21
 ARIs were measured using conventional validated criteria 




example showing the measurement and the stability of recordings is illustrated in 
Figure 8-1.  
 
Figure 8- 1 An example of LV unipolar electrogram raw data recording demonstrating 
activation recovery interval (ARI) 
 
Responders to CRT were defined as those demonstrating a ≥15% reduction in LV 
end-systolic volume (ESV) at 6 months. The echocardiography assessor was blinded 
to the ARI results.  
 
8.3.2 Statistical analysis 
(See Chapter 3.6 for General statistical methods) 
Additional post hoc power analysis based on the collected data assuming non-
parametric distribution was performed using G*Power, version 3.1.5, Kiel, Germany. 
8.4 Results 
The baseline patient characteristics are shown in Table 8-1.  
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Table 8- 1 Baseline patient characteristics 
*During the follow-up, three of the six patients in the responder group had increased 
Bisoprolol dosages. None of the patients in the non-responder group had changed Bisoprolol 
dosages. The only patient who was on Amdiodarone in the responder group continued 
its usage during the follow up, whereas the only patient who was on Amdiodarone in 
the non-responder group discontinued its usage 2 months after CRT. These changes in 
 Responders Non-responders 
Patient, n (%) 7 (100) 6 (100) 
Age 70±7 69±11 
Male n (%) 4 (57) 6 (100) 
NYHA Class (II/III/IV) 0/5/2 1/5/0 
Minnesota heart failure score 50±32 42±23 
LVEF (%) 22±6 29±5 
LVEDV (ml) 199±57 188±32 
LVESV (ml) 157±50 130±24 
Ischaemics/Non-ischaemics n (%) 1 (14) /6 (86) 4 (67) / 3 (33) 
Sinus rhythm/atrial fibrillation n (%) 4 (57) /3 (43) 3(50) /3 (50) 
QRS duration pre-implant (ms) 150±28 166±28 
QRS duration during CRT (ms) 134±19 161±16 
QRS morphology  
(LBBB/RBBB/nonspecific IVCD) n 
5/0/2 6/0/0 
Bi-V pacing (%) 97±4 97±3 
Bisoprolol* n (%) 6 (85) 6 (100) 
Amdiodarone* n (%) 1 (14) 1 (17) 
ACEi/ARB n (%) 7 (100) 6 (100) 
Statins n (%) 3 (43) 4 (67) 
 166 
medication could not have accounted for the divergent changes in the ARI observed 
in our study. 
EF=ejection fraction; EDV=end-diastolic volume; ESV=end-systolic volume; 
IVCD=intraventricular conduction delay; LBBB=left bundle branch block; 
RBBB=right bundle branch block; ACE=angiotensin converting enzyme inhibitor; 
ARB=angiotensin receptor blocker. 
 
All thirteen patients underwent successful CRT implant. The epicardial LV leads were 
targeted in the lateral and posterior walls in all subjects. The positions of the LV lead 
tip where UEG recordings were made are illustrated in Figure 2. There were no 
significant difference between the positions of the RV lead between the responder and 
non-responders.  
 
Figure 8- 2 Positions of the left ventricular lead tip where unipolar electrograms are made, 
according to American Heart Association 17-segments heart model 
 
Although four of six patients in the non-responder group, compared with three of 
seven patients in the responder group, had LV lead tip positioned in the apical region, 
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the use of quadripolar leads allowed pacing sites away from the apex in some cases in 
order to maximise clinical benefit for the patient and avoid phrenic nerve stimulation. 
The mean absolute distance between the LV lead tip from which ARI was measured 
to the LV pacing cathode were 10mm±13mm in the in responder group and 
11mm±19mm in the non-responder group. (Note that these measures are derived from 
the absolute distance between the vectors along the quadripolar leads and absolute 
accuracy is limited due to the oblique course of epicardial vein and the position and 
shape of lead sitting within the vein.) During the 6 months CRT, all the patients 
(responders and non-responders) were paced via bipolar vectors (LV and RV). The 
pacing vectors and pacing outputs were not changed during the 6 months study 
duration. The percentages of the bi-ventricular pacing were the same between the two 
groups. There were no major differences between the optimised A-V delays and V-V 
delays between the responder and non-responders in the study cohort. A-V delays 
were 127ms±10ms and 123±5ms in the patients with sinus rhythm in the responders 
and non-responder groups. Four of seven patients in the responder group had V-V 
delays of 0ms, the other three patients had LV ahead of RV by 30ms. Three of six 
patients in the non-responder group had V-V delays of 0ms, one of six patients had 
LV ahead by 20ms, and the other two had LV ahead by 30ms.  
 
Based on the LVESV reduction ≥ 15% at 6 months post implant, 7 patients (54%) 
were considered to be echocardiographic responders. The mean change in LVESV at 
6 months post CRT device implant was -36%±15% in the responder group and 
+3%±5% in the non-responder group compared with baseline, p<0.001. The mean 
LVEF at 6 months was 39%±7% in the responder group and 31%±5% in the non-
responder group, p=0.045. The mean NYHA class improved by 1.5±0.9 class in the 
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responder group and remained unchanged in the non-responder group. Minnesota 
heart failure questionnaires score at 6 months were 31±23 in both groups. The clinical 
and echocardiographic indices at 6 months post CRT are shown in Table 8-2.  
 Responders Non-responders P values 
    
Patient, n 7 6  
NYHA Class 1.8±0.6 2.6±0.5 P<0.01 
Minnesota heart failure score 31±23 31±23 NS 
    
LVEF (%) 39±7 31±4.5 P=0.04 
LVEDV (ml) 157±45 192±29 NS 
LVESV (ml) 98±37 134±27 NS 
Δ LVEDV (%) -20±12 -3±5 P<0.01 
Δ LVESV (%) -36±15 -3±5 P<0.01 
 
Table 8- 2Table 8-2. Patient clinical and echocardiographic indices at 6 months 
Δ=% change compared with baseline echocardiographic parameters; NS=not significant. 
 
LV UEGs were recorded during DDD-RV or VVI-RV pacing at a fixed heart rate 
ranged from 80bpm to 120 bpm within the cohort (the same heart rates were 
maintained during recordings at day 0, 6 weeks and 6 months for individual patients). 
The LV ARI during RV pacing at day 0, 6 weeks and 6 months are summarised in 
Table 8-3.  
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LV ARI  (ms) Responders Non-responders 
      
      
Day 0   mean 259±53  253±25  
              median 238; IQR: 213, 303  262; IQR: 224, 270  
      
   Δ at 6weeks  Δ at 6weeks 
Week 6  mean 255±50 -4±18 *265±25 13±12 
 median 252; IQR:  224, 287 0; IQR -20-11 *278; IQR: 234, 284 12; IQR: 7, 21 
      
   Δ at 6 months  Δ at 6 months 
Month 6 mean *246±47 -13±12 *272±22 19±16 
 median *235; IQR: 215, 287 -16; IQR: -19, -
2 
*277; IQR: 258, 284 17; IQR: 8, 35 
 
Table 8- 3 Epicardial LV ARI during steady rate RV pacing at day 0, 6 weeks and 6 months 
of CRT 
Δ=changes compared with day 0. Data are expressed as mean±standard deviation and median 
and interquartile range (IQR). * where p<0.05 compared with day 0.  
 
The paired changes in LVARI at 6 weeks and 6 months compared with day 0 among 
the responders and non-responders are shown in Figure 8-3. At 6 months the 
responders showed a significant decrease in ARI (p = 0.043) whereas conversely the 
non-responders showed a significant increase in ARI (p=0.046). These divergent 
effects were evident by 6 weeks although not reaching significance for the responders. 
Mean, median values and confidence intervals for the data are shown in Table 8-3.  
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Figure 8- 3 Changes in regional left ventricular activation recovery intervals, ΔARIs, during 
right ventricular pacing at day 0, 6 weeks and 6 months post-cardiac resynchronisation 
therapies.  
 
In Figure 8-4, changes in LVARI at 6 months compared with day 0 amongst the 
responders and non-responders are plotted against changes in LVEF response to CRT. 
The changes between the LV ARI and the changes in LV function were not linear. In 
the responders, the LV ARI during RV pacing decreased with an improvement in LV 
function however the LVARI increased in the non-responders despite insignificant 




Figure 8- 4 Scatter plots of changes in LV ARI with changes in LVEF, from day 0 to 6 
months post cardiac resynchronisation therapy 
 
Post hoc power calculation showed that the study had a 95% power to detect a change 




We have shown, for the first time, that LV APD (ARI) changes during CRT with 
APD shortening in responders and lengthening or remaining the same in non-
responders to CRT. These changes appear to be coupled with positive reverse 
remodelling in the CRT responders.  This supports the hypothesis that electrical 
remodelling accompanies the haemodynamic remodelling associated with CRT in 
heart failure patients with dyssynchrony.  
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8.5.1 Comparison with previous studies 
Our results are in keeping with the observed APD shortening in the LV lateral wall 
after three weeks of resynchronisation therapy in a canine dyssynchrony heart failure 
model.
173
 Recent human studies using ECG QT and T wave measurements have 
shown evidence suggestive of remodelling of APD associated with CRT in heart 
failure patients with dyssynchrony. Wecke et al. demonstrated an increase in 
repolarisation changes, measured by T-wave vectors and T-peak to T-end intervals, in 
the first two weeks of initiating CRT therapy treatment in heart failure patients with 
LBBB.
174 
In a group of established responders of CRT, Braunschweig et al. 
demonstrated a transient initial increase followed by a sustained reduction of QT and 
JT interval following re-initiation of resynchronisation therapy.
175
 Perhaps more 
comparable with the results of our study, Lellouche et al. observed a reduction in QT 
intervals in responders to CRT which was associated with a lower incidence of 
appropriate ICD therapies.
176
 Our results also lend support to the in silico modelling 
of the adaptive effects of mechano-electrical coupling relationship in the 
dyssynchronous heart by Kuijpers et al.
177
  
8.5.2 Mechanisms for APD changes 
APDs are lengthened in the myocytes of the failing heart. The mechanisms underlying 
APD changes in heart failure and APD changes during CRT are at present unclear. A 
fairly consistent finding is a down-regulation of repolarising K
+
 currents together with 




 currents and calcium cycling.
65,173,178,179
 Studies 
of animal models of heart failure have demonstrated that considerable heterogeneity 




Dyssynchronous heart failure, as in the present patient cohort, is associated with 
regional variation in myocardial strain patterns; with low strain occurring in early 
activated antero-septal regions and high strain in late activated lateral posterior LV 
walls. In heart failure patients with LBBB, the lateral wall is usually the latest area of 
activation. This discordant contraction between the early and late activated segments 
increases the strain and workload of the late activated regions.
181,182
 As a result there 
is an increase in the left ventricular preload, further stretching the myocardium 
leading to long term structural modelling. However mechanical dyssynchrony can 
also occur in the absence of intraventricular electrical delays. An animal study has 
demonstrated that simple changes in LV afterload by clamping the aorta can acutely 
induce dyssynchrony in the presence of normal ventricular electrical delays,
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suggesting a close mechano-electrical coupling involved in the LV activation. Studies 
with canine dyssynchrony heart failure models have demonstrated APD shortening in 
the early activated low strain regions and APD prolongation in the late activated 
regions of high strain.
168,173
 These observations suggest that the myocardium can 
respond to changes in stretch by altering its electrical properties through a process of 
mechano-electrical feedback.
168,173,184-186
  This mechanism may be a trigger for the 
changes in APD seen with dyssynchronous heart failure and with its reversal through 
CRT. Jeyaraj et al.
16811
 have suggested that this trigger may be mediated through 





 and stretch activated signal transduction pathways.
190
 
However, the observation that sarcolemmal ion channels and even individual 
potassium channels appear to be differentially regulated in models of heart failure 
suggests that multiple mechanisms may be involved.
173
 CRT results in partial reversal 
of the electrophysiological consequences of heart failure including the down-
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regulation of repolarising K
+
 currents. This would be consistent with the shortening of 
APD at the lateral LV wall that we observed at 6 weeks and 6 months following the 
initiation of CRT in the responders. Our results are also in line with the APD 




The mechanisms of reverse electrical remodelling during CRT have yet to be fully 
elucidated. Several mechanisms have been proposed including reversal of the 
abnormal activation pattern, reversal of abnormal regional strain patterns, and a role 
for improved beta-adrenergic function. Considerable overlap is likely to exist between 
these multiple mechanisms that underlie remodelling and reverse remodelling. For 
example, mechano-electrical feedback and changes in electrotonic current load due to 
altered activation sequence are component of myocardial memory.
168
 It is possible 
therefore that the memory function may play a role in our results. Varied coupling 
between these mechanisms in responders and non-responders may in part explain the 
non-linear relationship between the differential changes in action potential we 
observed in the responders and non-responders. It is worth noting there were a greater 
proportion of patients with ischaemic cardiomyopathy in the non-responder group.  
The regional scars may hinder both mechano- and electrical remodelling to CRT in 
patients with previous myocardial infarction.  During device implant, LV leads were 
positioned outside scarred myocardium on the basis of electrical sensing parameters 
and prior knowledge of scar location identified from cardiac magnetic resonance 
imaging. Our study is underpowered to assess the influence of the ischemic aetiology 
on the changes in LVARI. However it would be of interest for future studies to 
combine with cardiac magnetic resonance imaging with scar geometry and examine 
the possible influence of scar on reverse remodelling.  
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Relation of electrophysiology to mechanical changes 
Several mechanisms could underlie the parallel changes in APD and mechanical 
strain during CRT, and the differences between responders and non-responders. 
(a) Mechano-electric feedback:  In patients with heart failure and LBBB the lateral 
wall is usually the latest to be activated. The discordant contraction between early and 
late activate regions increases strain and work in late activated regions resulting in 
increased preload, further increased stretch and structural remodeling.
181,182
 Canine 
models of myocardial dyssynchrony show APD changes with APD shortening in the 
early activated low strain regions and APD lengthening in the late activated high 
strain regions, suggesting the myocardium responds to stretch by altering the 
electrophysiology by MEC.
167,191
 In humans, Kroon et al have recently demonstrated 
a good correlation between LV depolarization pattern and strain pattern in heart 
failure patients,
192




The notion of MEC as a mechanism for functional remodeling and its reversal by 
CRT receives support from computer modeling studies highlighting a role of L-type 
Ca
2+
 current and calcium handling.
194
  A number of studies have demonstrated 
changes in gene and protein expression resulting in abnormal calcium handling and 
distribution in dyssynchronous hearts.
169,173
  In canines with dyssyncronous heart 
failure L-type Ca
2+
 current was 20% higher in early activated regions and 20% lower 
in late activated regions and CRT normalized the distribution of the calcium 
transient.
173
 It has been suggested that feedback of external work on the L-type 
calcium current could represent a true feedback mechanism whereby regional 
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contractility of the myocardium is regulated in order to maintain or restore uniform 
mechanical load.
195
 It has been proposed that changes in stress and strain may be 




Our finding of divergent changes in responders and non-responders supports the 
hypothesis of a breakdown in the MEC amongst non-responders whereas the coupling 
relationship is maintained in the responder group. One plausible cause for this 
decoupling may be the presence or the extent of myocardial fibrosis as the presence of 
scar at the LV pacing sites adversely affects CRT response.
51”  
 (b) Other mechanisms 
A number of other mechanisms could be involved in reverse electrical remodeling 
during CRT. There is increasing evidence for a role of cardiac mitochondria in 
modulating calcium handling and the electrophysiology.
197
 Changes in a variety of 
ionic currents have been observed in animal experiments following prolonged 
dyssynchony induced by ventricular pacing or LBBB, including L-type calcium 





8.5.3 Significance of APD changes, impact on arrhythmogenesis 
The effect of CRT on arrhythmogenesis remains controversial. It has been suggested 
on the basis of clinical and experimental evidence that CRT incorporating left 
ventricular epicardial pacing may promote rather than reverse electrical remodelling 
and be potentially proarrhythmic.
169,170,199-201
 APD changes in heart failure are 
characteristically heterogeneous resulting in increased dispersion of repolarisation 
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which is potentially proarrhythmic.  Biventricular pacing incorporating an LV 
epicardial lead reverses the normal activation sequence across the lateral LV wall. 
This has been shown in canine wedge preparations to result in increased dispersion of 
transmural repolarisation across the LV wall and be proarrhythmic.
169,170
 Others have 
further demonstrated that in the canine dyssynchrony heart failure model, the trans-
regional dispersion of APD occurs to a greater extent than the trans-mural dispersion 
of APD in response to dyssynchrony.
168,202
 In a recent clinical study, increased 
dispersion of repolarisation measured by interlead difference in T-peak to T-end 




Reversal of APD lengthening by CRT has been shown experimentally to reduce 
dispersion and hence be potentially arrhythmia protective.
173
 Interpreting our results 
in this context must remain speculative, as we have no evidence that APD at the 
lateral LV wall at the site of our recordings was actually prolonged as a result of heart 
failure. However, since it is well known that APD prolongation at the lateral LV wall 
is a consistent finding in heart failure we would suggest that APD shortening at this 
site in the responders would generate a more favourable anti-arrhythmia substrate 
profile. Conversely the APD lengthening that we observed in the non-responders 
would create a less favourable arrhythmia substrate. The observation that APD 
prolongs in non-responders despite insignificant changes in LV function and 
dimension suggests in the absence of positive reverse functional and structural 
remodelling, LV epicardial pacing may potentially be proarrhythmic.
169,170 
This would 
be in keeping with clinical observations suggesting a reduced arrhythmia risk in 
responders to CRT
164,204
 and an increased arrhythmic risk in non-responders.
199 
It is 
possible the additional electrical remodelling that accompanies the structural and 
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functional remodelling observed in responders of CRT outweighs the initial pro-
arrhythmic increase in repolarisation dispersion caused by LV epicardial and 
biventricular pacing.
175
   
8.5.4 Limitations  
Our study was limited, but was large enough to demonstrate significant result at 95% 
power. Due to a limitation of the device programmer we were only able to record 
unipolar electrograms from distal pole of the quadripolar lead; improved spatial 
mapping could be of interest for future studies. Though we did not have a measure of 
regional wall stress or strain in our study, previous studies have demonstrated CRT 
results in a more synchronous LV strain patterns in responders compared to non-
responders.
45,46
 Further study is needed to explore the regional strain pattern in the 
accompanying regions where we measured LV ARI in order to elucidate whether 
mechanical stretch or strain may be the trigger for our observed changes in APD. It 
has been shown that increased dispersion of repolarisation measured from body 
surface ECG leads varied between responders and non-responders. The ARI measured 
only reflected regional electrical activity at the site of the distal LV lead. It would be 
of interest to see how this regional change related to the global LV repolarisation time 
and dispersion. A much larger patient cohort with longer follow-up period is needed 
to achieve this and relate to the arrhythmic outcomes in these patients. 
8.6 Conclusion 
In patients with dyssynchronous heart failure left ventricular epicardial APD 
measured by ARI altered during CRT, the effect on APD was opposite in patients 
showing a positive echocardiographic remodelling response compared to non-
responders. The findings may provide explanation to the persistent high incidence of 
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arrhythmias in some patients with CRT and the additional mortality benefit observed 




Chapter 9. Coupling of ventricular action potential duration 
and local strain patterns during reverse remodeling in 
responders and non-responders to cardiac 
resynchronization therapy 
 
This chapter describes the work built on the foundation outlined in chapter 8. Using 
the new technique (developed during the work described in the last chapter) of 
measuring regional activation recovery interval via LV pacing lead and coupling that 
with echocardiographic myocardial speckle tracking measurement of strain, the study 
assessed the relationship between the mechanical remodeling (regional strain) and 
electrical remodeling (regional APD) induced by CRT. This provides the evidence 
that suggests the two processes are linked. 
 
9.1 Abstract 
Background: Ventricular action potential duration (APD) changes in patients with 
dyssynchronous heart failure during cardiac resynchronisation therapy (CRT). 
Evidence suggests the electrophysiological effect may vary dependent on the 
myocardial contractile properties. We hypothesized that diverse APD changes 
occuring between responders and non-responders to CRT would correlate with similar 
diverse changes in regional myocardial strain.  
Methods: ARI were recorded from the left ventricular epicardium in 20 CRT patients 
6 weeks and 6 months post implant. Two-dimensional speckle tracking 
echocardiography was performed at the same time to assess myocardial strains. 
Patients with ≥15% reduction in end-systolic volume at 6-months were classified as 
responders.  
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Results: ARI reduced in responders, 263±46ms vs. 246±47ms, p<0.01; and increased 
in non-responders, 235±23ms vs. 261±20ms, p<0.01. Time-to-peak (TPS) radial, 
circumferential and longitudinal strains increased in responders (+41±27ms, 
+35±25ms, +56±37ms; p<0.01); and reduced in non-responders (-58±26ms, -
47±26ms, -64±27ms; p<0.01). There was a non-linear correlation between changes in 
TPS and ARI (r≥0.70; p<0.01).  Baseline QRS >145ms and QRS shortening with 
biventricular pacing was associated with ARI shortening during CRT. 
Conclusions: Changes in ventricular wall mechanics predict local APD lengthening or 
shortening during CRT. Non-responders have a worsening of myocardial strain and 
local APD. Baseline QRS >145ms and QRS shortening on biventricular pacing 
identified patients who exhibited improvement in APD. 
 
Key Words: Cardiac remodeling, cardiac resynchronisation therapy, mechano-electric 
feedback, activation recovery interval, action potential duration, myocardial strain 
 
9.2 Introduction  
Cardiac resynchronization therapy (CRT) has been demonstrated to provide 
symptomatic improvement, induce structural reverse remodeling and improve 
survival in heart failure patients with prolonged QRS durations.
66-68
 However, 
approximately one third of patients do not derive benefit and the incidence of 
arrhythmias remains substantial.
36,43
 The further understanding of the 
electromechanical changes during CRT therefore remains an important challenge.  
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The response to CRT in patients with broad QRS complex is generally considered to 
be multifactorial including QRS width, mechanical dyssynchrony, the presence of 
scar, lead position and the reversibility of advanced heart failure.
205
 Several studies 
demonstrating the beneficial effects of CRT on LV remodeling have suggested that 
improvement of LV mechanical synchrony was the predominant mechanism,
206
 while 




Numerous ion channels changes are associated with heart failure usually resulting in 
prolonged action potential duration (APD) and hence prolonged refractoriness 
together with slowed conduction.
173,207,208
 Studies in a canine model of heart failure 
showed APD prolongation to be inhomogeneous occurring preferentially in the late 
activated lateral wall where circumferential strain was shown to be increased.
168
 Aiba 
and colleagues have demonstrated APD prolongation in cells from late activated 
regions and detailed a range of cellular alterations involved in the remodeling 
process.
173
 However, Spragg et al. found APD shortening in the late activated 
segment in dyssynchronous animal model in the absence of LV dysfunction.
186
 Both 
APD and the abnormal strain pattern were partially normalized by CRT. As has been 
pointed out, these observations during CRT have been made in an animal model 
where chamber dilatation and dysfunction persist and therefore most likely represent 
the effect of dis-coordinated contraction that is resynchronized.
208
  
Information in humans is limited. We have recently reported activation recovery 
interval (ARI), as a surrogate measure of APD, changes in heart failure patients  
during CRT, with LV free wall APD shortening in subjects classified as responders 
and lengthening in non-responders.
209
 The clinical response to CRT is known to be 
closely linked to reversal of dyssynchrony.
210
 Improved LV function by CRT has 
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been shown to be associated with a reduced arrhythmia burden,
211
 whereas persistent 
or new radial dyssynchrony or abnormal longitudinal strain is associated with an 
increased rate of ventricular arrhythmias or death.
212,213
 The effect of LV 
resynchronization on the electrophysiologic substrate is a suggested mechanism. 
However, at present it has not been determined whether changes in APD during CRT 
relate to changes in regional mechanical function in humans. 
We aimed to explore the relationship between LV APD and strain following LV 
reverse remodeling in response to CRT. To assess this we recorded ARI from the 
epicardial CRT LV lead as a conventional measure of local APD together with 
speckle tracking analysis of regional ventricular strain at 6 weeks and 6 months 
following the initiation of CRT.  
 
9.3 Methods 
9.3.1 Study population and protocol  
(See Chapter 3.2 for General patient selection criteria) 
We prospectively studied 20 consecutive patients receiving CRT in our institution. All 
patients were invited to participate in the study in the pre-CRT assessment clinic. The 
selection criteria included drug refractory symptomatic heart failure with New York 
Heart Association (NYHA) class II-IV, impaired left ventricular ejection fraction 
(LVEF) ≤ 35% with a QRS duration ≥ 120ms.  
Clinical status according to NYHA class and Minnesota heart failure questionnaires 
(MLHFQ) and echocardiographic measures of LV function were assessed pre and 6 
months post CRT implant.  
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Simultaneous echocardiography and LV unipolar electrogram recordings were 
performed 6 weeks and 6 months post CRT implant to assess LV functional and 
electrical remodeling in response to CRT.  
A positive LV functional response was defined by ≥ 15% reduction in LV ESV on 
TTE assessment coupled with improvement in clinical heart failure symptoms at 6 
months post implant. 
9.3.2 Functional remodeling assessed by transthoracic echocardiography  
Transthoracic echocardiography were performed by independent operators who were 
blinded to the outcome of the electrical remodeling data, at baseline, 6 weeks and 6 
months post implant. 
(See Chapter 3.4 for General echocardiography methods)  
Short axis and longitudinal images focusing on the AHA segment of LV lead position 
were acquired at 6 weeks and 6 months post CRT implant in preparation for off-line 
speckle tracking analysis in order calculate the time (gated from the onset of QRS 
body surface electrocardiography complex) to peak radial, circumferential and 
longitudinal strain of the respective myocardial segment (see Figure 9-1). Speckle-
tracking analysis was performed using independent 2D Cardiac Performance Analysis 




Figure 9- 1 Speckle tracking analysis 
A: Different types of left ventricular myocardial strains during contraction 
B: Strain curve with time to peak strain gated to ECG, different color represent different left 
ventricular segment (AHA classification) 
C: Transthoracic echocardiographic grey scale images for automated speckle tracking 
analysis 
 
CRT device optimisation was performed at 6 weeks post-implant as per our standard 
clinical protocol. At this time the AV and VV delays were adjusted under 
echocardiographic guidance using mitral valve inflow Doppler signals and aortic 
valve outflow velocity-time-intervals to achieve the best hemodynamic benefit. 
Fluoroscopic image acquisitions in right and left anterior oblique views during CRT 
implant were used to estimate the LV segment where the LV lead was positioned for 
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each individual. Each segment was classified according to the American Heart 
Association 16 segment classification.  
9.3.3 Electrical remodeling assessed by activation recovery interval, ARI, 
measurement 
All 20 patients were implanted with a LV pacing lead via the coronary sinus (St. Jude 
Medical, Minnesota, USA). At 6 weeks and 6 months post CRT implant, a 30 second 
recording of the LV unipolar electrogram (UEG) signal was made via the device 
programmer (Merlin Patient Care System, Model 3650, St Jude Medical) during 
DDD-RV or VVI-RV pacing, depending on whether the patient was in sinus rhythm 
or in atrial fibrillation. In order to eliminate the influence of variable heart rate on ARI, 
UEG recordings were made after at least 2 minutes of pacing at a constant rate of 10 
beats above the patient’s intrinsic heart rate. This enabled comparisons between 
patients with sinus rhythm and those with atrial fibrillation at identical heart rate and 
eliminated the influence of heart rate on ARI. The 30 second LV UEG recordings 
were analyzed off-line using a custom software script within MATLAB (MathWorks, 
Massachusetts, USA) to derive the activation recovery interval (ARI). ARIs were 
measured using conventional validated criteria from minimum dv/dt of the QRS of the 
UEG to maximum dv/dt of the local T wave as previously described.
209
 There were no 
changes in the LV pacing vectors and output stimulus strength in the patients between 
6 weeks and 6 months post CRT implant. The LV pacing output strength was 
unchanged at 0.5ms pulse width for all patients during this period. 
9.3.4 Statistical analysis 
(See Chapter 3.6 for General statistical methods) 
Correlation between time to peak strain and ARI were expressed using Spearman’s 
correlation coefficient. A p value < 0.05 was considered to be statistically significant. 
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9.4.1 Study population 
Twenty patients fulfilling standard indications for CRT
45 
participated and completed 
the study. 25% of the cohort was female and mean age was 61±12yrs. All of the 
patients were in NYHA class III or IV. The mean QRS duration was 143±21ms, 45% 
of the patient had an ischemic etiology and 55% dilated cardiomyopathy on the basis 
of World Health Organisation criteria. The baseline characteristics of the patients 












 Responders  Non-responders P 
Patient, n  11 9   
Age, years 60±11 61±13 n/s 
Female 3  2  n/s 
COPD,  2 2 n/s 
DM,  4 2 n/s 
HTN,  3 2 n/s 
CVA, 2 1 n/s 
AF (persistent),  1 1 n/s 
eGFR<60 2 5 n/s 
Etiology: ICM/DCM 4/7 5/4 n/s 
Beta blocker  11 8 n/s 
Amiodarone 1 1 n/s 
ACEI/ARB 11 9 n/s 
Loop diuretics 6 7 n/s 
MR antagonist 7 5 n/s 
Statins 8 6 n/s 
NYHA class II/III/IV 0/10/1 0/9/0 n/s 
MLHFQ score  51±22 51±21 n/s 
LVEF, %  23±9 22±4 n/s 
LVESV, ml  177±87 173±50 n/s 
QRS duration, ms 148±25 133±7 n/s 
QRS morphology LBBB 11 9 n/s 
























A-V delays, 120/130/140ms 4/5/2 4/4/1 n/s 
LV>RV offset, 30/20/10/0 7/3/0/1 6/2/0/1 n/s 
>25% transmural scar near 
LV pacing site 
2 5 n/s 
>50% transmural scar near 
LV pacing site 
0 3 0.038 
 
Table 9- 1 Baseline patient characteristics  
ICM = ischemic cardiomyopathy; DCM = dilated cardiomyopathy; COPD = chronic 
obstructive pulmonary disease; AF = atrial fibrillation; CVA = cerebral vascular accident; 
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; LV= 




9.4.2 Left ventricular functional remodeling  
At 6 months post CRT, LVESV reduction ≥15% occurred in 11 patients (55%), all of 
whom reported an improvement in heart failure symptoms (NHYA class reduction ≥ 1 
class and quality of life questionnaires reduction of ≥20% in MLHFQ scores). These 
patients were considered to be positive responders with functional reverse remodeling. 
The mean LV ESV in the responders group improved from 177±87ml at the baseline 
pre CRT implant to 107±51ml (p<0.01) at 6 months post CRT. The mean LV EF 
improved from 23±9% to 36±11%. In contrast, the mean LV EF in the non-
responders group was 22±4ml at the baseline and was 23±4ml at 6 months post CRT. 
The changes in clinical LV functional status between responders and non-responders 
at 6 months are shown in Table 9-2.  
 Responders Non-responders P 
Patient, n 11 9  
NYHA Class 2±1 3±0 P=0.01 
Minnesota heart failure 
score 
27±15 45±23 P<0.01 
    
Δ LVEF, % +13±7 +1±6 P<0.01 
Δ LVESV, % -37±15 +8±23 P<0.01 
 
Table 9- 2 Clinical and LV functional response at 6 months 
Δ = change; LVEF = left ventricular ejection fraction, LVESV = left ventricular end-systolic-





9.4.3 Changes in LV electrical remodeling and time to peak strains 
During the 6 months receiving CRT, all the patients (responders and non-responders) 
were paced via bipolar vectors (LV and RV). The pacing vectors and pacing outputs 
were not changed during the 6 weeks to 6 months post CRT implant study period. The 
percentages of the bi-ventricular pacing were the same between the two groups. There 
were no major differences between the optimized AV delays and VV delays between 
the responder and non-responders in the study cohort. Median AV delays were 
130ms±10ms and 130±10ms in the patients with sinus rhythm in the responders and 
non-responder groups. Variations in VV delays between responders and non-
responders group were not significantly different. 
LV UEGs were recorded during DDD-RV or VVI-RV pacing at a fixed heart rate 
ranged from 70bpm to 100 bpm within the cohort (the same heart rates were 
maintained during recordings at 6 weeks and 6 months for individual patients; paced 
heart rate of the two patients with atrial fibrillation were 75bpm and 80bpm, which 
were similar to the other patients in sinus rhythm, mean 80bpm). There was a clear 
divergent change in ARI seen between CRT responders and non-responders from 6 
weeks to 6 months post CRT implant. In the responders ARI decreased from 263 +/-
46 to 246 +/-47 (p<0.01) whereas in the non-responders ARI increased from 235+/-23 
to 261+/-20 (p<0.01). This trend is shown in Figure 9-2.  
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Figure 9- 2 Divergent changes in activation recovery interval ARI between 6-weeks and 6-
months post CRT between responders and non-responders. 
Δ = changes between 6weeks and 6months post CRT 
 
The corrected QT (QTc, Bazett’s correction) intervals averaged across all 12 surface 
ECG leads estimated by an electronic caliper were manually checked at 6-weeks and 
6-months post CRT during RV pacing to allow comparison with ARI data. The trend 
of changes in QTc intervals reflected regional ARI measured in the responders and 
the non-responders. At 6 weeks, the QTc was 554±52ms (responders), 543±50ms 
(non-responders); and at 6 months 536±54ms, 558±49ms, respectively. The changes 
were Δ -17±14 for responders; and Δ +16±11 for non-responders, p<0.01. A weak 
correlation was observed between Δ ARI and Δ QTc, r= 0.59, p <0.01. 
A similar divergent change was observed in TPS between the two groups with 
responders showing a decrease in TPS in radial, circumferential and longitudinal 
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strains between 6 weeks and 6 months of CRT and non-responders showing an 
increase. (See Figure 9-3 and Table 9-3). The mean values of LVARI at 6 weeks 
differed (263±46ms vs. 235±23ms), although not significantly different, p=0.12. The 
difference in ARI between the responders and the non-responders at the 6 weeks post 
CRT is reflected in the time to peak strain between the responders and the non-
responders. A possible explanation for this perceived difference is the differences 
(although not statistically significant) in baseline QRS duration between the 
responders and the non-responders. 
The LV ARI and times to peak strains during RV pacing at 6 weeks and 6 months 




n = 11 
Non-responders 
n = 9 
p 
6-week ARI,  263±46 235±23  
 Δ -17±10 Δ +26±17 <0.01 
6-month ARI,  246±47 261±20  
6-week TPS radial,  375±59 311±34  
 Δ -58±26 Δ +41±27 <0.01 
6-month TPS radial,  317±58 352±50  
6-week TPS circumferential 370±58 322±39  
 Δ -47±26 Δ +35±25 <0.01 
6-month TPS circumferential 322±59 357±43  
6-week TPS longitudinal 397±61 333±31  
 Δ -64±27 Δ +56±37 <0.01 
6-month TPS longitudinal 332±63 389±46  
ARI = activation recovery interval; TPS = time to peak strain. 
 




Δ = changes between 6weeks and 6months post CRT; Rad. = radial strain; Circ. = circular 
strain; Long. = longitudinal strain; ARI = activation recovery time, ms, Strain = % myocardial 
displacement 
 
Figure 9- 3 The LV activation recovery times and times to peak strains during RV pacing at 6 
weeks and 6 months post CRT 
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9.4.4 The relationship between changes in ARI and changes in TPS 
Although for each of the strain measures (radial, circumferential and longitudinal 
strain), shortening during CRT was associated with APD shortening and vice-versa, 
the relationship between ARI local strain and TPS was likely to be non-linear 
(Spearman correlation coefficient 0.72 radial; 0.70 circumferential; 0.71 longitudinal 
strain). Nevertheless whether local strain increased or decreased indicated whether 
APD shortened or lengthened with a high degree of sensitivity and specificity. See 
Figure 9-4.  
 
r = Spearman’s correlation coefficient 
Figure 9- 4 Correlation between changes in activation recovery time (ARI) and changes in 
time to peak strain  (TPS) 
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9.4.5 Changes in ARI and QRS duration 
The relation between changes in ARI during CRT and baseline QRS duration is 
shown in Figure 9-5 (upper panel). Above a QRS duration of 145ms ARI shortened 
during CRT in all patients whereas patients with a baseline QRS below 145ms 
showed either ARI shortening or lengthening. Changes in ARI in relation to the effect 
of biventricular pacing on the QRS duration (i.e. difference in QRS duration during 
biventricular pacing vs. baseline QRS), are shown in Figure 9-5 (lower panel). A QRS 
decrease during biventricular pacing was associated with ARI shortening whereas a 
QRS increase was associated with either ARI shortening or lengthening. 
 
Figure 9- 5 Relationship between changes in activation recovery interval ARI and baseline 




The main findings of our study are: (1) patients with heart failure receiving CRT 
classified as responders exhibit LV ARI shortening in the late activated region, 
whereas non-responders show ARI lengthening confirming our previous observations; 
(2) ARI shortening was associated with local decrease in time to peak radial, 
circumferential and longitudinal strain, whereas ARI lengthening was associated with 
an increase in all three strain patterns; (3) non-responders have a worsening of local 
myocardial strain and prolongation of local ARI; (4) the relationship between changes 
in ARI and changes in local strain patterns was non-linear; (5) a baseline QRS of 
145ms separated patients in whom ARI and local strain decreased (>145ms) from 
patients in whom ARI and local strain either decreased or increased  (<145ms) in 
response to CRT; (6) a decrease in QRS duration during biventricular pacing 
compared to baseline was associated with ARI shortening in response to CRT, 
whereas an increase in QRS duration was associated with either ARI shortening or 
lengthening.  
Comparison with previous work 
9.5.1 Electrophysiology 
A consistent finding in experimental models of heart failure is ventricular action 
potential duration prolongation.
65
 In a canine model with LBBB ablation, cells 
isolated from the LV lateral wall after 6 weeks showed APD prolongation which was 
attenuated by CRT.
173
  In humans several studies using body surface ECG 
measurements have reported repolarization changes during CRT. Braunschweig and 
colleagues found an initial increase in QT and JT interval followed by a sustained 
reduction in a group of responders.
175
 Lellouche and colleague compared the peak to 
end of T wave and corrected QT measurements at the time of CRT implantation and 
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after 1 year, and observed a decrease in responders and an increase in QT dispersion 
and T wave peak-to-end dispersion in non-responders.
176
 We recently reported APD 
shortening in responders and APD lengthening in non responders during CRT in 




9.5.2 Mechanical strain pattern 
While the mechanism underlying reverse electrical remodeling during CRT in heart 
failure is considered to be multifactorial a general consensus is that LV mechanics 
play an important role.
173,205-208
 Canine models of myocardial dyssynchrony show 
APD changes with APD shortening in the early activated low strain regions and APD 
lengthening in the late activated high strain regions.
167,191
 In humans, Kroon et al have 
recently demonstrated a good correlation between LV depolarization pattern and 
strain pattern in heart failure patients,
192
  and our group has also found a similar 
correlation in heart failure patients with LBBB.
193
 Several studies have investigated 
the effect of CRT on LV mechanics. Strain patterns have been shown to improve in 
CRT in responders with lesser changes or worsening in non-responders.
214
   
At the present time we are unaware of any previous report on the relationship between 
APD and regional wall mechanics in humans.  In the present study we showed 
concordance between the change in APD and the change in strain pattern during CRT. 
However, the relation between delta APD and delta strain was not linear. Such a 
relationship would be consistent with the interaction of dyssynchronous contraction 
with the electrophysiology being multifactorial resulting in ion channel remodeling 
involving stretch activated receptors, gap junctions via connexins, calcium handling, 





9.5.3 Relation of electrophysiology to mechanical changes 
APD prolongation, particularly in the late activated lateral wall, is a consistent 
manifestation of heart failure and may contribute to the substrate for ventricular 
arrhythmias. Changes in all three strain patterns identified whether APD would 
lengthen or shorten during CRT with a high degree of sensitivity and specificity 
(Figure 9-4). Therefore an increase in regional strain would indicate a likely 
worsening of APD. If this effect were inhomogeneous it would favor re-entry 
arrhythmia. The prolongation in ARI observed in the non-responders may provide an 
explanation for the potential harmful effects of CRT in patients with narrow baseline 
QRS duration.
215
 Conversely, improvement in strain pattern has been shown to be an 




The trend of changes in QTc intervals appears to reflect that of regional ARI 
measured in the responders and the non-responders. Our results are in keeping with 
prior findings that QTc interval shortened amongst the responders to CRT.
176
 
However the weak association between the ARI and QTc reflects that ARI is a local 
measure of repolarization unlike the QT interval which is a global measure. Other 
mechanisms in addition to changes in local strain may contribute to the global 
electrical remodeling following CRT.  
Above a baseline QRS duration of 145ms all patients showed APD shortening during 
CRT whereas below QRS of 145ms patients showed either shortening or lengthening 
(Figure 5). These electrophysiological changes lend support to the current 
recommendation for heart failure patients with baseline QRS ≥150ms to receive CRT. 
In our data a shortening of QRS during biventricular pacing compared to baseline was 
associated with APD shortening and a lengthening of QRS was associated with either 
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APD shortening or lengthening. This is in keeping with findings of other studies.
217,218
 
Bonakdar and colleague also found baseline QRS >145ms to be an independent 
predictor of CRT response with the best sensitivity and specificity.
218
 
In the studied cohort, I observed that above a baseline QRS duration of 145ms ARI 
shortened during CRT in all patients whereas patients with a baseline QRS below 
145ms showed either ARI shortening or lengthening. A QRS decrease during 
biventricular pacing was associated with ARI shortening whereas a QRS increase was 
associated with either ARI shortening or lengthening. This implies that in patient with 
broad baseline LBBB QRS and its reversal with CRT, there is sufficient electrical 
resynchrony and as a result positive electrical remodeling as reflected the local ARI 
shortening. The narrower QRS duration with CRT is a reflection of inter- and intra-
ventricular synchrony, which is largely determined by the RV-LV transeptal time. 
The lack of QRS shortening with CRT coupled with ARI prolongation in the non-
responder group is a reflection of adverse electrical remodeling. LV epicardial may 
further exacerbate adverse electrical remodeling through a reversal of electronic 
gradient across myocardium, increasing dispersion of repolarization, especially in 
patient cohort with narrower baseline QRS. 
9.5.4 Methodological considerations 
ARI has been extensively theoretically and experimentally validated as a reliable 
surrogate for local APD.
79
 Unlike other measures of repolarization ARI has the 
advantage of providing local information in contrast to the QT interval and avoids the 
proarrhythmic risk of premature stimulation during estimation of refractory periods. 
Two dimensional speckle tracking echocardiography has been shown to be effective 
and simple in providing useful insights to the mechanics of myocardial contraction. 
Based on standard grey scale images, strain defined by percentage change of the 
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myocardial fiber length from its relaxed state in end systole is used to quantify 
myocardial deformation.
219
. Speckle tracking echocardiography has certain 
advantages compared with tissue velocity imaging and is an accurate way of indexing 




I did not specifically study any beat-to-beat dynamic variations in AT and ARI. I 
ensured a steady rate of pacing for two minute before taking ARI measurement in 
order to eliminate the influence of variable heart rate on ARI. Our research group 
however did investigate the effects of respiratory oscillation (at a frequency 
approximately at 0.25Hz) and arterial pressure oscillation (at a frequency of 
approximately 0.1Hz, coupled with synchronous oscillations of sympathetic nerve 
activity) on ventricular APD in heart failure patients. We found that ARI oscillated 
with the respiratory frequency in all heart failure patients, but only oscillated with the 
arterial pressure frequency in a third of heart failure patients with mental arousal 
(through provocative visual stimuli). These finding may help to understand the role of 
sympathetic activity-related arrhythmogenesis. 
9.5.5 Limitations 
The study cohort is relatively limited in number, but has sufficient power (>95%) to 
detect a change in LV remodeling based on the data gathered previously.
209
 The 
device programmer only enables recordings of unipolar electrograms to be made from 
the distal pole of the LV lead, consequently limiting to single site recordings. It has 
been shown that increased regional dispersion of repolarization varied between 
responders and non-responders.
168,203
 It would be of interest to see how this regional 
change related to the global LV repolarization time and dispersion as depending on 
the extent of the region exhibiting the changes; there might be either pro- or 
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antiarrhythmic effects. We are unable to comment on the initial response because no 
LV strain measurements were acquired immediately after CRT implant due to clinical 
constraints of patient discomfort. Anatomical features such as regional scars may alter 
local stress / strain relations and influence the remodeling process. The present study 
however was not designed to assess the influence of pathogenesis on the ARI. 
Regional scars at the site of the LV lead implant has been shown to impact on the 
response to CRT. This has been the focus on several prior studies.
49,50,58
 I did not 
make a direct comparison between the locations of the scar and the proposed 
qualitative scar assessment indices and their association with CRT response for two 
reasons. Firstly, in the present study correlation analysis between scar location and 
LV lead position showed that none of the LV pacing segment had evidence of focal 
LGE≥ 50% of myocardial wall thickness. This is because given the prior clinical 
efforts and with the benefit of scar information on CMR prior to device implant, 
conscious efforts were made by the implanter to avoid regions of high scar burden. 
This however precluded us to make the same analysis on impact of scar location as 
previously studied. Secondly, our study cohort consisted both ischemic 
cardiomyopathy and non-ischemic cardiomyopathy patients. The pattern and 
distribution of scar are distinct between these two cohorts. ICM typically has 
segmental scar in the distribution of coronary artery territories that extend from an 
endocardium to epicardium direction. In comparison, the scar pattern seen with DCM 
can be patchy, diffuse, mid-myocardial and epicardial in distribution on LGE image. 
The co-correlation of two distinct scar patterns with aetiology is likely to create 




Cardiac resynchronization therapy in heart failure patients with dyssynchronous LV 
electromechanical activation sequence resulted in LV epicardial APD shortening in 
CRT responders and APD lengthening in non-responders. Changes in regional 
ventricular wall mechanics, i.e. radial, circumferential and longitudinal strain patterns 
predicted local APD shortening or lengthening during CRT. Baseline QRS duration 
and change in QRS between baseline and biventricular pacing could identify patients 












Chapter 10. Focal but not diffuse myocardial fibrosis 
burden quantification using cardiac magnetic resonance 
 203 
imaging predicts left ventricular reverse modeling following 
cardiac resynchronisation 
 
The prior studies have demonstrated a close coupling between the electrical and 
mechanical remodeling processes secondary to CRT. As myocardial scar can have a 
structural and functional impact on the remodeling process, I aimed to prospectively 
assess the prognostic value of quantitative scar assessment using CMR in predicting 
reverse remodeling to CRT in dyssynchronous heart failure patients  
 
10.1 Abstract 
Background: Many heart failure patients with dyssynchrony do not reverse remodel 
(RR) in response to cardiac resynchronisation therapy (CRT). The presence of focal 
and diffuse interstitial myocardial fibrosis may explain this high non-response rate. T1 
mapping is a new cardiac magnetic resonance imaging (CMR) technique that 
overcomes the limitations of conventional contrast CMR and provides reliable 
quantitative assessment of diffuse myocardial fibrosis. The study tested the hypothesis 
that focal and diffuse fibrosis quantification would correlate with a lack of left 
ventricular (LV) RR to CRT.  
Methods: In a prospective study of 48 consecutive patients (27 ischemic 
cardiomyopathy, 21 dilated cardiomyopathy) LV scar burdens were quantified (scar 
core and grey zone using late gadolinium enhancement LGE CMR; interstitial fibrosis 
using T1 mapping) before CRT implant. LV RR was defined by a ≥ 15% reduction in 
LV end-systolic volume 6 months post implant.  
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Results. Twenty-seven (56%) patients were responders with RR. Association between 
scar quantification and LV RR were assessed using Poisson regression model. 
Univariate analysis showed that QRS duration/morphology, scar core and grey zone 
volumes expressed as % of LV mass and extracellular volume index (ECV) (a 
measure of interstitial fibrosis from T1 mapping) to be significant predictors of LV 
RR. Multivariable-adjusted analyses demonstrated scar core quantification (≥13.7% 
LVmass) to be the only independent predictor of LV RR (Prevalence ratio 0.40, 
p=0.038).  
Conclusions: Focal scar burden detected by LGE CMR is associated with a poor 
response to CRT. Diffuse interstitial fibrosis assessment by T1 mapping however is 
not independently predictive of CRT response. 
 




Since the first reported case of cardiac resynchronisation therapy (CRT) two decades 
ago, it has established its effectiveness, improving morbidity and mortality in 
selective heart failure patients with evidence of dyssynchrony.
43
 Prolonged QRS 
duration (QRSd), usually manifests as left bundle branch block (LBBB) are the 
recommended criteria in patient selection for CRT.
44
 However responder rates vary 
between half to two-thirds in reported cohorts, with left ventricular remodeling 




explanation for this high non-response rate may be the presence of focal and diffuse 
interstitial myocardial fibrosis, which can disrupt the concordance between 
mechanical and electrical dyssynchrony mediated through lines of structural and 
functional block thus attenuating the effect of CRT.  
Cardiac magnetic resonance imaging (CMR) using late gadolinium enhancement 
(LGE) is the gold standard for the non-invasive assessment of myocardial regional 
fibrosis. Regional scar imaging with LGE is well known to be associated with a poor 
response to CRT especially if there is postero-lateral scar at the usual site of LV lead 
placement.
49
 Patients with heart failure may however have more diffuse myocardial 
fibrosis which is not imaged using LGE-CMR that may be associated with a 
diminished response to CRT.  Myocardial tissue characterisation using T1 mapping is 
a new CMR technique with the potential to overcome the limitations of conventional 
LGE-CMR and provide reliable quantitative assessment of diffuse myocardial fibrosis 
on a standardised scale.
159
  
We hypothesised that diffuse myocardial fibrosis assessment on a quantitative scale 
may contribute to the selection of patients prior to CRT implant and identify those 
less likely to demonstrate volumetric response. We therefore tested the hypothesis that 
diffuse fibrosis detected by CMR would correlate with a lack of LV RR in patients 
with ischemic and non-ischemic dilated cardiomyopathies (ICM, DCM) receiving 
CRT.  The ability of diffuse fibrosis to predict non-response was also tested against 
the burden of scar core and scar border zone i.e. grey zone (an area of admixture of 





10.3.1 Study population and protocol 
(See Chapter 3.2 for General patient selection criteria) 
We undertook a prospective study of 48 consecutive patients undergoing CRT pre-
assessment clinic in our institution.  
Clinical status according to NYHA class and Minnesota living with heart failure 
questionnaires (MLHFQ) were assessed at pre- and 6 months post-CRT implant.  
Trans-thoracic echocardiographic (TTE) assessment of cardiac structure and function 
were assessed at the same consultation as the clinical assessment, using a GE Vivid 7 
scanner (General Electric-Vingmed, Milwaukee, Wisconsin). Standard 2-dimensional 
images of LV dimensions and ejection fraction (EF) were acquired during breath-hold 
in standard apical 2- and 4-chamber views. LV end-diastole and end-systole volumes 
(EDV, ESV) were used to estimate LVEF using the 2-dimensional modified biplane 
Simpson’s method (EchoPac 0.0.1, General Electric Vingmed). 
Cardiac magnetic resonance imaging protocol 
(See Chapter 3.3.1 for General CMR methods protocol) 
All patients underwent CMR assessment on the same day as their TTE, prior to their 
CRT implant. 
10.3.2 Quantitative scar measurement  
Focal fibrosis quantification using LGE CMR 
Two independent CMR experts blinded to the study outcome visually assessed LGE 
CMR images. In case of discrepancy, these experts jointly reviewed the data to reach 
a consensus.  
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Patient specific LV mass was quantified using dedicated software CMR42 (Circle 
Cardiovascular Imaging Inc., Calgary, Canada) and used to index the LGE 
quantification, representing myocardial focal scar burden. The extent of LGE was 
quantified using the 2-standard deviation (2SD) method, defined as the region with 







defined as the region with SI above the 
50% of the maximal SI of the enhanced area was used to quantify the scar core, i.e. 
Scarcore
_FWHM







. Each of these indices 
was expressed as a percentage of the LV mass (%LV).  
Diffuse interstitial fibrosis quantification 





) and ECV, as previously described.
72
 Care was taken to avoid 
the endocardium/blood pool interface. If regional enhancement was seen in the 
septum on the LGE image a ROI was chosen away from the enhanced region for 
analysis. The geometry of the T1 map slice was the same as that of the LGE images to 
allow for this comparison. T1
_Native 
<1000ms were considered to be the normal 
reference in our institution (1.5T scanner with a 32–channel coil, Philips Healthcare, 
Best, Netherlands). Blood tests were taken 1-2 hours immediately post CMR for 
estimation of patients’ hematocrit levels.  
The T1 derivative, extracellular volume index (ECV), was calculated as using the 
following formula:  
ECV =   
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Device implant  
All patients underwent CRT implant successfully. The LV lead was preferentially 
targeted in a postero-lateral, lateral or anterolateral branch at the discretion of the 
operator and the confines of patient-specific anatomy; with a pacing site preferentially 
chosen in a position more basal than apical and away from regions of scar seen on 
CMR and to ensure optimal pacing parameters.  
10.3.3 Outcome measure – LV RR  
At 6 months post implant, a positive LV RR was defined as ≥ 15% reduction in LV 
ESV on TTE assessment and improvement in patient clinical heart failure symptoms 
by ≥1 NYHA class and ≥20% reduction in MLHFQ scores. 
10.3.4 Statistical analysis 
(See Chapter 3.6 for General statistical methods) 
The univariate and multivariate associations between pre-specified variables of 
interest and outcome (LV RR) were examined using Poisson regression model with 
robust standard errors estimation.  
This was used to avoid overestimation of the risk ratio by odds ratio in view of the 
high prevalence of positive outcome.
221
  
All reported associations in this study were prevalence ratios (PR) and their 
corresponding 95% confidence intervals (CI). Moreover, to avoid spurious 
associations due to the inclusion of correlated variables in a single model, the 
multivariate analysis studied each of the LGE CMR and T1 mapping derived indices 
separately, thus limiting the maximum number of variables to four in a single 
multivariate model.  
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Intra- and inter-observer assessments of T1 values were assessed for reproducibility. 
The differences in repeated continuous variables measurements were expressed as 
mean ± SD and coefficient of variation (COV), and the correlation assessed using 
Pearson correlation coefficient (r). All data analyses were performed using SPSS 
statistical software (version 21, IBM, New York, USA) 
 
10.4 Results 
10.4.1 Study population 
Forty-eight patients fulfilling class I and II indication guidelines for CRT
45
 
participated and completed the study, 17% were female, the mean age was 65±11 
years, 92% of the patients were in NYHA class III and the mean QRSd was 139±26ms. 
Significant mechanical inter- and/or intra-ventricular mechanical dyssynchrony were 
demonstrated in all patients with tissue Doppler imaging. Twenty-two patients had 
“strict” LBBB, defined by QRS≥140ms for men / ≥130ms for women and mid QRS 
notching/slurring in ≥ 2 contiguous leads.  On the basis of World Health Organisation 
criteria 56% of subjects had an ischemic etiology.  The baseline characteristics 
including focal and diffuse scar quantification are shown in Table 10-1 with patients 
categorised as ICM or DCM. There were no significant differences in terms of pre-
implant baseline characteristics in terms of QRS duration/morphology and heart 
failure symptoms. Baseline LVEF was lower in the DCM group. Notably at baseline 
the ICM had higher levels of regional fibrosis although this was not statistically 
significant; 27/27(100%) of ICM patients had LGE vs. 19/21(90%) of DCM patients; 
scar core burden as a percentage of the LV was non-significantly higher in ICM (14±6 
vs. 10±9, p=0.094). In terms of diffuse fibrosis quantification, there was no significant 
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 and ECV).  
 Whole cohort ICM DCM  P 
N (%) 48 27 (56) 21 (44)  
Age, years 66±12 68±9 64±14 0.486 
Female,  8 (17) 6  2 0.437 
COPD,  8 (17) 4 4 0.715 
DM,  14 (29) 8 6 1.000 
HTN,  17 (35) 9 8 0.769 
CVA, 4 (8) 2 2 1.000 
AF (persistent),  10 (21) 3 7 0.081 
eGFR<60 24 (50) 14 10 1.000 
Beta blocker  47 (98) 26 21 1.000 
ACEI/ARB 47 (98) 26 21 1.000 
Loop diuretics 37 (77) 21 16 1.000 
MR antagonist 27 (56) 15 12 0.776 
NYHA class    0.160 
II 3 (6) 3 0  
III 44 (92) 24 20  
IV 1 (2) 0 1  
MLHFQ score  51±22 50±23 51±20 1.000 
LVEF, % 24±8 27±6 22±8 0.011 
LVESV, ml 173±84 156±61 189±108 0.388 
QRSd, ms 139±26 136±25 142±26 0.512 
QRSm “strict” LBBB 22 12 10 1.000 
Presence of LGE 46 (96) 27 19 0.077 
Scarcore
_FWHM
, %LV 12±8 14±6 10±9 0.094 
Greyzone 
_2SD-FWHM
, %LV 8±5 9±4 7±7 0.112 
T1
_Native
, ms 1060±78 1048±72 1075±83 0.262 
T1
_Contrast
, ms 419±72 428±54 407±91 0.117 
ECV 0.32±0.06 0.32±0.06 0.32±0.06 0.925 
 
Table 10- 1 Baseline patient characteristics  
ICM = ischemic cardiomyopathy; DCM = dilated cardiomyopathy; COPD = chronic 
obstructive pulmonary disease; AF = atrial fibrillation; CVA = cerebral vascular accident; 
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; LVEF 
= left ventricular ejection fraction; LVES =  left ventricular end-systolic volume; QRSd = 
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QRS duration; QRSm = QRS morphology; FWHM = full width half maximum; SD = standard 
deviation; ECV = extracellular volume index; MR = mineralcorticoid receptor  
 
10.4.2 Outcome measure 
At 6 months post CRT, LVESV reduction ≥15% occurred in 27 patients (56%), all of 
whom reported an improvement in heart failure symptoms, assessed by NHYA class 
(reduction ≥ 1 class) and quality of life questionnaires (a reduction of ≥20% in 
MLHFQ scores). These patients were considered to be positive responders with 
reverse remodeling. The mean LV ESV in the responder group was 180±69mls at 
baseline which improved to 146±47 ml (p<0.01) 6 months post CRT. Amongst the 21 
patients who failed to demonstrate LV RR, 9 patients reported an improvement in 
clinical symptoms with an improvement in at least 1 NYHA class and ≥20% 
improvement in quality of life score giving a symptomatic response rate of 75%. The 
patient characteristic separated by responder demonstrating LV RR and non-
responders are shown in Table 10-2. There were no significant differences in terms of 
LV lead position using a modified clock-face method in left anterior oblique and right 
anterior oblique projection taken with fluoroscopy at the time of lead implant as 
previously described.
222
 Despite efforts of avoiding scarred segments by the operators 
during LV lead implants, 5 patients (3 non-responders, 2 responders, p = 0.641) had ≥ 
50% transmural focal LGE in close proximity of the LV pacing site. Biventricular 
pacing percentage was comparable between responders and non-responders (96±4% 





 Non-responder Responder P 
N  21 27  
Etiology: ICM/DCM 14/7 13/14 0.248 
Age, years 63±14 68±9 0.323 
Female 3 5 1.000 
COPD,  3 5 1.000 
DM,  7 7 0.750 
HTN,  7 10 1.000 
CVA, 2 2 1.000 
AF (persistent),  2 8 0.152 
eGFR<60 15 9 0.019 
Beta blocker  21 26 1.000 
ACEI/ARB 20 27 0.438 
Loop diuretics 15 22 0.498 
MR antagonist 8 19 0.040 
NYHA class*   0.092 
II 3 0  
III 18 26  
IV 0 1  
MLHFQ score * 50±21 51±22 0.780 
LVEF, % * 25±7 23±8 0.486 
LVESV, ml * 154±103 183±68 0.478 
QRSd, ms 129±22 146±26 0.031 
QRSm, “strict” LBBB  5 17 0.009 
Scarcore 
_FWHM
, %LV 16±8 9±7 0.002 
Greyzone 
_2SD-FWHM
, %LV 11±4 7±6 0.002 
T1
_Native
, ms 1071±77 1051±79 0.271 
T1
_Contrast
, ms 406±71 430±73 0.304 
ECV 0.34±0.06 0.30±0.06 0.043 
 
Table 10- 2 Characteristics of responder vs. non-responders 
ICM = ischemic cardiomyopathy; DCM = dilated cardiomyopathy; QRSd = QRS duration; 
QRSm = QRS morphology; FWHM = full width half maximum; SD = standard deviation; 
ECV = extracellular volume index; MR = mineralcorticoid receptor 
* Baseline measurement. 
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10.4.3 Characteristics of responders 
QRS duration was significantly greater in the responder group versus the non-
responder group (146±26ms vs.129±22ms, P=0.031). The prevalence of  “strict” 
LBBB was markedly higher in responders (63% vs. 24%, P=0.009).  
Focal fibrosis and diffuse fibrosis quantification with CMR: 
The responder group had a significantly reduced regional scar burden with a smaller 
scar core and grey zone
_
 expressed as a percentage of LV mass compared to non-
responders (Scar
_FWHM
: 9±7% vs. 16±8, p=0.002; and Greyzone
_2sd-FWHM
: 7±6 vs. 
11±4%, p=0.002). None of the LV pacing segment had evidence of focal LGE ≥ 50% 
of myocardial wall thickness. 




 were not statistically 
different in responders and non-responders (1051±79 vs. 1071±77ms, p=0.271; and 
430±73 vs. 406±71, p=0.304). ECV was lower in the responders group (0.30±0.06 vs. 
0.34±0.06, p=0.043) suggesting a lesser degree of diffuse interstitial fibrosis in the 
responders.  
10.4.4 Predictors of response 
The association between the variables of QRS, focal and diffuse fibrosis 
quantifications and the LV RR were assessed using Poisson regression model. 
Univariate analysis demonstrated a significant association between 1ms increment in 
QRS duration and presence of “strict” LBBB in relation to positive LV RR. 
Percentage increment in Scarcore
-FWHM
 and ECV were negatively associated with LV 






Confidence intervals    P 
QRSd, +1ms 1.01 1.00-1.02 0.009 
QRSm “strict” LBBB 2.01 1.18-3.35 0.011 
Scar
_FWHM
, +1%LV 0.94 0.89-1.00 0.010 
Greyzone
_2sd-FWHM
, +1%LV 0.94 0.89-1.00 0.074 
T1
_Native
, +10ms 0.98 0.95-1.02 0.427 
T1
_Contrast
, +10ms 1.02 0.99-1.05 0.206 
ECV, +1% 0.96 0.92-1.00 0.028 
QRSd = QRS duration; QRSm = QRS morphology; FWHM = full width half maximum; SD = 
standard deviation; ECV = extracellular volume index 
Table 10- 3 Univariate analyses 
 
Receiver operator curve analysis identified optimal cut-off values for focal and 
diffuse fibrosis indices in order to predict LV RR in the study cohort. These cut-off 
values were then used to dichotomise the focal and diffuse fibrosis indices and tested 
in multivariate analyses including QRS variables in the total patient cohort. 
Scarcore
_FWHM
 using a thresholding value of  ≥13.7% of the LV was shown to be the 
only significant independent variable associated with LV RR with a PR 0.39 
(p=0.029), suggesting a strong negative predictor of LV reverse remodeling. The 
results from the multivariate analyses and Forest plot of the PR for each variable and 





 In order to avoid spurious associations due to the inclusion of correlated variables in a 
single model, the multivariable adjusted analysis studied each of the T1derived 
indices separately. QRSm “strict” LBBB but not QRSd was included in the 
multivariate analyses because the definition of “strict” LBBB has already included 
QRS duration into consideration (≥140ms for men / ≥130ms for women). This is to 
avoid potential confound effect in the analyses due to correlation between these 
variables.  
Figure 10- 1 Multivariate analyses* 
 
10.4.5 Reproducibility of T1 measurements 
T1 measurements were repeated in a subgroup of randomly selected patients from the 
study cohort (10 ICM and 10 DCM). For T1
_native
 measurement, the intra-observer 
average difference in values was 5±3ms, coefficient of variation (COV) was 
0.3±0.2%; the inter-observer average differences in values were 6±5ms and COV was 
0.4±0.3%. For T1
_Contrast
 measurement, the intra-observer average difference in values 
was 5±4ms and COV was 0.8±0.6%; the inter-observer average differences in values 
were 5±4ms and COV was 0.9±0.7%. There were good agreements in inter and intra-






We assessed whether regional myocardial scar characterisation and diffuse fibrosis 
quantification was able to predict LV volumetric response to CRT.  
The main findings of the current study in a prospective cohort of patients with both 
ICM and DCM undergoing CRT are as follows:  
1) CRT responders had a significantly reduced focal scar burden with a smaller scar 
core and grey zone
 
(expressed as % of LV mass) compared to non-responders. Scar 
core burden of ≥13.7% of the LV was a strong independent negative predictor of LV 
RR to CRT in a combined cohort of ICM and DCM patients. 




 was not statistically 
different in responders and non-responders (1051±79 vs. 1071±77ms, p=0.271; and 
430±73 vs. 406±71,p=0.304). ECV, was lower in the responder group (0.30±0.06 vs. 
0.34±0.06, p=0.043) but was predictive of response only in univariate analysis 
10.5.1 Comparison with previous studies 
Heart failure patients with ischemic etiology tend to benefit less from CRT than 
patients with DCM. Prior studies have demonstrated that total scar burden (without 
differentiating between scar core and grey zone) is lower in CRT responders defined 
by clinical functional status rather than LV volumetric response.
50
 Long-term 
prognosis after CRT has been shown to correlate with LV RR rather than clinical 
symptomatic response.
57
 Prior studies that assessed LV volumetric responses to CRT 
have focused on scar burden at the LV lead pacing site.
49,51,58
 Our results confirm 
these previous findings and further show that regional scar differentiation with focal 
scar core burden quantification from LGE images assessed before CRT implant is a 
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strong independent negative predictor of LV RR even when compared with “strict” 
LBBB morphology.  
To our knowledge the current study is the first to assess the prognostic value of T1 
mapping and its derived indices (ECV) in predicting volumetric response to CRT. The 
presence of diffuse fibrosis is overlooked in routine clinical CMR studies due to the 
inherent limitation of conventional LGE CMR technique. It requires the nulling of 
apparently “normal” myocardium in order to provide contrasting image signal 
intensities to highlight the region of focal scar represented by gadolinium 
enhancement. The degree of transmurality in LGE has been shown to correlate with 
contractile improvement after revascularisation suggesting that the greater proportion 
of surviving myocardium the greater the capacity for the myocardium to recover.
59
 
Measures of diffuse interstitial myocardial fibrosis may likewise represent a measure 
of viable/recoverable myocardium.  
10.5.2 Diffuse fibrosis assessment 
In order to address the clinical need for better myocardial tissue characterisation, 
native T1 and ECV are the two indices that have been the main focus of clinical 
research interest. The derivation of ECV from native, post contrast myocardial/blood 
T1 values and haematocrit level is based on an important assumption that the contrast 
concentration reaches equilibrium between blood and tissue. It has been well 
validated against histological measures of interstitial fibrosis and has been shown to 
be a sensitive and robust measurement of collagen volume fraction, whereas post 
contrast T1 is more susceptible to contrast kinetics.
223
 Native T1 removes the 
dependence of contrast kinetics and has been shown to be a valid biomarker of 
changes in extracelluar volume and matrix composition.
224
 It is a relative simpler 
measurement making its translation to clinical practice attractive. However we must 
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exercise caution in interpreting the native T1 value because though we speculate it 
reflects similar changes based on its accordance with the trend observed with post-
contrast T1 and ECV, others has failed to find a significant difference in non-contrast 
T1 value between the regions with and without LGE in the septum in patients with 
HCM or DCM.
154
 Furthermore, a stronger correlation of native T1 with impaired 
myocardial energetics measured by magnetic resonance spectroscope than with LGE 
suggests that native T1 may additionally reflect intracellular metabolic state 
associated with myocardial disease.
153
  
10.5.3 Clinical implications 
Given that the burden of scar core, i.e. homogeneously non-viable myocardium, is 
ubiquitously high amongst advanced heart failure patients, the assessment of the 
remaining viable tissue may play an important role in predicting the capacity of the 
LV to positively remodel with CRT. ICM typically has segmental scar in the 
distribution of coronary artery territories that extend from an endocardium to 
epicardium direction. In comparison, the scar pattern seen with DCM can be patchy, 
diffuse, mid-myocardial and epicardial in distribution on LGE image. The presence of 
focal fibrosis detected by LGE in our DCM cohort appeared to be higher than 
previous studies which focused on the presence of mid-wall fibrosis.
112,225
 The 
presence of mid-wall fibrosis has been shown to have a strong correlation with long-
term mortality and morbidity in DCM patients and lack of RR post CRT.
225
 Past 
studies that assessed the association between scars detection by LGE CMR and CRT 
response have largely focused on the locations of LGE scars i.e. its presence at the 
site of LV lead implant.
49,50,58
 In practice, LV lead placement is mostly dictated by 
coronary venous anatomy and electrical parameters. So dictating the precise site of 
LV lead implant according to LGE sites from CMR in order to influence CRT 
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response is sound in theory but often not always practical. The results of the current 
study suggest that global LV diffuse scar quantification does not predict volumetric 
response to CRT in a cohort combined of ICM and DCM.  
10.5.4 Limitations 
Although this was the largest clinical study to date to address the importance of 
extracellular volume mapping with CMR for the response to CRT, we acknowledge 
the fact that the study may be underpowered given the sample size. Nevertheless this 
is a real world prospective study of consecutive patients undergoing CRT at our 
institution.  The optimal thresholding values for the scar and T1 mapping indices 
should be taken in the context of the study and a larger population study is needed to 
validate these optimal thresholding values. T1-mapping was limited to a single slice 
of myocardium and the assumption is made that diffuse fibrosis imaged is truly 
diffuse/uniform in the remote myocardium. Notably T1-mapping was performed not 
at the site of myocardium where the LV lead is sited. This “selective” sampling may 
be biased against ECV measurement when “whole heart ECV” have been showed to 
best correlated with collagen volume fraction.
226
 Knowledge of the degree of diffuse 
fibrosis at the site of LV lead placement may be of importance and should be 
addressed in further studies. The absolute T1 values of interest can be influenced by a 
number of technical parameters including magnetic field strength and acquisition 
sequence as well as post-acquisition image processing including motion correction 
and image registration. Conducting a single center study allowed standardisation of 
the imaging protocol across the entire cohort, however it may have introduced 
systematic bias including the timing of post-contrast T1 measurement. A multicenter 




We have systematically characterised and quantified the burden of scar core and grey 
zone from conventional LGE CMR images and the degree of interstitial fibrosis using 
T1 mapping technique in predicting LV volumetric response to CRT. Our results 
confirm that focal scar burden detected by LGE CMR is associated with a poor 
response to CRT.  CMR markers of diffuse interstitial fibrosis were not however 
predictive of CRT response. This finding may have an important bearing on patient 




Chapter 11 Conclusion 
 
The over all aim of this thesis is to assess whether quantitative left ventricular 
myocardial fibrosis assessment using cardiac magnetic resonance imaging can  
1) predict the risk of ventricular arrhythmia and provide additional predictive 
value in identifying patients with increased risk of VT in both ischaemic and 
non-ischaemic cardiomyopathy (ICM, NICM) patients;  
2) predict reverse remodeling following CRT in dyssynchronous heart failure 
patients.  
 
11.1 Original contributions 
The proceeding chapters in this thesis have demonstrated that these primary aims have 
been achieved.  
1. Chapter 5 has shown for first time that quantitative myocardial tissue assessment 
using T1 mapping is an independent predictor of ventricular arrhythmia with a hazard 
ratio comparable to scar or grey zone quantification detected by conventional LGE-
CMR in both ischemic and non-ischemic cardiomyopathies. 
2. Chapter 10 has systematically characterised and quantified the burden of scar core 
and grey zone from conventional LGE CMR images and the degree of interstitial 
fibrosis using T1 mapping technique in predicting LV volumetric response to CRT. 
The results confirm that focal scar burden detected by LGE CMR is associated with a 
poor response to CRT.  CMR markers of diffuse interstitial fibrosis were not however 
predictive of CRT response. 
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In the course of setting up the prospective clinical outcome study, other exploratory 
studies have also made original contributions.  
3. Chapter 4 revealed some of the important limitations T1 mapping in terms of 
imaging acquisition and data analysis. It demonstrated that pre-contrast and post-
contrast T1 maps derived from MOLLI and more specifically the R1 (
1
/T1) and rΔR1 
(
R1,pre - R1,post
/R1,pre) values could be used for characterisation of different myocardial 
tissue sub-types in patients with ischaemic cardiomyopathy. There was a suggestion 
that rΔR1 was best at distinguishing different tissue sub-types in ischaemic 
cardiomyopathy. 
4. Chapter 5 has shown for the first time that HybridPAWS can reliably improve 
respiratory navigator efficiency and shorten scan time during high-resolution isotropic 
3D LGE-CMR. However suboptimal motion compensation may still affect the image 
quality without the freedom of real-time correction. 
5. Chapter 6 provided new insights into the prediction of VT circuits using a 
biophysical model. Patient-speciﬁc spatial heterogeneity of restitution properties were 
the distinguishing features of ventricular arrhythmogenicity, with re-entrant VT exit 
points present in regions of higher maximum APD-RC slopes compared with the 
surrounding tissue. These regions were within the grey zone identified by LGE CMR. 
Personalised biophysical model was able to predict macroscopic VT circuits and exit 
point locations in agreement with clinically observed datasets. 
6.  Chapter 8 and 9 have shown for the for the first time, that LV APD (ARI) changed 
during CRT with APD shortening in responders and lengthening or remaining the 
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same in non-responders to CRT. The opposite changes in APD in responders vs. non-
responders were strongly correlated with similar changes in regional myocardial strain. 
These findings were consistent with a role of MEC in ventricular remodeling in 
patients with heart failure. This supported the hypothesis that electrical remodelling 
accompanies the haemodynamic remodelling associated with CRT in heart failure 
patients with dyssynchrony. 
 
11.2 Clinical perspective, implications and limitations 
At present, international guidelines for selecting patients for ICD or CRT do not 
include myocardial scar quantifications. Evidences from the studies described in the 
current thesis support the notion that scar quantification by CMR may add 
incremental prognostic value to the current selection criteria.  
Regional myocardial fibrosis, conventionally detected by LGE-CMR provides 
potential substrate for the initiation and maintenance of ventricular arrhythmia. 
Myocardial tissue characterisation using T1 mapping has emerged as a new CMR 
application, which has the potential to overcome the limitations of conventional LGE-
CMR techniques and characterise diffuse fibrosis. The current study demonstrated 
that an incremental increase in non-contrast native T1 measurement (a marker of 
diffuse fibrosis) is independently associated with the incidence of ventricular 
arrhythmia in patients with ICD.  The study also provided further confirmation that 
the extent of scar and grey zone derived from LGE-CMR are independently 
associated with ventricular arrhythmia, and highlights the importance of grey zone in 
patients with NICM. Such CMR applications have the potential to improve risk 
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stratification in selecting patients for ICD therapy and may be particularly useful for 
the primary prevention group in whom there is considerable risk heterogeneity.  
Given that the burden of scar core, i.e. homogeneously non-viable myocardium, is 
ubiquitously high amongst advanced heart failure patients, the assessment of the 
remaining viable tissue may play an important role in predicting the capacity of the 
LV to positively remodel with CRT. ICM typically has segmental scar in the 
distribution of coronary artery territories that extend from an endocardium to 
epicardium direction. In comparison, the scar pattern seen with DCM can be patchy, 
diffuse, mid-myocardial and epicardial in distribution on LGE image. The presence of 
mid-wall fibrosis has been shown to have a strong correlation with long-term 
mortality and morbidity in DCM patients and lack of remodelling post CRT.
225 
 Past 
studies that assessed the association between scars detection by LGE CMR and CRT 
response have largely focused on the locations of LGE scars i.e. its presence at the 
site of LV lead implant.
49,50,58
 In practice, LV lead placement is mostly dictated by 
coronary venous anatomy and electrical parameters. So dictating the precise site of 
LV lead implant according to LGE sites from CMR in order to influence CRT 
response is sound in theory but often not always practical.  
The association between myocardial scar and ventricular arrhythmia is long 
recognised, however the relationship between the two and the mechanism by which 
one contribute to another remains clear-cut. Though the number of clinical subjects 
studied in order to validate the computational VT modeling is small, the initial results 
nevertheless support the notion that personalised computational model incorporating 
both scar (from CMR scar imaging) and electrical parameters can help us to gain 
insights to this relationship. The study showed that patient-speciﬁc spatial 
heterogeneity of restitution properties were the distinguishing features of ventricular 
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arrhythmogeneicity, with re-entrant VT exit points present in regions of higher 
maximum APD-RC slopes compared with the surrounding tissue. These regions were 
within the grey zone identified by LGE CMR.  
This implies that scar heterogeneity has a major influence to the functional and 
electrical remodeling of the ventricle. Heart failure is associated with mechanical and 
electrophysiological remodeling. A consistent feature of importance in 
arrhythmogenesis is ventricular APD prolongation. CRT is associated with anatomic 
and electric reverse remodeling. Using ARI as a surrogate measure of APD from the 
left ventricular epicardial lead of a CRT device at intervals during the first 6 months 
after implantation, we found that in patients with dyssynchronous heart failure, left 
ventricular APD changed during CRT. APD shortened in responders with clinical 
improvement and lengthened or remained the same in non-responders to CRT. This 
supports the hypothesis that electric remodeling accompanies the reverse remodeling 
associated with CRT in heart failure patients with dyssynchrony. The effect on APD 
was the opposite in patients showing a positive echocardiographic remodeling 
response compared with non-responders. These findings may provide an explanation 
for the persistent high incidence of arrhythmias in some patients with CRT and the 
additional mortality benefit observed in responders of CRT. 
I acknowledge that there is currently a lack of standardisation of quantitative 
myocardial tissue assessment with CMR in clinical practice and we are limited by our 
continuing understanding of this emerging T1 mapping technique. The initial research 
into the clinical applications of T1 mapping has focused on post-contrast T1 values. 
Iles et al. first demonstrated a correlation between post-contrast T1 values with a 
quantitative histological measure of fibrosis, CVF, in patients with heart failure of 
various aetiologies.
93
 Lower post-contrast T1 values were correlated with a higher 
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histological percentage of collagen and associated with worsening diastolic function 
markers detected by transthoracic echocardiograph. Recently, in a larger cohort of 
forty-five patients with cardiomyopathies of mixed aetiologies, most of whom had 
evidence of diffuse fibrosis on histology, Sibley et al. also found that post-contrast T1 
values had a significant correlation with histological measure of fibrosis.
147
 Ng et al. 
also found lower global post-contrast T1 correlated with diastolic dysfunction in 
diabetic patient free of coronary artery disease and regional fibrosis.
116
 Sparrow et al. 
showed that segmental post-contrast T1 values were increased in regions with 




T1 measurements can also be performed in regional fibrosis caused by scar post 
myocardial infarction. Messroghli et al. found lower post-contrast T1 values in the 
infarct region compared with non-infarct region in acute and chronic myocardial 
infarction.
7 
Increases in the interstitial space can also be caused by processes such as 
the protein deposition in amyloidosis and Maceira et al. found an association of lower 
subendocardial post-contrast T1 in patients with amyloidosis compared with 
controls.
228
 However the application of T1 measurements in these areas with regional 
changes is potentially problematic because the derived ECV measurement relies on 
the prerequisite of a two-compartment model with contrast equilibrium between the 
blood and the myocardium. An assumption is made that there is a constant myocardial 
plasma volume fraction, reflecting homogeneous capillary density in the myocardium, 
which is not necessarily the case in conditions such as amyloidosis and replacement 
fibrosis post myocardial infarction.  
It was recognised early on that converse to post-contrast T1, non-contrast T1 is higher 




Though still susceptible to the influence of acquisition sequence and magnetic field 
strength, native non-contrast T1 can remove the dependence on contrast kinetics and 
avoid the potential of contrast associated nephrogenic systemic fibrosis. In two 
separate studies, Puntmann et al. and Dass et al. have both recently demonstrated a 
significant higher non-contrast T1 values in hypertrophic cardiomyopathy (HCM) and 
non-ischemic dilated cardiomyopathy (NIDCM) compared with normal controlled 
group with T1 mapping acquired on 3Tesla scanners.
153,154
 Dass et al. not only 
noticed a difference between regions with LGE, but also regions without LGE, in the 
cardiomyopathy group and the normal control group. Both studies suggest the 
potential implication of non-contrast native T1 being a useful biomarker in detecting 
diffuse disease in cardiac pathologies. Puntmann et al. further demonstrated a higher 
non-contrast native T1 in systemic lupus erythematous patients with normal 
myocardial function, implying that native T1 mapping can be a sensitive detector of 
subclinical myocardial disease.
229
[21] Indeed, Karamitsos et al. found a higher non-
contrast T1 value in patients with amyloid light-chain (AL) amyloidosis in the 
absence of definitive cardiac manifestations.
156
 The scale of T1 value correlated with 
markers of cardiac systolic and diastolic function. Others have found non-contrast 
native T1 value to be useful for assessing areas of myocardial oedema in Takotsubo 
cardiomyopathy and quantifying areas-at-risk in acute myocardial infarction, 
comparable with the conventional T2 weighted images.
230-232
 In a systematic analysis 
and an attempt to establish a normal reference range of non-contrast T1 values 
acquired with ShMOLLI on 1.5T scanner (a cohort of 342 healthy volunteers, 50% 
females, age 11-69), Piechnik et al. found the non-contrast T1 to be a highly 




Given the reported correlation of non-contrast native T1 with disease pathology, we 
must however be cautious in interpreting the value of native T1. We know that T1 
increases with increased water content. We therefore speculate that the increase in 
native non-contrast T1 is due to an expansion of extracellular volume and change in 
extracellular matrix composition. This assumption seems to be in accordance with the 
trend observed with post-contrast T1 and ECV, for example Scholz et al. 
demonstrated a correlation between T1 with the amount of free water content and 
collagen in canine hearts.
234
 Bull et al also found a correlation between native T1 with 
CVF on histology samples from patients with moderate and severe aortic stenosis.
224
 
This however may not be the complete picture. Puntmann et al. did not find a 
significant difference in non-contrast T1 value between the regions with and without 
LGE in the septum in patients with HCM or NIDCM
154
 and Dass et al. found a 
stronger correlation of non-contrast T1 with impaired myocardial energetics measured 
by magnetic resonance spectroscope than with LGE, suggesting that non-contrast T1 





11.3 Future directions 
Like with any emerging technique, we can only explore the potentials of T1 mapping 
through a better understanding of its limitations. Though, differences in T1 mapping 
acquisition sequences and protocols make the absolute T1 values difficult to compare 
across studies, the evidence presented so far shows great promise for T1 mapping in 
becoming another cornerstone in the clinical application of CMR, but it needs to be 
performed in rigorous conditions with accurate post-processing registration in order to 
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improve its efficacy. Larger cohort studies are needed to establish the “ideal” 
thresholding values of diffuse and regional fibrosis to enable the translation of non-
invasive myocardial fibrosis quantification using LGE-CMR and T1 mapping to the 
clinical management of patients at risk of life threatening arrhythmias or predicting 
CRT positive response.  
These threshold levels can then be tested prospectively to quantify an “area-at-risk”. 
The thresholding mapping can be generated through an automated image process 
algorithm pipeline (Figure 11-1) to improve reproducibility and shorten processing 
time to aid clinical translation.  
 
Figure 11- 1 Proposed automatic segmentation of area at risk for CMR scar quantification.  
Typical ranges of T1 and ECV values of myocardial tissue, scar core, grey zone and blood are 
shown in (a). Single T1 or ECV maps cannot be used for area at risk segmentation using 
thresholds since the different tissue classes overlap in their value ranges. By combining the 
images, the different tissue types can be separated (b). In this work, native T1 and ECV were 
used to segment and quantify scar core, grey zone and healthy myocardium. 
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